The development and utilization of an in vivo RNA interference protocol to elucidate gene functions and identify potential drug targets in the filarial nematode Brugia malayi by Song, Chuanzhe
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2011
The development and utilization of an in vivo RNA
interference protocol to elucidate gene functions
and identify potential drug targets in the filarial
nematode Brugia malayi
Chuanzhe Song
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Medical Sciences Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Song, Chuanzhe, "The development and utilization of an in vivo RNA interference protocol to elucidate gene functions and identify
potential drug targets in the filarial nematode Brugia malayi" (2011). Graduate Theses and Dissertations. 10346.
https://lib.dr.iastate.edu/etd/10346
  
The development and utilization of an in vivo RNA interference protocol to elucidate gene 
functions and identify potential drug targets in the filarial nematode Brugia malayi 
 
By 
Chuanzhe Song 
 
A dissertation submitted to the graduate faculty 
In partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
Major: Neuroscience 
Program of Study Committee: 
Michael J. Kimber, Major Professor 
Timothy A. Day 
Steve Carlson 
Lyric Bartholomay 
Thomas J. Baum 
 
 
 
Iowa State University 
Ames, Iowa 
 
2011 
 
ii 
 
 
 
 
 
 
 
 
 
 
To my family, wife Hannah, and daught Kathryn for their support and encouragement 
  
iii 
 
 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES                     vii 
LIST OF TABLES                     ix 
ABSTRACT                    x 
CHAPTER 1. INTRODUCTION                       1 
BRIEF OVERVIEW OF CURRENT SITUATION IN PARASITIC NEMATODES       1 
BRIEF INTRODUCITON TO THE LYMPHATIC FILARIASIS PROBLEM                5 
Pathogenesis of Lymphatic Filariasis                      5 
Socio-Economic Impact of Lymphatic Filariasis                  6 
Biology / Life Cycle of Brugia malayi                    7 
Global Effort in the Control of Lymphatic Filarial Infection                12 
A BRIEF OVERVIEW OF RNA INTERFERENCE                 16 
The RNAi Mechanism                      16 
Uptake of RNAi Trigger                 18 
Dissemination of RNAi Signal               18 
Primary siRNA Biogenesis                19 
Secondary siRNA / RNAi Signaling Amplification                   22 
RNAi-induced Silencing Complex (RISC)             25 
RISC Loading Complex (RLC)                25 
RISC Function                  28 
Regulating the RNAi Mechanism               28 
HISTORY OF RNAi IN PARASITIC NEMATODES            30 
iv 
 
 
 
 OBJECTIVES                    40 
 THESIS ORGANIZATION                42 
CHAPTER 2. DEVELOPMENT OF AN IN VIVO RNAI PROTOCOL TO INVESTIGATE    43 
GENE FUNCTION IN THE FILARIAL NEMATODE, BRUGIA MALAYI     
ABSTRACT                   43 
INTRODUCITON                         45 
MATERIALS AND METHODS                     48 
Mosquito Maintenance and Injection Protocol                             48 
Establishing Brugia Infection                     48 
siRNA and dsRNA Generation and Injection                49 
Relative Quantitative RT-PCR                50 
Quantitative RT-qPCR                       51 
Phenotype Analysis                 54 
Microscopy                       55 
Statistical Analysis                   56 
RESULTS                       57 
A Brugia RNAi Trigger Rapidly Disseminates Throughout the Mosquito Host        57 
Brugia Gene Suppression In Vivo is Potent and Specific                 59 
Bm-cpl-1 Suppression Elicits Marked Motility and Developmental Phenotypes        65 
Bm-cpl-1 Suppression Enhances Mosquito Survival and Decreases Parasite          76 
Prevalence  
DISCUSSION                          79 
CHAPTER 3. CONFIRMING THE ROBUSTNESS OF THE IN VIVO RNAI PROTOCOL     85 
THROUGH INVESTIGATING GENE FUNCTION OF KNOWN AND POTENTIAL 
DRUG TARGETS IN THE FILARIAL NEMATODE, BRUGIA MALAYI  
v 
 
 
 
ABSTRACT                         85 
INTRODUCTION                        87 
MATERIALS AND METHODS                      90 
Mosquito Maintenance and Injection Protocol                    90 
Establishing Brugia Infection                      90 
Gene Selection & dsRNA Generation              91 
Relative Quantitative RT-PCR                      93 
Quantitative RT-qPCR                         95 
Phenotype Analysis                        98 
Statistical Analysis                         99 
RESULTS                          100 
Target Genes were Expressed During Mosquito Life Cycle Stages                    100 
In Squito Suppression of Target Genes was Potent and Specific                103 
Brugia Gene Suppression Result in Aberrant Motility          110 
Effect of dsRNA Exposure on Normal Knotting Behavior of L3 B. malayi       113 
Worm Distribution is Significantly Altered with RNAi Suppression        116 
Effect of B. malayi Target Gene Suppression on Worm Survival        120 
Effect of B. malayi Target Gene Suppression on Mosquito Survival         120 
DISCUSSION                        122 
The Robustness of the “In Squito” RNAi Protocol                  122 
Bm-tub-1                        122 
Bm-GluCl-α3A                      123 
Bm-gar-2                         125 
vi 
 
 
 
Bm-flp-21                       127 
Bm-pc-2                        128 
CHAPTER 4. GENERAL CONCLUSIONS             130 
REFERENCES                  133 
ACKNOWLEDGEMENTS               151 
 
 
  
vii 
 
 
 
LIST OF FIGURES 
Figure 1. Brugia malayi life cycle.               10 
Figure 2. RNAi pathway.                     17 
Figure 3. Schematic representation of the siRNA synthesis mechanism.                20 
Figure 4. Secondary siRNA synthesis.                   23 
Figure 5. Loading of siRNA duplex onto Argonaute.               27 
Figure 6.  Dissemination and persistence of intrathoracically injected Cy3-labelled          58 
  Brugia malayi Cathepsin-L1 siRNAs in Aedes aegypti. 
Figure 7. Concentration-dependent, in vivo suppression of Brugia malayi Cathepsin          62 
-L1 (Bm-cpl-1) using siRNA (Top) or dsRNA (Bottom) RNAi triggers.  
Figure 8. Quantitative PCR demonstrates significant reduction in Bm-cpl-1 transcript       63 
levels as a result of siRNA and dsRNA RNAi trigger injection into Brugia  
malayi infected Aedes aegypti.  
Figure 9. Aberrant motility of dsRNA Bm-cpl-1 exposed Brugia malayi.               66 
Figure 10. Disrupted motile phenotypes of dsRNA Bm-cpl-1 exposed Brugia malayi.         69 
Figure 11. The frequency of caudal paralysis and kinked posture of dsRNA Bm-cpl-1         70 
 exposed Brugia. malayi. 
Figure 12. dsRNA Bm-cpl-1 exposed Brugia malayi fail to migrate to the head of the         73 
mosquito.  
Figure 13. Bm-cpl-1 suppressed Brugia malayi are significantly shorter than control           74 
worms.     
Figure 14. Ae. aegypti survival significantly increases as infection prevalence decreases     77 
in Bm-cpl-1 dsRNA exposed mosquitoes.  
Figure 15. Target genes are expressed during mosquito life cycle stages.                     101 
Figure 16. Target genes are suppressed using in squito RNAi protocol.             105 
Figure 17. Quantitative RT-PCR demonstrates significant reduction in transcript        108 
abundance of Bm-tub-1, Bm-GluCl-α3A, Bm-gar-2, and Bm-flp-21  
and dramatic up-regulation of Bm-pc-2 following dsRNA. 
viii 
 
 
 
Figure 18. Bm-tub-1, Bm-GluCl-α3A, Bm-gar-2, and Bm-pc-2 dsRNA exposure        111 
elicited reduced motility. 
Figure 19. Suppression of target Brugia malayi genes altered normal knotting        114 
behavior.  
Figure 20. Frequency distribution of worms extracted from control and         117 
dsRNA injected mosquito. 
Figure 21. Parasite mean intensity of control and dsRNA injected Aedes aegypti.        121 
 
  
ix 
 
 
 
LIST OF TABLES 
Table 1. Primer and TaqMan probe sequences for RT-qPCR experiment.              53 
Table 2. Reportable information on RT-qPCR experiment.                  61 
Table 3. Targets for in squito suppression.              91 
Table 4. Primer sequence for dsRNA generation.             92 
Table 5. Primer sequence for relative quantitative RT-PCR.            94 
Table 6. Primer and TaqMan probe sequences for RT-qPCR experiment.          97 
Table 7. Reportable information on RT-qPCR experiment.          107 
 
 
  
x 
 
 
 
ABSTRACT 
Since its first characterization in 1998 in the free-living nematode Caenorhabditis elegans, 
RNA interference has been considered a powerful reverse genetics tool to investigate nematode 
biology.  But to date, current RNAi protocols for parasitic nematodes have proven unreliable and 
inconsistent.  
We established an alternative RNAi protocol targeting the filarial nematode Brugia malayi 
in-host whereby the parasites are exposed to RNAi triggers as they develop within the 
intermediate host, the mosquito Aedes aegypti. Using this in vivo RNAi protocol, we successfully 
quantified the suppression of five B. malayi genes associated with known or putative drug targets. 
Administration of a random exogenous dsRNA resulted in no phenotypic abnormalities, 
demonstrating the specificity of the in vivo RNAi protocol.  
In vivo RNAi experiments revealed that the cathepsin L-like cysteine protease Bm-cpl-1 
plays a role in worm migration, survival and overall health. Suppression of Bm-cpl-1 resulted in 
inhibited worm motility and capacity to properly navigate to the head for transmission thus 
abolishing the transmission potential of the worm. Bm-cpl-1 suppression also affected worm 
development as evident by a reduction in worm length post Bm-cpl-1 suppression.  
The potential of the in vivo RNAi protocol to aid drug development was further validated 
using four known or putative drug targets of interest: β-tubulin (Bm-tub-1), a glutamate-gated 
chloride channel alpha subunit (Bm-GluCl-α3A), a G protein-coupled acetylcholine receptor 
(Bm-gar-2), and a FMRFamide-like peptide (Bm-flp-21). Suppression of these genes resulted in a 
combination of decreased motility, worm survival, migration, and worm physiological 
xi 
 
 
 
abnormalities verifying or validating each of the four drug targets potential for anthelmintic drug 
development.  
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CHAPTER 1. INTRODUCTION 
 
I. BRIEF OVERVIEW OF THE CURRENT SITUATION IN PARASITIC 
NEMATODES 
Parasitic nematodes pose major economic and health problems to humans, animals, and 
plants globally. It is estimated that over 2 billion people, mainly in the developing regions, are 
infected with one or more species of parasitic nematode [1]. Human parasitic infection leads to 
varying degrees of morbidity for the infected individual. In the case of the filarial nematode 
Onchocerca volvulus, the circulating microfilariae beneath an infected individual’s skin can 
causes debilitating adverse effects ranging from itching to severe dermatitis and vision loss [2]. 
Persistent infection with gastrointestinal parasitic nematodes in humans is associated with 
chronic and long term health problems such as anemia, stunted growth, nutritional deficiency 
and cognitive deficiencies [3, 4] which can lead to lifelong adverse effects. Pre- and school aged 
children tend to harbor the greatest parasite burden than any age group [1]. As a result, the 
negative health impact for these children can be chronic and long-lasting [1]. For example, 
hookworm infection in children can lead to reduced memory and cognition [4] resulting in 
diminished educational performance, school attendance [5], and ultimately a reduction in the 
future wage-earning capacity [6].  
Aside from the detrimental effects parasitic nematodes have on human health and quality of 
life, they also inflict a heavy toll on economics. For example, the parasitic roundworm Ascaris 
suum, which inhabits the pig intestine, results in an estimated $155 million economic loss 
annually in the US swine industry alone [7, 8]. In agriculture, crop loss due to plant parasitic 
nematodes is estimated to be over $100 billion annually [9].  
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The health implications associated with parasitic nematodes are significant. In the absence of 
effective vaccines to prevent and guard against infection in both human and animals, the burden 
of controlling parasite infection and alleviating symptoms falls on chemotherapeutic drugs [10]. 
Although a variety of anthelmintic drugs are currently available such as ivermectin, 
benzimidazoles, and levamisole [11], in comparison to the number and diversity of parasitic 
nematodes, the available drugs are few.  
To further complicate the matter, the development of new anthelmintic drugs is slow in 
coming. Of the 1,556 new chemotherapeutic compounds brought to market between 1975 and 
2004, only two, albendazole and ivermectin, were developed to treat human parasitic nematodes 
[12, 13].  
The limitation mentioned above is evident in lymphatic filariasis for which available 
chemotherapeutic options are limited to two drugs, ivermectin and diethylcarbamazine (DEC) 
[14].  While both drugs are efficient in eliminating the microfilariae from the host body, neither 
can eliminate the adult parasite from the host [15 - 17].  
Intensive use of the limited drug types in veterinary health have led to instances of drug 
resistance with resistance reported for broad spectrum anthelmintics such as albendazole, 
levamisole, and ivermectin as well as to narrow spectrum anthelmintics such as closantel [18]. 
Although to date no anthelmintic drug resistance has conclusively been documented in human 
health, the potential is a continual concern. For example, the nicotinic acetylcholine receptor 
targeted drug, levamisole, was introduced in 1970 and resistance was reported in 1979 in 
Trichostrongylus colubriformis and Ostertagia circumcincta [10, 301]. Similarly, one of two 
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available drugs for filarial worm control, ivermectin, was introduced in 1981 and resistance was 
reported seven years later in 1988 in Haemonchus contortus [10, 302].  
Similar situations have been documented for the various other wide spectrum anthelmintics 
such as benzimidazole and a relatively recently introduced macrocyclic lactone, moxidectin [10].    
The limited number and effectiveness of available anthelmintic drugs against parasitic 
nematodes, along with the potential for drug resistance, brings to light the urgent need for new 
and more effective anthelmintic drugs. But the development of new and more efficient 
anthelmintic drugs requires a thorough understanding of both parasitic nematode biology and the 
mode of action of currently available drugs.  
The paucity of understanding of the mechanism of action for anthelmintic drugs is evident in 
the case of the filarial worms where the pharmacological mode of action for ivermectin and DEC 
is not fully understood [19]. Although ivermectin has been found to act as an agonist at 
invertebrate glutamate-gated chloride channels [20], paradoxically the in vitro treatment of 
cultured microfilariae with ivermectin at pharmacologically relevant concentrations did not 
produce an effect consistent with our understanding of this channel [21]. Thus the effect of 
ivermectin on filarial worms may not be primarily a result of action mediated through the 
glutamate-gated chloride channels as is more likely the case in adult and larvae of other 
gastrointestinal and lung worms that exhibited inhibition of both body motion and feeding when 
treated with the drug [19]. Similarly, the mode of action for DEC after over 60 years of use 
remains a mystery [19]. To date no candidate receptor for DEC has been found [19]. In 2005, 
McGarry et al. found pharmacological and genetic evidence that implicates DEC interaction with 
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both host arachidonate- and nitric oxide- dependent pathways in eliciting the anti-filarial effect, 
but how DEC interacts with these pathways remains unknown [22].  
In conclusion, parasitic nematodes inflict debilitating and potentially lifelong morbidity and 
mortality on infected individuals as well as cause global economic losses [8, 9]. With the limited 
quantity and effectiveness of available drugs, new drugs need to be developed. In order for the 
efficient development of new and novel anthelmintic drugs to combat parasitic nematode 
development, better understanding of parasitic nematode biology and pharmacology of current 
anthelmintic drugs is needed. One family of parasitic nematodes that is in need of more potent 
and efficient anthelmintic chemotherapeutic agents is filarial nematodes.  
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II. BRIEF INTRODUCTION TO THE LYMPHATIC FILARIASIS PROBLEM 
Lymphatic filariasis (LF) is a disease caused by filarial nematodes, primarily Wuchereria 
bancrofti (90% of cases) and Brugia malayi (10% of cases) [23], which are transmitted through 
the bite of infected mosquitoes. In 1997, the World Health Organization identified lymphatic 
filariasis as the second leading infectious cause of permanent and long-term disability [24], and 
the World Health Assembly’s International Task Force for Disease Eradication identified 
lymphatic filariasis as one of six potentially eliminable diseases [25].  
It has been estimated that 120 million people, or approximately 2% of the global population, 
are infected with LF and 1.2 billion at risk of infection in 81 endemic countries [24, 26]. LF is a 
health problem that has accompanied humans throughout history [27] causing crippling 
morbidity and debilitating stigmatization that perpetuates socioeconomic instability.  
A. Pathogenesis of Lymphatic Filariasis 
Filarial worm infection causes damage to the individual’s lymph system and induces lymph 
vessel dilation [28-35]. Damage to the lymphatic system is caused by a combination of 
mechanical [36, 37] and induced [28-35] damage. The subsequent release of microfilaria larvae 
further stimulates lymph vessel dilation as the host innate immune response is triggered by 
phagocytosis of degenerating microfilariae [28, 32, 35]. Furthermore, antigen from the filarial 
worm endosymbiont Wolbachia also contributes to the pathogenesis of lymphatic filariasis 
through stimulation of host immune responses [38].  
Despite damage to the lymph system, most infected individuals do not develop clinical 
symptoms and in many cases, these individuals are unaware that they are infected [23]. In 
general, these individuals tend to have high parasitemia (as measured by circulating microfilariae, 
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the stage of the parasite that is taken up by the vector) and a down-regulated immune response 
associated with the significant lymph damage, despite a lack of visible clinical symptoms [39-43].  
Among infected individuals in endemic regions, approximately 12.5% exhibit clinical 
symptoms, primarily lymphedema [44], where the lymph vessels become dilated and inefficient 
at transporting lymph leading to fluid extravasation into the surrounding tissues [38]. 
Lymphedema can occur in the legs and arms of the infected individual, but it can also occur in 
the breast as well [45]. In addition to the accumulation of fluid in the arm, leg, breast and/or 
scrotum resulting from an impaired lymph system, bacterial infection of the skin and lymph 
system readily takes place resulting in pachyderma, the thickening and hardening of the affected 
skin [52]. 
B. Socio-Economic Impact of Lymphatic Filariasis 
It is estimated that 5 million Disability Adjusted Life Years (DALY) are lost yearly to 
lymphatic filariasis [53]. The annual economic loss due to LF disability is estimated to be 
approximately $1 billion but these estimates are likely underestimated [53]. A study comparing 
the productivity of male weavers in rural India determined that a 27.4% productivity loss is 
attributed to chronic LF [54].  
In addition to the economic loss associated with chronic filarial worm infection, the infected 
individual also faces significant social stigmatization. Social shame, fear, and embarrassment are 
common psychological traumas endured by infected individuals [55]. Individuals report 
suffering from shame and suicidal thoughts, and marriages are often devoid of physical intimacy 
[55].  
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In conclusion, LF causes significant morbidity as a result of damage to the lymph system of 
infected individuals, and significant economic losses to the community. In addition, for the 40 
million infected individuals that exhibit clinical symptoms of lymphatic filariasis such as 
elephantiasis and hydrocele, social stigmatization is a daily burden.  
C. Biology / Life Cycle of Brugia malayi 
The development of juvenile microfilaria to the infectious L3 stage takes place within the 
mosquito intermediate host while maturation and propagation occur in human and a few other 
mammalian definitive hosts [56].  There are several genera of mosquitoes that are natural vectors 
for the filarial worms that cause LF, including: Aedes, Anopheles, Culex, and Mansonia [56].  
Larvae Development within the Mosquito Intermediate Host 
Susceptible mosquitoes become infected with filarial worms by ingesting juvenile 
microfilariae during the blood meal. Once ingested, the microfilariae sense temperature and 
environmental changes [57-60] and quickly penetrate the midgut epithelium such that they gain 
access to the hemocoel within hours of ingestion [25]. Once the microfilariae penetrate through 
the midgut epithelium, they migrate in the hemolymph toward the thoracic musculature [56].  At 
the thoracic musculature, the microfilariae penetrate and take up harborage within indirect flight 
muscle cells and differentiate into non-feeding sausage-shaped L1 larvae [56, 62]. Within the 
infected indirect flight muscle cell, the parasite undergoes the L1 to L2 molt. The L2 stage 
parasites actively ingest mosquito cellular components and multiply several times in size before 
undergoing one more molt into the L3 infectious stage and exit the cell (Figure 1) [61]. Filarial 
worm parasites within the mosquito host grow several times in size from a microfilaria of ~200 
µm to the infectious L3 larva of ~ 1,350 µm in length [62]. The development from microfilariae 
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to L3 infectious parasite within the mosquito takes approximately 10 to 12 days depending on 
environmental factors such as temperature [56]. 
Ultrastructural studies of infected Aedes flight muscle cells reveal that the cell undergoes 
nuclear enlargement, indicative of a repair response, while the parasite develops within the cell 
[61]. But once the developing larvae mature to the L3 stage and exits the cell, the severely 
compromised cell undergoes degeneration [61]. Upon exiting the indirect flight muscle cell, the 
L3 infectious parasites migrate to the head and proboscis of the mosquito where they wait until 
the mosquito takes a blood meal [56]. During the blood meal, the L3 will exit by penetrating 
through the labellum of the mosquito proboscis onto the host skin residing within a drop of 
mosquito hemolymph [56]. The infectious L3 parasites then infect the human/mammalian host 
through entry by the mosquito puncture hole [56, 62].  
Filarial Worm Development within the Mammalian Host 
Within the human/mammalian host, the infectious L3s migrate to the lymphatic vasculature 
where they undergo two additional molts into L4 then adult worms [56]. Within the lymphatics, 
the mature male and female filarial worms, whose life span is 5-15 years, mate. The mated 
female worms then produce large quantities of immature progeny microfilariae that are released 
into the blood stream for a new mosquito host to take up and perpetuate the transmission cycle 
(Figure 1) [63].   
In summary, microfilariae released by adult female filarial worms are taken up by 
mosquitoes during a blood meal. Microfilariae develop into infectious L3 in the course of 
roughly two weeks within the mosquito intermediate host. Upon blood feeding, the infectious L3 
exit through the proboscis of the mosquito and enter the mammalian host using the puncture hole 
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made by the mosquito. Once inside the mammalian host, worms develop into the adult lymphatic 
filarial worm and reside within the host lymphatic system for upwards of 15 years. Within the 
host lymphatic system, mated female filarial worms will produce progeny and perpetuate the 
cycle.  
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Figure 1: Brugia malayi life cycle. (1) The infective mosquito carrying infectious 
L3 Brugia malayi larvae (~1,350 µm in length) takes a blood meal. The L3 larvae 
burrow out of the mosquito’s proboscis onto the host skin and reside in a pool of 
mosquito hemolymph. The L3s enter the host via the mosquito puncture hole and 
migrate to the host lymphatic system where they undergo two additional molts 
into L4 and finally adult parasites. (2) Within the lymphatics, the male and female 
Brugia malayi mate and the female produce microfilariae (mf) of approximately 
200 µm in length. (3) The mf migrates into the lymph and blood stream. (4) An 
uninfected mosquito takes a blood meal from a microfilariamic individual taking 
up the mf. (5) The ingested mf rapidly penetrates through the midgut epithelium 
within 2 hours and migrates toward the thoracic musculature. (6) Microfilariae 
penetrate and take harborage within the indirect flight muscle cell and 
differentiate into non-feeding L1 larvae 6 hrs to 3 days post mosquito infection. 
The L1 larvae molts into the L2 larvae, which actively feed off intracellular 
component 3 to 5 day post mosquito infection. (7) The L2 larvae molt into 
infectious L3 larvae. (8) The developmentally arrested L3 larvae exit the indirect 
flight muscle cell and migrate into the head and proboscis of the host mosquito 
starting as early as 8 days post infection depending on environmental condition. 
Images from Erickson, et al. (2009) [62] and CDC (2010) [76]. Images 
reproducible under the Open Access Creative Commons Attribution License.  
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D. Global Effort in the Control of Lymphatic Filarial Infection  
Despite decades of effort and promising research results [64-69], a vaccine against a filarial 
worm has yet to emerge. Vector controls have been considered and proven effective in certain 
geographically isolated locations such as the Solomon Islands where both malaria and filarial 
worm transmission have been reduced, with prevalence of microfilaremia reduced to less than 2% 
[70]. Unfortunately, vector control is both labour intensive and costly [71]. The rapid 
development of insecticide resistance further challenges the success of vector control programs 
[72]. Despite its draw backs, vector control when accompanied with chemotherapeutic drug 
treatment have been shown to be significantly more effective at interrupting transmission than to 
vector control alone [300]. Thus it would appear chemotherapy will continue to play an integral 
role in transmission control [68, 300]. 
Chemotherapeutic Efforts  
Prior to the Global Programme to Eliminate Lymphatic Filariasis (GPELF) and associated 
Mass Drug Administration (MDA) programs, chemotherapeutic control of lymphatic filarial 
worm transmission for mass population in endemic regions relied on the use of 0.1 to 0.4% 
diethylcarbamazine (DEC) fortified salt. This concept was first introduced in 1967 and employed 
in Brazil when Hawking and Marques found that DEC is stable even after cooking [73]. This 
method has since been successfully carried out in parts of China, Taiwan and India [74]. In one 
county in Shandong, China, the use of 0.24% DEC fortified salt reduced the microfilaremia rate 
from 9% to less than 1% after 6 months of use [74]. The success of DEC fortified salt programs 
requires considerable effort to ensure the cooperation of salt manufactures and local officials as 
well as the effective prevention of individuals acquiring non-medicated salt, as in the case of 
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Papua New Guinea where food is often prepared using seawater, thereby  rendering the use of 
DEC fortified salt ineffective [72].  
DEC, which has been used to treat filarial infection since 1947 [75], is widely used in regions 
not co-endemic with other filarial worms such as Onchocerca volvulus where its use is 
contraindicative as it can lead to severe and fatal post-treatment reactions [72]. DEC 
administration to patients who also have onchocerciasis have lead to the worsening of 
onchocerciasis related vision-loss [76]. In co-endemic regions, ivermectin is used in place of 
DEC [45]. The use of ivermectin on patients co-infected with O. volvulus is generally safe but in 
rare incidences serious and sometimes fatal adverse reactions have occurred [19], but the 
pathogenesis for this toxic syndrome in humans has yet been resolved [77, 78].  
The current Global Programme to Eliminate Lymphatic Filariasis (GPELF) effort to alleviate 
morbidity and eliminate transmission of the lymphatic filarial worms uses annual administration 
of oral anti-filarial drug combinations to endemic or at risk communities through the MDA 
program [79]. Depending on the co-endemic situation, either DEC or ivermectin is given in 
conjunction with the benzimidazole anthelmintic, albendazole [24]. Albendazole administered 
alone to infected individuals appears to be ineffective as either a microfilaricide or 
macrofilaricide, but when administered together with ivermectin or DEC, albendazole appears to 
enhance the effectiveness of the two drugs [80].  
GPELF Progress, Success and complications 
In the first 8 years of the GPELF program from 2000 to 2007, approximately 570 million 
infected and at risk individuals in 48 lymphatic filariasis endemic countries were treated through 
the MDA program. Based on the report an estimate of approximately 6.6 million newborns were 
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spared filarial worm infection [81]. An added benefit of the MDA program is that ivermectin 
ingested from a treated individual by mosquitoes resulted in decreased mosquito survival rate 
and fertility [82, 83, 84] thus reducing the number of vector hosts for filarial worm transmission.  
Despite the success of GPELF reported so far, there is no convincing evidence that the 
GPELF goal of complete lymphatic filarial worm elimination can be achieved [45]. For one, the 
lack of cooperation or inappropriate use of anti-filarial drugs by at risk or infected individuals 
poses a significant challenge for the success of the GPELF program. In the case of patients in the 
Colombo district of Sri Lanka, only 61% reported taking the recommended DEC treatment 
course [299]. Further challenges to the GPELF program effort arise when socio-economic 
troubles such as regional conflicts and famine force infected populations to migrate into regions 
without MDA coverage.  
Problem with Current Chemotherapeutic Drugs  
To complicate matters further, at present DEC and ivermectin are the two only drugs safe for 
human use without incurring any serious adverse side effects. Unfortunately both drugs are only 
effective as microfilaricides. Unlike ivermectin, which appears to have little to no 
macrofilaricidal activity against adult filarial worms, DEC has been found to kill up to 40% of 
the adult worms [45, 86, 87], but this macrofilaricidal activity of DEC is insufficient to cure an 
infected individual. 
To date, the mechanism of action for ivermectin and DEC remains uncertain. Ivermectin has 
been found to act on glutamate-gated chloride channels in free-living nematodes as well as 
certain gastrointestinal parasitic nematodes, inhibiting the motility and feeding capacity of these 
worms [19, 20]. In culture, microfilariae of human lymphatic filarial nematodes appear 
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unaffected by clinically significant concentration of ivermectin [21, 88, 89]. The reason for this 
has yet to be resolved. Thus the pharmacological basis for the microfilaricidal effect of 
ivermectin remains poorly understood. Similarly, the pharmacological basis of DEC, which was 
introduced in 1947, remains a mystery. Recent work by McGarry et al. found pharmacological 
and genetic evidence implicating the host arachidonate- and nitric oxide-dependant pathways in 
the microfilaricidal and limited macrofilaricidal effect of DEC [22].  
In conclusion, lymphatic filariasis causes significant socio-economic losses and morbidity. 
The GPELF effort to eliminate lymphatic filariasis relies on the mass drug administration of 
either ivermectin or DEC, the two only anti-filarial drugs available, along with albendazole 
which have been found to enhance the potency of the two anti-filarial drugs. Due to the 
effectiveness of ivermectin and DEC only as a microfilaricide, the only current option for 
eradicating lymphatic filariasis is to prevent worm transmission. This does not do much for the 
12.5% of the 120 million infected individuals suffering from lymphadema. Due to the long 
lifespan of adult filarial worms and problems associated with patient noncompliance, the 
availability of an efficacious microfilaricide would both simplify control and facilitate 
eradication. Limited understanding of filarial worm biology and the mode of action for existing 
drugs challenge our ability to develop more effective anti-filarial drugs.  
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III. A BRIEF OVERVIEW OF RNA INTERFERENCE 
First characterized by Fire et al. in 1998 on the free-living nematode Caenorhabditis elegans¸ 
RNAi allows investigators to suppress specific genes of interest using RNA triggers to mediate 
target-specific mRNA destruction resulting in transcriptional suppression [94]. This relatively 
new technique provides a simple and inexpensive tool for reverse genetics on difficult to 
manipulate organisms such as parasitic nematodes [90-92]. Despite the difficulty experienced so 
far, RNAi in parasitic nematodes has the potential to assist in elucidating the biology of parasitic 
nematodes and anthelmintic drug mode of action paving the way for the development of new and 
more efficient anthelmintic drugs.  
A. The RNAi Mechanism 
RNAi is elicited either when exogenous long double-stranded RNA (dsRNA) is introduced 
into the cell or when endogenous dsRNA / short hairpin RNA (shRNA) is produced 
intracellularly, and then processed into short interfering RNA (siRNA) duplexes of 21~23 base 
pairs (bps) in length, called primary siRNA, by the RNaseIII endoribonuclease enzyme Dicer. 
Synthetic siRNA can also be applied exogenously to bypass Dicer and substitute for primary 
siRNA. Primary siRNA can either be incorporated into the RNAi-induced Silencing Complex 
(RISC) or be used in RNAi signal amplification through RNA Dependent RNA Polymerases 
(RdRP) to produce secondary siRNAs [95, 96]. Gene specific suppression is elicited via 
targeting mRNA cleavage by RISC which consists of the incorporated siRNA guide strand and 
several other essential components, one of which is a catalytic Argonaute protein (Figure 2) [95, 
96]. 
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Figure 2: RNAi Pathway. Exogenous siRNA or dsRNA is taken up into the cell 
whereby DICER processes dsRNA into primary siRNA. RNA Dependent RNA 
Polymerase (RdRP) utilizes the primary siRNA or exogenous siRNA as template 
for RNAi signal amplification. The amplified siRNA (Secondary siRNA), 
Primary siRNA and/or exogenous siRNA is incorporated into the RNA-induced 
Silencing Complex (RISC) to mediate gene specific suppression through 
cleavage of the target mRNA.  
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B. Uptake of RNAi Trigger 
The mechanism of dsRNA uptake, or how the exogenous RNAi trigger enters the cell, is 
most extensively studied in C. elegans. Among the currently identified proteins mediating 
dsRNA uptake is Systemic RNA Interference Deficient (SID)-2 [98, 102].  SID-2 deficient C. 
elegans mutant are resistant to both RNAi via soaking and feeding, but fully susceptible to both 
the microinjection and transgenic RNAi methods [98]. Expressing C. elegans SID-2 in C. 
briggsae, which is refractory to environmentally supplied RNAi triggers, restores RNAi 
susceptibility, but expression of the C. briggsae ortholog of the C. elegans SID-2 protein in C. 
elegans SID-2 mutants does not rescue the dsRNA uptake capability [98].   
Several other protein families related to the dsRNA uptake mechanism have been found: 
Feeding Defective (FED) [103] and RNAi Spreading Defective (RSD) [104]. Both FED and 
RSD family mutants are refractory to RNAi induced by feeding on dsRNA-producing bacteria 
[103, 104]. Based on the structure and interaction of RSD family proteins it would appear that  
ingested dsRNA is endocytosed by vesicles through the gut lumen [105, 106].  
C. Dissemination of RNAi Signal 
Studies done by Feinberg and Hunter using transgenic C. elegans expressing GFP in both the 
pharynx and body wall muscles demonstrated the capacity for an RNAi trigger, introduced by 
bacteria feeding, to disseminate to the body wall muscles [108]. Further experimentation on SID-
1 mutants showed that with SID-1 mutants only GFP expression at the pharynx (site of dsRNA 
uptake) was silenced indicating an incapability to disseminate the silencing signal [108]. Thus 
SID-1 is important for the systemic spread of RNAi trigger.  
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To determine whether SID-1 is responsible for the export or import of RNAi trigger, SID-1 
protein was functionally expressed in Drosophila cells, which lack both an SID-1 homology as 
well as efficient dsRNA uptake mechanism [109], enabled rapid uptake of environmental dsRNA 
[109]. The presence of the RNAi trigger cellular export mechanism has been confirmed [105], 
but its identity remains elusive.   
D. Primary siRNA Biogenesis 
Before RNAi can take place, the internalized dsRNA needs to be first processed into short 
(21 to 30 nucleotide) siRNA duplexes [113-117]. The processing of dsRNA into siRNA is 
primarily mediated by the Dicer complex which contains the ~200 kDa RNaseIII enzyme, Dicer. 
[118]. 
In C. elegans, four components form the Dicer complex [204] to process long dsRNA into 
short siRNA [119, 120, 204]: the dsRNA binding protein (dsRBP) Rde-4, the PAZ (Piwi, 
Argonaute and Zwille)-PIWI (P element-induced wimpy testes) Argonaute protein Rde-1, the 
catalytic enzyme Dicer, and a DexH Box Helicase Drh-1 (Figure 2). Following siRNA 
processing, the PAZ-PIWI Argonaute protein, Rde-1, binds to the processed siRNA duplex and 
transports it to appropriate downstream RNAi pathway complex [170] (Figure 3). 
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Figure 3: Schematic representation of the siRNA synthesis mechanism. In C. 
elegans, exogenously supplied dsRNA is processed into siRNA by the Dicer 
Complex consisting of the dsRNA binding protein (dsRBD) Rde-4, the PAZ (Piwi, 
Argonaute and Zwille)-PIWI (P element-induced wimpy testes) Argonaute 
protein Rde-1, the catalytic enzyme Dicer, and a DexH Box Helicase Drh-1. The 
PAZ-PIWI Argonaute protein, Rde-1 binds to the siRNA products and transports 
them to downstream elements of the RNAi pathway. 
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The Catalytic Enzyme Dicer 
The endonuclease Dicer protein, which functions as a monomer [116], consists of two 
conserved RNase III domains, a dsRBD located in the carboxyl terminus, an amino terminal 
DExH/Helicase-box domain, a small domain DUF283 of unknown function, and a PAZ domain 
[125].  
Incorporating Exogenous dsRNA onto DICER Protein 
The exogenous dsRNA, which tends to be blunt on both ends, initially undergoes a 
nonspecific cleavage to produce 3’ dinucleotide overhangs thus allowing it to be anchored in the 
3’ overhang binding pocket of the PAZ domain [127]. In vitro studies on human Dicer indicate 
that Dicer produces siRNA unidirectionally from one end of the dsRNA substrate to the other 
through processive dicing [128].  
PAZ Domain of Dicer 
The PAZ domain, which contains roughly 130 residues, serves to anchor the 3’ end of the 
dsRNA, rendering it stationary and thus making it possible for subsequent cutting of the dsRNA 
to produce siRNA of a fixed length [129].  
DExH/Helicase Box Domain of Dicer Protein 
Kinetic analysis on wild type and mutant human Dicer complex indicates that the 
DExH/Helicase-box domain function to inhibit Dicer catalytic activity since removal of the 
DExH/Helicase-box domain from Dicer increased Dicer production of siRNAs [127, 130].  
Internal Molecular Ruler of Dicer 
In Dicer the distance between the PAZ and the two RNaseIII domains acts as a molecular 
ruler [127]. In Giardia intestinalis Dicer, the distance between the PAZ and the two RNaseIII 
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active sites is 65Å, equivalent to a 25 nucleotide long RNA duplex, which is exactly the same 
length as G. intestinalis Dicer’s siRNA product length [127, 205]. This was validated using 
truncated G. intestinalis Dicer complex lacking the PAZ domain, which resulted in the 
production of siRNA products of varying length [127, 205]. This explains the variation in 
product size across different organism species and Dicer enzymes.  
E. Secondary siRNA / RNAi Signaling Amplification  
In C. elegans, primary siRNA generated by Dicer is further amplified via a cytoplasmic RNA 
Dependent RNA Polymerase (RdRP) [131, 132, 135-137]. This amplification step, which occurs 
in the presence of target mRNA, is essential in eliciting the RNAi effect in C. elegans because 
inhibiting secondary siRNA synthesis resulted in a lack of RNAi [131-133]. Using transgenic C. 
elegans over-expressing unc-22:GFP chimeric mRNA at the intestine, Jose and Hunter 
demonstrated  the presence of RNAi signal amplification when unc-22 mutant phenotype was 
observes with GFP suppression despite the lack of unc-22 functions at the site of unc-22:GFP 
expression (unc-22 function in the body wall muscles) [100].  
In C. elegans, the Argonaute Protein Rde-1 Transports Primary siRNA from Dicer 
Complex and Recruit the Formation of RDRP Complex to Make Secondary siRNA 
In C. elegans, the PAZ-PIWI Argonaute protein Rde-1 selectively binds to the siRNA strand 
that is thermodynamically less stable at the 5’ end called the guide strand [138, 139] and 
dissociates from the Dicer complex [204]. The dissociated Rde-1 + siRNA duplex complex 
triggers the formation of the secondary siRNA amplification machinery to produce secondary 
siRNAs (Figure 4) [140]. 
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Figure 4: Secondary siRNA Synthesis. The PAZ-PIWI Argonaute Rde-1 binds 
to Dicer produced primary siRNA and dissociates from the Dicer Complex. Rde-1 
triggers the formation of the RNA Dependent RNA Polymerase (RdRP). RdRP 
attaches onto a target mRNA and produces RNAi signal amplification in the form 
of secondary siRNAs.  
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In the Rde-1 assembly, the passenger strand can be viewed as the guide strand’s first RNA 
target [138, 139, 158]. After discarding the passenger siRNA strand, the conformation of the 
Argonaute protein is one where the seed region (bases 2 to 6 from the 5’ end of the guide strand) 
is arranged so that it is fully exposed and protruding outward toward the intracellular 
environment [166, 167] allowing for the efficient locating of target mRNA [168]. 
Upon binding to a target mRNA, bases 2-8 of the guide strand starting from the 5’ end form a 
Watson-Crick paired A-form double helix with the complementary region of the target mRNA 
[168, 169]. Simultaneously, RDE-1 recruits the amplification machinery RdRP to the target 
mRNA to perform unprimed RNA synthesis of secondary siRNA [114, 133]. The secondary 
siRNA is characteristically different from primary siRNA in that it possess a 5’ triphosphate as 
opposed to a 5’ monophosphate end [114, 133], it is slightly shorter in length than primary 
siRNA, and it cleaves target mRNA more efficient than primary siRNA [170]. The secondary 
siRNA can either re-enter the RdRP associated pathway to further amplify the RNAi signals or it 
can be incorporated into RISC and facilitate in RNAi mediated mRNA cleavage [170]. 
Regulation of the Secondary siRNA Synthesis Mechanism 
The existence of a secondary siRNA synthesis mechanism appears to be an essential step in 
the RNAi machinery, but it needs to be carefully controlled to prevent adverse problems such as 
amplification of off-target silencing signals in the absence of target mRNA. To guard against this, 
the RdRP amplification mechanism only takes place in the presence of target mRNA [133, 171]. 
To prevent the exponential growth of RNAi triggers leading to persistent gene suppression, a 
class of argonaute proteins called Secondary Argonaute Proteins (SAGO), which lack the 
catalytic residues for cleaving target mRNA, bind to and reduce the number of available siRNA 
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for further amplification [172]. Other RNAi control mechanisms exist to prevent escalating 
RNAi signal amplification and they will be discussed later.  
F. RNAi – induced Silencing Complex (RISC)  
RISC is the heart of the RNAi machinery. RISC identifies and binds to target mRNA using 
the incorporated siRNA guide strand and carries out endonucleolytic cleavage of target mRNAs. 
The cleaved mRNA is then released and degraded through exonuclease activity, resulting in the 
reduction of post-transcriptional gene expression [118]. 
As with secondary siRNA synthesis, siRNA duplexes are loaded in a selective orientation 
based on the asymmetry rule [173], allowing the strand with the thermodynamically less stable 5’ 
end to serve as the guide strand [138, 139]. The asymmetry rule in which the guide stand is 
selected depends on the thermodynamic stability of the first 4 bases of each strand [138, 139]. 
The incorporation of the siRNA duplex requires the aid of the RISC Loading Complex (RLC) 
[174, 175].   
G. RISC Loading Complex (RLC) 
At the heart of RLC is the Dicer + dsRBP heterodimer [160, 161, 176]. In the case of 
Drosophila, the absence of Dicer-2 and dsRBP R2D2 results in a deficient RNAi machinery in 
both in vivo and in vitro models [177, 178]. But when Dicer-2 is restored in vivo through 
transgenic expression or supplemented with Dicer-2 and R2D2, the RNAi machinery is restored 
[177, 178]. In addition to the Dicer-2 + R2D2 heterodimer, the Drosophila RLC appears to be 
comprised of several other factors based on the slower migration speed of extracted Drosophila 
RLC on native gels [161, 162]. However, what these additional factors are remains a mystery.  
26 
 
 
 
Sontheimer and colleagues demonstrated that during siRNA loading of the Drosophila 
Argonaute (Ago)-2, the Argonaute protein associates with Dicer-2 and R2D2 in forming the 
RISC complex [179]. The unique binding feature of the Dicer-2 + R2D2 heterodimer allows for 
the preferential incorporation of the guide strand onto the Argonaute protein [138, 139, 180]. 
Dicer-2 holds the 3’ dinucleotide overhang of the passenger strand (the strand with the 3’ end at 
the thermodynamically less stable end of the siRNA duplex) leaving the 5’ end of the guide 
strand free to be incorporated onto the argonaute protein. At the same time, R2D2 binds to the 
more stable 5’ end of the passenger strand [138, 139, 180].  
All Argonaute proteins identified to date contain a PAZ domain, which has a large binding 
pocket for the 3’ dinucleotide overhang insertion [129]. Therefore it is most likely that in loading 
the siRNA duplex onto Argonaute, the 3’ overhang of the guide strand will be loaded into the 
Argonaute PAZ domain which requires the 5’ end of the passenger strand to be immobilized by 
R2D2. Similarly, the 5’ end of the guide strand whose complementary 3’ is held by Dicer-2 is 
incorporated into the deep pocket between the Argonaute MID and PIWI domain (Figure 5) [149, 
150].  
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Figure 5: Loading of siRNA duplex onto Argonaute. Dicer-2 of RLC binds to 
the 3’ end of the passenger strand (strand that does not have the 5’ 
thermodynamically less stable end) and R2D2 binds to the passenger strand’s 5’ 
end. The Argonaute PAZ domain binds to the 3’ end of the guide strand and the 
thermodynamically less stable 5’ end of the siRNA duplex is held at the pocket 
between the MID and PIWI domain.  
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H. RISC Function 
As in secondary siRNA synthesis, once the guide strand is loaded onto the argonaute protein 
of RISC, the passenger strand acts as a RNA target [158]. Once the passenger strand is cleaved 
and discarded, the RISC complex is ready to actively seek out target mRNAs for destruction.  
The “seed region” of the guide strand, base pairs 2 to 6 from the 5’ end, is arranged in a near 
A-form conformation in the RISC complex protruding outward in an exposed orientation [166, 
167]. Upon complementary binding to a target mRNA, the PIWI domain of the Argonaute 
protein initiates target RNA cleavage through nucleophilic attack between bases 10 and 11 of the 
guide strand from the 5’ end [95, 154]. 
I. Regulating the RNAi Mechanism 
While much has been pieced together about the mechanism leading up to the RNAi mediated 
mRNA cleavage, very little information is known about how RNAi is regulated. All 
experimental data indicate that RNAi is transient with the exception of certain targeted genes in 
C. elegans whereby gene suppression is hereditary. At present, only bits and pieces of 
information exist to give a glimpse as to RNAi regulation.  
One regulatory process is the expression of siRNA degradation proteins such as Enhanced 
RNAi (Eri)-1 in C. elegans [181]. In Eri-1 mutants, the presence of higher than normal 
concentrations of siRNA were noticed indicating either that more secondary siRNA are produced, 
or siRNA degradation is inhibited. Because Eri-1 is an evolutionary conserved protein containing 
a SAP/SAF-box domain and a DEDDh family exonucleases domain, it is highly probable that 
the function of Eri-1 is siRNA degradation [181]. Furthermore the nerve tissues cells of C. 
elegans, where Eri-1 is preferentially expressed, are refractory to RNAi, but in Eri-1 mutants 
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exogenously supplied dsRNA can elicit RNAi [181]. Thus neuronal tissue resistance to RNAi 
may be partially attributed to Eri-1 degradation of silencing triggers and in doing so preventing 
siRNA amplification and subsequent RNAi at a detectable level [181]. 
Another mechanism regulating RNAi is adenosine deaminase. The gene product of 
Adenosine Deaminase that Acts on RNA (ADAR) mutates the adenosines in the dsRNA into 
inosine. The progressively increasing amount of A-U pairs converted to I-U wobble pairs render 
the deaminated dsRNA more and more resistant to Dicer [182, 183]. Thus ADAR, like Eri-1, 
modulates RNAi by reducing the level of silencing trigger available for amplification and RISC 
assembly. Without an adequate supply of new RNAi triggers, the aforementioned RNAi 
regulation methods would result in the eventual removal of RNAi triggers. In addition, Tudor-
SN substrate binds to and promotes the degradation of hyper-edited dsRNA.  
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IV. HISTORY OF RNAi IN PARASITIC NEMATODES 
RNA interference was originally characterized in the free-living nematode Caenorhabditis 
elegans by Fire et al. in 1998 and emerged as a new technology to down-regulate target genes of 
interest using gene specific, double-stranded RNA (dsRNA) [94]. The RNAi technique has since 
been demonstrated in various other organisms including protozoa [184, 185], amphibians [186], 
insects [187, 188], and mammals [189]. Based on the successful implementation of RNAi in 
numerous organisms, it is logical to try and transfer the technology for use in the field of 
parasitic nematodes.  
In C. elegans, the RNAi triggers (dsRNA or siRNA) can be delivered by several methods: 
microinjection, soaking, feeding of dsRNA-expressing bacteria, and electroporation. Although 
all four methods are effective in C. elegans, other Caenorhabditis species such as C. briggsae 
demonstrated varied susceptibility to both the soaking and bacteria feeding methods [190]. As 
such, to date the “gold standard” for RNAi in Caenorhabditis species remains microinjection.  
In applying RNAi to parasitic nematodes of both human and veterinary interest, the use of a 
microinjection method would be impractical. In 2002, Hussein et al. utilized RNAi soaking 
method on the rodent gastrointestinal parasitic nematode Nippostrongylus brasiliensis [191]. The 
successful suppression of the secreted acetylcholinesterase B (AChE B) in adult N. brasiliensis 
was achieved. 1799 bp dsRNA derived from the full length AChE B cDNA suppressed AChE B 
mRNA level by 80%. The suppression was immediate, beginning on the first day of dsRNA 
exposure and rapidly returned to control levels over the next four days. The use of a shorter 240 
base-paired dsRNA that corresponded to the 5’ region of the AChE B coding sequence produced 
a more potent suppression of over 90% and the RNAi effect persisted throughout the 6 day 
culture period. Although no phenotypic abnormalities were observed in worms after either the 
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long or short dsRNA treatment, this experiment provided the first proof that RNAi is feasible in 
parasitic nematodes [191]. 
Following the success of Hussein et al., Aboobaker and Blaxter successfully suppressed three 
genes of interest: β-tubulin (Bm-tub-1), RNA polymerase II large subunit (Bm-ama-1), and mf 
sheath protein 1/mf22 (Bm-shp-1) in the adult filarial nematode Brugia malayi in vitro using a 
soaking protocol. Suppression of all three target genes was confirmed using non quantitative RT-
PCR with lethal phenotype observed for both Bm-ama-1 and Bm-tub-1. dsRNA treatment of 
either Bm-ama-1 or Bm-tub-1 both resulted in unhealthy worms with reduced motility and death 
24 hours post dsRNA treatment began. Suppression of Bm-shp-1 resulted in a marked decrease 
in quantity of mf released in culture. Of the released mf, 50% exhibited fully elongated sheaths 
[112]. 
Following Aboobaker and Blaxter’s successful demonstration of RNAi on the filarial 
nematode Brugia malayi, Lustigman et al. in 2004 carried out a similar in vitro RNAi 
experiment on the human filarial nematode, O. volvulus, to examine the role of cathepsin L and 
Z like cysteine proteases in L3 to L4 molting. Unlike the prior two RNAi experiments, 
Lustigman et al. demonstrated O. volvulus uptake of dsRNA in culture medium by using 
fluorescent-labeled Cy3 dsRNA for cathepsin L (cpl) and cathepsin z (cpz cysteine proteases). 
Cy3 labeled dsRNA was found in the esophagus and along the length of the intestine. In a few 
worms, Cy3 labeled dsRNA was also found in the cuticular and hypodermal regions. Although 
they did not perform RT-PCR to confirm RNAi mediated suppression, suppression was 
confirmed using immunoelectron microscopy. The immunostaining reduced significantly in cpl 
and cpz dsRNA exposed L3 worms in comparison to control worms. Furthermore, exposure to 
cpl or cpz dsRNA resulted in a 92% and 86% inhibition of L3 to L4 molting. In comparison to 
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normal L3 to L4 morphological changes, the dsRNA treated worms examined under electron 
microscopy revealed a lack of separation between the L3 cuticle and the newly synthesized L4 
cuticles. The successful use of RNAi in O. volvulus was another positive step forward 
demonstrating the potential use of RNAi as an investigative tool in studying parasitic nematodes. 
Unfortunately, Lustigman et al. also noted that exposure to the C. elegans homologue of human 
Rh protein, Ce-rhr-1, or O. volvulus cpz intronic sequence Ov-cpz-int2, dsRNA also resulted in a 
49.8% and 30% reduction in molting rate compared to control. This was an indication that RNAi 
in parasitic nematodes may not be as target specific as previously thought, or according to 
Lustigman et al. that it incurs the activation of a non-specific toxic effect by a yet unknown 
mechanism. [2] 
With the successful demonstration of RNAi in three parasitic nematodes from 2002 to 2005, 
interest in RNAi as a potential tool for studying parasitic nematode biology increased such that 
there were  seven publications between 2005 and 2006. All seven publications utilized RNAi 
soaking methods for dsRNA delivery with several groups also exploring the capability of several 
other delivery methods as well.  The results collectively suggested that RNAi in parasitic 
nematodes may not be as straight forward as previous thought. Problems with reliability, 
consistency, and susceptibility arose in some of the parasitic nematode systems examined.  
In 2005, Islam et al. published work investigating an inorganic pyrophosphatase in the pig 
gastrointestinal parasite Ascaris suum (AsPPase). L3 Ascaris suum were soaked in a 
concentration of 2 µg/ml AsPPase dsRNA containing culture medium for 24 hr and maintained 
in a dsRNA free culture medium for an additional 9 days. The dsRNA treatment completely 
abolished AsPPase mRNA level and immunofluorescence staining revealed that dsRNA 
exposure reduced the native enzyme activity by 56.3%. dsRNA exposed L3s also demonstrated a 
33 
 
 
 
reduced L3 to L4 molting by 31% compared to control in the in vitro molting assay. Exposure to 
AsPPase dsRNA resulted in no morphological defects or adverse effect on worm viability [192]. 
Following the successful suppression of cathepsin L and Z-like cysteine protease in the 
filarial worm O. volvulus, Ford et al. identified and investigated the function of a novel filarial 
serine protease inhibitor (Ov-SPI) on L3 stage O. volvulus using the RNAi soaking method 
previously described. A 200-fold suppression of the target gene, Ov-SPI, transcript was observed 
and immunoelectron microscopy confirmed the reduction in Ov-SPI expression. The RNAi 
mediated suppression of Ov-SPI transcript produced an 84.2% reduction in molting and a 39.4% 
L3 mortality compared to control which exhibited only 2.2% mortality. Closer examination of 
the dsRNA exposed L3s that failed to molt revealed incomplete separation between the L3 and 
L4 cuticle. Similar to the previous O. volvulus RNAi experiment, L3 to L4 molting was affected 
by non-target dsRNA though not as dramatically as with target dsRNA (dsRNA of Plasmodium 
falciparum gene Pf-ebe-140 produced a 24.7% reduction in O. volvulus molting) [193]. 
During that same year, RNAi was carried out on the sheep gastrointestinal parasite 
Trichostrongylus colubriformis. Issa et al. attempted RNAi suppression of ubiquitin and 
tropomyosin by soaking, bacteria feeding and electroporation methods with varying success 
[194]. Feeding newly hatched L1 larvae in culture medium with bacteria expressing ubiquitin 
produced no defect on larval development, but ingesting tropomyosin dsRNA expressing 
bacteria resulted in a dramatic reduction in the number of worms developed into the infective L3 
larvae from approximately 80% exhibited by control worms to 20%. Unlike previous RNAi on 
parasitic nematodes, Issa et al. utilized dsRNA as well as siRNA to evaluate the soaking and 
electroporation methods. For soaking and electroporation, only ubiquitin suppression was tested. 
Soaking L1 in ubiquitin dsRNA resulted in no developmental phenotype, but soaking in 
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ubiquitin siRNA resulted in a 69% reduction in number of worms that developed into L3s. 
Electroporation using ubiquitin dsRNA and siRNA both resulted in either death or 
developmental delays in more than 90% of the worms.  Delivery of the RNAi trigger using 
electroporation produced abnormal phenotypes (shrunken and non-motile with granular 
appearance) as early as 2 hours after treatment began. This dramatic phenotypic effect was 
confirmed not to be the effect of electroporation as L1s exposed to either C. elegans ubiquitin 
dsRNA or siRNA produced no significant developmental defects. As the results imply, RNAi did 
take place in certain circumstances, but transcriptional suppression was not confirmed. [194] 
In 2006, two groups independently investigated the feasibility of RNAi in the sheep and goat 
intestinal parasitic nematode, Haemonchus contortus. Kotze and Bagnall tested the potential for 
soaking mediated RNAi gene suppression on L3 H. contortus by targeting two β-tubulin genes of 
interest, tub 8-9 and tub 12-16. A 1000 fold reduction in tub 8-9 transcription level was observed 
that persisted for up to 6 days [195]. The RNAi mediated suppression of tub 12-16 was much 
less dramatic with an approximate 10 fold decrease, but the suppression persisted beyond 6 days. 
The proportion of L3s that developed into L4s in both gene suppression groups was reduced, 
particularly for the tub 12-16 dsRNA exposed group. A migration assay revealed that tub 12-16 
suppression resulted in a reduced migratory ability but tub 8-9 RNAi exhibited no migration 
abnormality. While the successful use of RNAi on H. contortus adds another parasitic nematode 
to the growing list of RNAi tractable parasitic nematodes, the target specificity of the RNAi 
method is called to question as significant off-target suppression of none target genes were 
observed [195].  
Simultaneously, Geldhof et al. explored the effectiveness of RNAi in H. contortus using 
soaking, bacteria feeding and electroporation methods. Contrary to the positive report by Kotze 
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and Bagnall, Geldhof et al. were only successful in suppression two of the five genes examined 
using the soaking method.  Β-tubulin isotype 1 (Hc-ben-1) transcription level in the L3 stage was 
completely suppressed following dsRNA exposure. COPII component (Hc-sec-23) targeted 
dsRNA exposure resulted in significant but not complete suppression of transcript. Unlike Hc-
ben-1 suppression, Hc-sec-21 suppression proved unreliable because RNAi-mediated 
suppression was not achieved in two out of five experimental repeats. Microscopic examination 
of larvae H. contortus soaked in fluorescently labeled cathepsin L (Hc-cpl-1) dsRNA containing 
medium revealed very little dsRNA uptake. Thus, the soaking method appears to be unreliable 
with variation between experiments and recalcitrance for certain genes. Feeding H. contortus 
L1/L2 with bacteria expressing dsRNA was evaluated on four different gene targets. Suppression 
was not achieved for all four targets. 50 volt and 100 volt electroporation was used on the same 
four target genes with transcriptional level reduced but not abolished for Hc-ben-1 and the Cu-Zn 
superoxide dismutase (Hc-sod-1), with no off-target effects noticed. Although the transcription 
level was suppressed for the two genes, worm survival was significantly compromised as a result 
of electroporation with high level of dead larvae found after 24 hours. [196] Thus it would 
appear that electroporation alone results in negative effects on the worms. 
Between 2005 and 2006, the actin gene (Ls-act) of the rodent filarial parasitic nematode 
Litomosoides sigmodontis was investigated using RNAi soaking method. Adult L. sigmodontis 
were extracted from infected cotton rats and incubated in media containing Ls-act dsRNA for 24 
hours before transfer into dsRNA free culture medium. Ls-act transcription level was reduced by 
81% after the first 24 hours to 93% at 48 hours and 97% at 72 hours. Checking the mRNA level 
of two non-target genes resulted in no suppression thus confirming no off-target effects. 
Suppression of Ls-act transcription resulted in worm paralysis demonstrated by a stretched out 
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body and slow movements. The release of microfilariae (mf) was also dramatically reduced with 
Ls-act dsRNA treatment [197]. 
In 2006, Visser et al. evaluated RNAi capacity of the cattle gastrointestinal nematode 
Ostertagia ostertagi by soaking and electroporation. Eight genes were examined using 
exsheathed L3 O. ostertagi larvae. Five of the eight genes showed susceptibility to RNAi when 
animals were soaked in dsRNA. The reliability of the RNAi method was called into question 
when repetition of the RNAi experiments was proven unreliable as in the case of β-tubulin where 
suppression was confirmed only in three out of five repeats. Furthermore, suppression level 
varied between different batches of dsRNA used. Electroporation on the same eight genes 
produced suppression in only two targets, tropomyosin and β-tubulin, but neither was 
reproducible. [198]  
Despite earlier success with RNAi, findings in 2005 and 2006 reveal that RNAi in parasitic 
nematodes is not as straightforward as previously thought. The recalcitrance of certain genes to 
RNAi and the unreliability of the RNAi mechanism diminished the hope of using RNAi as a tool 
to investigate genes of interest as well as screen for potential drug and vaccine targets. And 
interest in RNAi as a tool to study parasitic nematodes waned with no research papers related to 
RNAi in parasitic nematodes published in 2007.  
In 2008, Lendner et al. attempted to suppress tropomyosin using RNAi on larvae of the 
murine intestinal parasitic nematode Heligmosomoides polygyrus by bacteria feeding, soaking 
and electroporation methods. Feeding L3 larvae with tropomyosin dsRNA expressing bacteria 
did not produce any effect, but feeding the same H. polygyrus tropomyosin dsRNA-expressing 
bacteria to C. elegans produced the characteristic phenotype of tropomyosin suppression. Thus it 
37 
 
 
 
would appear that RNAi mediated by bacteria feeding is ineffective in H. polygyrus. 
Electroporation on L1 larvae resulted in a 70% to 90% mortality. Closer examination using Cy3 
labeled siRNA revealed that siRNA was not delivered into H. polygyrus by electroporation.  
Soaking larvae H. polygyrus in tropomyosin dsRNA reduced the lifespan of L1/L2 larvae and 
rendered L3s physiologically inactive. Worms soaked in tropomyosin dsRNA for 6 days 
exhibited morphological changes before dying with female worms exhibiting disintegrated 
ovaries and gut. In some cases, the presence of floating egg fragments in the pseudocoelomic 
cavity was observed. But quantitative PCR revealed no suppression of mRNA levels. As such 
Lendner et al. speculated that the observed RNAi phenotype might be a result of the stress and/or 
a toxic side effect induced by treatment rather than an RNAi effect [199].  
In 2009, Ford et al. again performed RNAi on filarial parasitic nematodes but instead of O. 
volvulus, the function of cathepsin L and Z like cysteine proteases on adult female B. malayi was 
examined using similar soaking method as Aboobaker and Blaxter. Reduction in target mRNA 
levels ranging from 51% to 66.5% was confirmed for dsRNA exposed worms and 37.4% to 48.9% 
was confirmed for siRNA exposed worms using quantitative PCR. The uptake of both Cy3 
labeled dsRNA and siRNA was confirmed using fluorescence microscopy. RNAi-mediated 
suppression of cathepsin L and Z resulted in a 61.3% to 92.8% reduction in microfilariae 
released. Closer examination of RNAi treated adult female B. malayi revealed malformed 
intrauterine embryos that were not fully developed with spacing between the embryo and the 
surrounding eggshell. Moreover, MTT viability staining revealed an 18% to 22% reduction in 
embryo viability [200].  
In 2010, Xu et al. successfully suppressed a newly identified Ascaris suum gene (06G09) by 
soaking infective L3 larvae in dsRNA culture medium. Suppression was confirmed using non-
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quantitative RT-PCR. The RNAi-suppressed L3s were then reintroduced into healthy BALB/c 
mice and larvae collected four days later. The RNAi mediated 06G09 suppression resulted in 
fewer larvae harvested from the livers and lungs of infected mice compared to controls, such that 
71.43 ± 14.35 dsRNA treated worms were recovered compared to 164.29 ± 21.51 control worms. 
Examination of body length and width of dsRNA treated larvae reveal a reduced length of 
200.57 ± 71.31 µm compared to 480 ± 105.77 µm of control larvae and a reduced width of 20.20 
± 2.43 µm compared to 23.93 ± 3.72 µm of control larvae [201].  
The following year, Chen et al. published data on RNAi mediated suppression of A. suum 
enolase. Again, infective L3 were soaked in dsRNA and then reintroduced into healthy BALB/c 
mice. RNAi-mediated mRNA suppression was confirmed using non-quantitative RT-PCR. The 
number of dsRNA treated larvae extracted four days post infection from infected mice was not 
substantially different from that of worms extracted from control mice. As with the previous 
study by Xu et al., the length of the extracted larvae was examined and dsRNA treated larvae 
exhibited a reduced length of 360 µm to 370 µm compared to 400 µm for control worms [202].  
The same year, Samarasinghe et al. reported successful suppression of four of six L3 stage H. 
contortus genes by soaking in culture medium containing dsRNA. Exposure to dsRNA for the 
major excretory secretory protein Hc-asp-1 or the highly protective gut amino peptides Hc-H11 
resulted in mRNA suppression of 80% and 76% respectively. Suppression was reproducible in at 
least 10 separate experiments but no phenotype abnormalities were detected within culture 
medium. Reintroduction of Hc-H11 RNAi suppressed worms into sheep resulted in a 57% 
reduction in fecal egg count, 40% reduction in worm burden and a 64% reduction in amino 
peptidase activity after 28 days post-infection when compared with control animals [203].  
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To date, the application of RNAi in parasitic nematodes has met with both success and 
significant problems. For some parasitic nematodes such as Ascaris suum, RNAi appears to be 
robust and reliable. But for other parasitic nematodes such as H. contortus, RNAi is both 
unreliable and sometimes unattainable. Thus as it stands, the unreliability of RNAi in parasitic 
nematodes preclude its potential as a powerful reverse genetic tool for studying parasitic 
nematodes. 
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V. OBJECTIVES 
The general goal of the studies presented herein is to develop an in vivo RNAi method to 
study and better understand the biology of filarial worm B. malayi. Previous studies of parasitic 
nematodes have been hindered by the difficulty in gene manipulation and in keeping parasitic 
nematodes alive and healthy exo-host for the duration of the experiment. RNAi may provide an 
excellent means to study the function of target genes but unfortunately RNAi in parasitic 
nematodes has been riddled with problems. The problems may be due to the fact that parasitic 
nematodes once outside the host body undergo biological changes that render them resilient to 
exogenously induced RNAi. No matter how close the in vitro culture medium is to the host 
environment, there are still subtle differences that parasitic nematodes may require. As such, we 
hypothesized that RNAi may be more feasible and reliably carried out in in vivo.  
The in vivo RNAi was accomplished by artificially infecting the B. malayi-susceptible Aedes 
aegypti (Liverpool strain) with B. malayi mf and exposing the developing parasite in vivo to 
RNAi triggers introduced into the mosquito host. Because mosquitoes have an open circulating 
system that effectively bathes developing B. malayi from the mf stage to the infectious L3 stage,  
it was my goal to take advantage of these and develop an in vivo RNAi method to study specific 
gene targets in juvenile B. malayi. The open circulatory system can be viewed as an in vivo 
culture solution. The infectious L3 stage B. malayi can be extracted from the mosquito host 
allowing for phenotype evaluation.  
A second major objective of this study is to verify the reliability of the in vivo RNAi method. 
An in vivo RNAi method on B. malayi is critical in gaining a deeper understanding of B. malayi 
biology and the role specific genes play on the parasite’s development and health.  
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A final major objective of the present study is to gain information concerning the importance 
of specific genes of interest to drug development. Many genes are predicted to be essential to 
parasite survival and are considered as potential drug targets. Through RNAi mediated 
knockdown and subsequent examination of the resulting phenotype, the relative potential of each 
gene for drug target development can be evaluated.  
The present study is divided into two sections, each of which addresses one or more of the 
above stated objectives. Each section contains a Summary, Introduction, Materials and Methods, 
Results and Discussion. It is hoped that the technique developed and information gained from 
these studies will provide insights into juvenile Brugia malayi biology and provide a basis for 
future studies.  
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VI. THESIS ORGANIZATION 
The above sections of this chapter provided a literature review that coincides with the 
research conducted herein. The subsequent chapter of this thesis contains papers that have either 
been accepted for publication or will be submitted to a peer-reviewed journal. Chapter 2 is a 
manuscript that has been published in PLoS Pathogens under the title “Development of an In 
Vivo RNAi Protocol to Investigate Gene Function in the Filarial Nematode, Brugia malayi”. The 
research was conducted and manuscript written by Chuanzhe Song under the supervision of Dr. 
Michael J. Kimber, Dr. Timothy A. Day and Dr. Lyric Bartholomay. The manuscript comprising 
Chapter 3 will be submitted under the working title “Confirming Robustness of the In Vivo 
RNAi Protocol Through Investigating Gene Function of Known and Potential Drug Targets in 
the Filarial Nematode Brugia malayi”. This paper confirms the robustness and consistency of the 
in vivo RNAi protocol and provides insights in the gene function of known or putative drug 
targets through application of the in vivo RNAi protocol. The research was conducted and the 
manuscript was written by Chuanzhe Song under the supervision of Dr. Michael J. Kimber, Dr. 
Timothy A. Day, and Dr. Lyric Bartholomay.  
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CHAPTER 2. Development of an In Vivo RNAi Protocol to Investigate Gene Function in 
the Filarial Nematode, Brugia malayi. 
 
A paper published in PLos Pathogens 
 
Chuanzhe Song, Jack M. Gallup, Tim A. Day, Lyric C. Bartholomay, and Michael J. Kimber 
 
I. ABSTRACT 
Our ability to control diseases caused by parasitic nematodes is constrained by a limited 
portfolio of effective drugs and a paucity of robust tools to investigate parasitic nematode 
biology.  RNA interference (RNAi) is a reverse-genetics tool with great potential to identify 
novel drug targets and interrogate parasite gene function but present RNAi protocols for parasitic 
nematodes, which remove the parasite from the host and execute RNAi in vitro, are unreliable 
and inconsistent.  We have established an alternative in vivo RNAi protocol targeting the filarial 
nematode Brugia malayi as it develops in an intermediate host, the mosquito Aedes aegypti.  
Injection of worm-derived short interfering RNA (siRNA) and double stranded RNA (dsRNA) 
into parasitized mosquitoes elicits suppression of Brugia malayi target gene transcript abundance 
in a concentration-dependent fashion.  The suppression of this gene, a cathepsin L-like cysteine 
protease (Bm-cpl-1) is specific and profound, both injection of siRNA and dsRNA reduce 
transcript abundance by 83%.  In vivo Bm-cpl-1 suppression results in multiple aberrant 
phenotypes; worm motility is inhibited by up to 69% and parasites exhibit slow-moving, kinked 
and partial-paralysis postures.  Bm-cpl-1 suppression also retards worm growth by 48%.  Bm-cpl-
1 suppression ultimately prevents parasite development within the mosquito and effectively 
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abolishes transmission potential because parasites do not migrate to the head and proboscis.  
Finally, Bm-cpl-1 suppression decreases parasite burden and increases mosquito survival.  This is 
the first demonstration of in vivo RNAi in animal parasitic nematodes and results indicate this 
protocol is more effective than existing in vitro RNAi methods.  The potential of this new 
protocol to investigate parasitic nematode biology and to identify and validate novel anthelmintic 
drug targets is discussed. 
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II. INTRODUCTION 
Lymphatic filariasis is a disease caused by filarial nematodes including Wuchereria bancrofti 
and Brugia malayi, transmitted through the bite of infected mosquitoes.  These parasites 
perpetuate socioeconomic instability in developing countries by inflicting crippling morbidity 
and debilitating stigmatization. The impact of this disease is vast - over 120 million people are 
infected in 81 endemic countries [24].  In an effort to alleviate morbidity and eliminate 
transmission of this disease, the Global Program for the Elimination of Lymphatic Filariasis 
(GPELF) has orchestrated a systematic mass drug administration (MDA) program centered on 
the repeated dosing of either diethylcarbamazine citrate (DEC) and albendazole or albendazole 
and ivermectin in areas where the other filarial worms, Onchocerca volvulus and Loa loa are co-
endemic.  This strategy has reduced prevalence in many areas [14] but lymphatic filariasis 
remains a significant global health concern.  Many factors contribute to continued transmission, 
but central is the inadequate portfolio of effective drugs; none of the MDA drugs are effective 
against all life stages of the parasite with notable inefficacy against adult worms [15-17].  This 
means MDA must be provided annually for the duration of the lifespan of adult parasites.  This 
situation is compounded by gaps in our understanding of mechanisms of drug action and 
pharmacology – the site of action of DEC is unknown despite being the drug of choice for 
lymphatic filariasis control for decades, and the filaricidal mechanism of ivermectin at 
therapeutic concentrations is also equivocal.  There is a very real and significant need for 
additional and more effective antifilarial drugs, and a better understanding of the mode of action 
of existing drugs [206]. 
A major obstacle to the rational development of such drugs is the experimental intractability 
of parasitic nematodes.  An example of this complication is RNA interference (RNAi), a reverse 
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genetic tool that allows researchers to rapidly and specifically ‘turn off’ genes of interest.  RNAi 
has fast become a standard tool in rational drug discovery for the identification and validation of 
potential new drug targets [207, 208]. By suppressing specific genes and examining the resulting 
phenotype, it is possible to delineate gene function and appraise the potential value of encoded 
proteins as drug targets.  Successful applications of present RNAi protocols to parasitic 
nematodes have been sporadically reported, limited in their effectiveness and seldom repeated 
[209].  Some success has been achieved with Nippostrongylus brasiliensis [210], Ascaris suum 
[211], Trichostrongylus colubriformis [212], Ostertagia ostertagi [198] and Haemonchus 
contortus [213, 214].  Germane to the study of filarial worms, RNAi has been described in B. 
malayi [112, 200], Onchocerca volvulus [2, 215] and Litomosoides sigmodontis [216].  The 
conclusion has been reached, however, that successful RNAi “only works on a limited number of 
genes, and in some cases the effect is small and difficult to reproduce” [213].  The inability to 
depend on present RNAi protocols with parasitic nematodes has proved a major stumbling block 
to the identification and validation of new drug targets, to a better understanding of anthelmintic 
mode of action, and to advancing our comprehension of parasite biology. 
The recalcitrance of animal parasitic nematodes to RNAi is perplexing, given that 
Caenorhabditis elegans, a free-living nematode, and plant parasitic nematodes are readily 
susceptible to the technique [94, 217-223].  One hypothesis advanced to explain this 
recalcitrance is that because present RNAi protocols employ in vitro approaches including 
soaking nematodes in an RNAi trigger, feeding nematodes bacteria producing the trigger, or 
electroporating of the trigger into the parasite, the RNAi trigger is not provided in a manner 
conducive to systemic gene suppression [261].  Implicit in the use of these protocols is the 
removal of a parasite from the host and its maintenance in a liquid culture.  Therefore these 
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protocols have distinct drawbacks such as difficulty maintaining healthy, viable worms that 
behave normally in vitro, limitation of use of parasites or life stages for which in vitro culture is 
defined, and poor efficacy in RNAi trigger delivery methods that can prove lethal to the parasite 
[225]. 
The aim of this study was to develop an innovative in vivo approach to RNAi in parasitic 
nematodes that overcomes the drawbacks associated with present in vitro experimental 
paradigms.  Our approach is based on the filarial nematode B. malayi.  We establish a B. malayi 
infection in an intermediate host, the mosquito Aedes aegypti, and then initiate suppression of 
parasite genes by injecting an RNAi trigger directly into the mosquito.  The mosquito acts as an 
ideal culture and delivery system, ensuring the RNAi trigger is exposed to healthy, developing 
parasites.  Using this approach we have effectively and quantifiably suppressed expression of 
Bm-cpl-1, a B. malayi gene encoding a cathepsin L-like cysteine protease.  Dramatic aberrant 
phenotypes accompany this suppression, including a marked retardation of motility, an inhibition 
of normal parasite migration behavior within the mosquito and impaired parasite growth and 
development.  Suppression is specific; non-target RNAi has no effect on nematode viability or 
behavior, and the level of gene suppression and extent of the resultant phenotypes suggest this 
new protocol is more effective than previous methods.  The development of an in vivo RNAi 
protocol to reliably suppress gene expression in filarial worms has great potential for the 
identification and validation of novel drug targets, and more broadly, to explore parasitic 
nematode biology and host-parasite interactions. 
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III. MATERIALS AND METHODS  
A. Mosquito Maintenance and Injection Protocol 
Aedes aegypti (Liverpool strain), previously selected for susceptibility to filarial worms [253], 
were maintained in a contained environment at a constant temperature of 25°C, 80% relative 
humidity and a 14 h light to 10 h dark photoperiod.  The mosquitoes were fed a diet of 0.3 M 
sucrose.  Throughout the study mosquitoes to be injected were anaesthetized on ice and 
immobilized on a vacuum saddle before being microinjected intrathoracically at the base of the 
head using a pulled borosilicate glass pipette attached to a manual syringe for injection by 
volume displacement.  A maximum volume of 0.5 µL can be injected using this approach with a 
high mosquito survival rate (>95%). 
B. Establishing Brugia Infection 
Brugia malayi microfilaria (mf) infected cat blood was obtained from the University of 
Georgia NIH/NIAID Filariasis Research Reagent Resource Center.  To establish a consistent and 
repeatable parasitemia, mf were first purified using a filtration protocol [254].  Blood containing 
the parasites was diluted with phosphate buffered saline (1:5 ratio, blood:PBS) then syringe 
filtered through a 0.45 µm Millipore filter.  Captured mf were washed three to five times with 
PBS then a further three to five times with Aedes physiologic saline [255] before centrifugation 
at 6,800 x g for five min.  Supernatant was removed and the pelleted mf resuspended in fresh 
Aedes saline to a concentration of 40 worms per µL.  To inoculate mosquitoes, 20 mf were 
injected as described.  Microdissection of the mosquitoes throughout a 14 dpi period confirmed 
this method established a controlled infection that progressed in a predictable and consistent 
manner.  We also tried a blood feeding approach to establish infection but this produced an 
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inconsistent worm burden that is too variable to reliably assess subsequent gene suppression 
experiments. 
C. siRNA and dsRNA Generation and Injection 
Short interfering RNAs (siRNA) targeting a B. malayi cathepsin L-like gene (Bm-cpl-1 
AF331035 [229]) were generated commercially (Qiagen, CA) and modified with a 3’-Cy3 
fluorophore on the sense strand.  The location of each siRNA was optimized using a proprietary 
algorithm and the sequence of each siRNA is as follows: BmCL1-1, 
AAGGCTTAGTTTCTTATACAA; BmCL1-2, CCGAATGGAAAGATTATGTAA; BmCL1-3, 
CAGAAGTGCATTGAAGGAATA; and BmCL1-4, CCGGTATTTACTCCAGTAATA.  
Equimolar amounts of each siRNA were combined and this mix was used for injection and gene 
suppression experiments.  dsRNA duplexes were generated in-house using a T7 transcription-
based approach.  A 410 base pair transcription template was polymerase chain reaction (PCR) 
amplified from a B. malayi L3 stage cDNA library (kindly provided by Dr. S. Williams, Smith 
College, MA) using gene specific oligonucleotides designed to incorporate a T7 promoter 
sequence (TAATACGACTCACTATAGGGTACT) at both the 5’ and 3’ ends of the amplicon.  
For the Bm-cpl-1 template, oligonucleotide sequence was: L1T7dsRNAF 5’ 
TAATACGACTCACTATAGGGTACTACGGTTACCAAATTC 3’ and L1T7dsRNAR 5’ 
TAATACGACTCACTATAGGGTACTCGACAACAACAGGTC 3’.  The location of this 
transcription template was carefully chosen so as to exclude the pro region of Bm-cpl-1, a 
domain with high sequence homology to other cathepsin L family genes, and consequently 
increase the specificity of this dsRNA duplex.  Transcription templates were gel purified and 
dsRNA duplexes synthesized using the MEGAscript RNAi Kit (Ambion, TX) according to 
manufacturer’s protocols.  dsRNA species were quantified with a NanoVue spectrophotometer 
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(GE Healthcare, NJ) prior to use.  The timing of siRNA or dsRNA injection into B. malayi-
infected mosquitoes coincided with the presence of the parasite stage of interest: to target second 
larval stage (L2) parasites siRNA or dsRNA were injected five to eight dpi; to target third larval 
stage (L3) parasites siRNA or dsRNA were injected nine to 12 dpi (and for the lifespan of 
mosquito) [62].  The mosquitoes were processed to confirm suppression of the target gene, as 
described below, 48 h post-injection of siRNA or dsRNA. 
D. Relative Quantitative RT-PCR 
Brugia infected, RNA-treated and control mosquitoes were cold-anesthetized on ice. Total 
RNA was extracted from individual mosquitoes using RNAqueous Kit (Ambion, TX) before 
DNase treatment using the TURBO DNA-free Kit (Ambion, TX) in thin-walled PCR tubes.  The 
RNA was stabilized with RNase Out Inhibitor (Invitrogen, CA) and stored in RNase-free 
microcentrifuge tubes at 4°C.  This RNA was used as a template for a relative semi-quantitative 
multiplex RT-PCR using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA 
Polymerase (Invitrogen, CA).  The principle of this reaction is to amplify a target gene of interest 
and compare its intensity with a multiplexed and normalized internal standard during the linear 
phase of product amplification.  A putative neuropeptide encoding gene, Bm-flp-14 (Accession 
number AI508026) served this role.  This gene was chosen as we had previously determined its 
stable transcript production during the B. malayi L3 stage by PCR (C. Song, unpublished).  The 
oligonucleotide primers used to amplify Bm-cpl-1 were: CPL-1 F 5’ 
ACAGGGCAATATGACGAGAC 3’ and CPL-1 R 5’ ATCGAAGCAACGTGGCACAT 3’.  
These primer locations flank the region of Bm-cpl-1 homologous to the dsRNA construct.  The 
oligonucleotide primers used to amplify the Bm-flp-14 internal standard were: FLP-14 F 5’ 
CTCGTCCACTCTTATCACTG 3’ and FLP-14 R 5’ ACCGCAATGATATACAACATATA 3’.  
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The profile for this PCR was: cDNA synthesis at 50°C for 30 minutes; an initial denaturation 
phase of 94°C for 2 min; 38 cycles of 94°C for 30 s, 60°C for 30 s, 68°C for 1 min and a final 
extension phase of 68°C for 5 min.  Reactions were visualized on a 1.2% agarose gel containing 
ethidium bromide. 
E. Quantitative RT-qPCR 
Total RNA was extracted from individual mosquitoes and DNase-treated as described above 
for three replicated RNAi experiments and before addition of RNase Out Inhibitor and storage, 
each RNA sample was quantified spectrophometrically per a previous report [256].  This RNA 
served as a template in our RT-qPCR assays using the qScript One-Step Fast RT-PCR Kit with 
ROX (Quanta BioSciences, MD). 
Establishing PREXCEL-Q Parameters 
PREXCEL-Q, a qPCR assay development and project management software, was used to 
establish our RT-qPCR parameters and to determine valid working ranges for all of our samples 
per target and reference genes.  A mixture of the RNA samples was used to determine the 
optimum template to use while avoiding RT-qPCR inhibition for each of the three targets at 
concentration ranges of between 0.01 and 0.08 ng/µL for the siRNA experiments and between 
0.02 to 0.14 ng/µL for the dsRNA experiments.  For subsequent quantitative assessment of 
transcript abundance, each RNA sample was diluted to 0.06 ng/µL for the siRNA RT-qPCR 
study and 0.11 ng/µL for the dsRNA RT-qPCR study, with 6 µL of sample used per 25 µL 
reaction. 
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Primers and Probes 
The target sequence under evaluation in the RT-qPCR study was the B. malayi cathepsin L-
like transcript previously described.  Two reference genes were used, a neuropeptide-encoding 
gene Bm-flp-14 also previously described, and Bm-tph-1 (Accession number U80971), a tumor 
protein homolog-encoding gene that is a proven reference gene for qPCR of Brugia development 
in mosquitoes [228].  TaqMan minor groove binding (MGB) probes were used in this study to 
facilitate the use of shorter gene specific primer-probe sets.  All probes and primers were 
designed using Primer Express v. 2.0 software (Applied Biosystems, CA) and synthesized by 
Applied Biosystems.  The primer and probe sequences used are shown in Table 1. 
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TaqMan RT-qPCR  
25 µL volume reactions were prepared in duplicate for each RNA sample, and 20 µL of this 
reaction mixture is applied per well on a 96-well plate (using white-well reaction plates, 
Eppendorf, NY).  Individual components of each RT-qPCR reaction were as follows: 6 µL 
prediluted RNA (as determined by PREXCEL-Q), 6.25 µL 4X One-step Fast Master Mix with 
ROX, 1.25 µL qScript One-Step Fast RT, 775 nM each primer, 150 nM probe, nuclease-free 
water to 25 µL.  Cycling conditions included an initial cDNA synthesis step of 50°C for 5 min 
followed by an RT denaturation/Taq activation phase of 95°C for 30 s then 45 cycles of 95°C for 
3 s and 58°C for 30 s.  Four point standard curves were created for each target (within the ng/µL 
ranges already specified above) by diluting the RNA sample mixture in each case according to 
precise, PREXCEL-Q-determined parameters (eight-fold dilution from highest to lowest 
concentration).  No-template control reactions substituted nuclease-free water for RNA, and 
thermocycling was performed on an ABI GeneAmp 5700 SDS (Applied Biosystems).  
Quantification cycle (Cq) values were obtained at an appropriate threshold per each target (~0.1 
DRn in all cases), and data were processed using custom Excel files by the efficiency-corrected 
(E∆∆Cq) relative quantification method [227]. 
F. Phenotype Analysis 
After confirmation of Bm-cpl-1 suppression, multiple assays were performed to describe 
worm phenotypes.  Each phenotypic assay was performed 14 dpi and at either four or seven d 
post-injection.  Mosquitoes were cold-anesthetized then the wings and legs removed and 
discarded using a dissecting microscope.  The head, thorax and abdomen were partitioned and 
further dissected to release the parasites.  The following characteristics of dissected parasites 
were observed:  (1) Parasite location.  In order to be successfully transmitted, these parasites 
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have to actively migrate to the head of the mosquito and vigorously writhe free of the proboscis.  
Parasite migration through the mosquito was recorded and measured according to escape point 
from the mosquito body (abdomen, thorax or head).  (2) Worm motility.  A scoring schema of: 
one (immobile), two (compromised motility, immobile for stretches of time), three (sluggish, 
partial movement), four (in motion, some straight segments), or five (all parts of the worm in 
constant motion) was used to quantify parasite movement in a blind fashion by an independent 
evaluator.  Additional observations of aberrant motility included knotting at one or both ends, 
paralysis of caudal region and presence of a distinct angular kink were also recorded.  (3) 
Parasite growth and development.  Digital images of RNAi and control worms were captured 
so that length and diameter could be calculated using NIS Elements D 2.30 software (Nikon, 
NY).  (4) Parasite viability.  The number of parasites that survived to the infectious stage was 
recorded so that infection prevalence and mean intensity could be calculated.  (5) Mosquito 
viability.  We documented the number of mosquitoes that survived through the development of 
parasites to the infectious stage because these parasites inflict significant pathology and decrease 
mosquito survival. 
G. Microscopy 
Nikon Eclipse 50i fluorescence microscope under UV light (EXFO, ON) equipped with a 
Hy-Q FITC filter set (Chroma, VT). Images were captured using a Digital Sight DS-2Mv camera 
and NIS Elements D 2.3 software (Nikon, NY). 
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H. Statistical Analysis 
t-tests were used to analyze the effect of RNAi treatment on gene expression in the RT-qPCR 
experiments and parasite size, and ANOVA to analyze the effect of RNAi treatment on worm 
motility based on our one through five blind-scoring schema.  Chi square tests were used to 
analyze the effect of RNAi treatment on all other worm and mosquito behaviors assayed.  In all 
tests, P values ≤ 0.05 were considered statistically significant. 
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IV. RESULTS 
A. A Brugia RNAi Trigger Rapidly Disseminates Throughout the Mosquito Host 
Our hypothesis is that mosquitoes provide an optimal culture and delivery system for an 
RNAi trigger targeted to developing Brugia malayi parasites.  Healthy, viable, developing 
parasites are subjected to the RNAi trigger because the parasites undergo growth and 
development in the mosquito intermediate host.  In order to test the extent of dissemination of 
the RNAi trigger from the site of intrathoracic injection, 150 ng of an equimolar mix of four 3’ 
Cy 3-labelled Bm-cpl-1 siRNAs was injected into adult Aedes aegypti mosquitoes as described.  
The dissemination of this RNAi trigger through the mosquito was tracked over 15 d post-
injection by periodic microdissection of the mosquito and evaluation of internal fluorescence 
compared to saline injected controls.  The labeled siRNA mix spread rapidly from the site of 
injection and maximal fluorescence was observed 24 h post-injection (Figure 6).  The intensity 
of fluorescence slowly decreased until reaching basal levels at five d post-injection after which 
fluorescence intensity was not appreciably different from control mosquitoes.  Our observations 
closely parallel those of a previous report that describes the spread of 140 ng AlexaFluor 555-
labeled siRNA in the mosquito Anopheles gambiae from an injection site to the midgut and 
pericardial cells 36 h post-injection [226].  Systemic dispersion and persistence of RNAi signal 
from the site of injection suggests B. malayi larvae are likely to be exposed to the RNAi trigger 
in our experimental model. 
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B. Brugia Gene Suppression In Vivo is Potent and Specific 
Recently it has been shown that B. malayi genes encoding cathepsin L-like enzymes can be 
suppressed in vitro by soaking adult parasites in culture media containing siRNA [200].  We 
tested the capacity of our novel methodology to suppress larval stage B. malayi gene expression 
in vivo by injecting mixed siRNAs specific to the cathepsin L-like Bm-cpl-1 gene directly into Ae. 
aegypti mosquitoes harboring L3 stage B. malayi parasites.  Gene suppression was assayed 48 h 
post-injection using a semi-quantitative RT-PCR in which the intensity of Bm-cpl-1 
amplification in the linear phase of the reaction was compared to an internal B. malayi reference 
gene (Bm-flp-14) that is expressed stably and at comparable levels to Bm-cpl-1.  Control 
mosquitoes were injected with equal volumes of Aedes physiologic saline.  This methodology 
was optimized to amplify Bm-cpl-1 from a heterogeneous mosquito/parasite total RNA 
preparation from a single mosquito. Suppression was concentration-dependent because injection 
of 0.15 ng siRNA did not appear to reduce Bm-cpl-1 transcript levels.  However, injection of 15 
ng or 1.5 ng of siRNA decreased transcript levels, and injection of 150 ng mixed siRNA into 
mosquitoes profoundly suppressed Bm-cpl-1 expression; the target parasite gene could not be 
amplified (Figure 7).  This suppression was also specific; expression of the Bm-flp-14 reference 
gene was unaffected by siRNA injection and target gene expression was normal in saline-
injected controls. 
Application of dsRNA is the commonly used method for triggering RNAi in parasitic 
nematodes and has advantages over siRNA; dsRNA can be generated in-house more quickly 
than commercially produced siRNAs at lower cost.  B. malayi-infected mosquitoes were also 
subjected to treatment with dsRNA as an RNAi trigger.   The effect of dsRNA was 
concentration-dependent such that injection of 15 ng dsRNA results in Bm-cpl-1 suppression but 
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1.5 ng dsRNA had no appreciable effect.  Injection of 150 ng of dsRNA potently suppressed Bm-
cpl-1 transcript abundance and suppression appeared specific, with Bm-flp-14 expression 
unaffected by dsRNA (Figure 7). 
RT-qPCR was used to quantify the level of Bm-cpl-1 suppression relative to two reference 
genes (Bm-flp-14 and Bm-tph-1) using the efficiency-corrected (E∆∆Cq) relative quantification 
method [227].  PREXCEL-Q software was used to optimize the performance of the RT-qPCR 
assay; and important data pertinent to PCR efficiency, linear dynamic range and normalization of 
the assay are documented in Table 2.  Bm-tph-1 showed stable Cq values across the experiment 
and therefore was the most appropriate reference gene for these studies, as shown previously 
[228].  The suppressive effects of both RNAi treatments were almost identical; injection of 150 
ng siRNA reduced Bm-cpl-1 transcript by 83% compared to saline-injected controls (P < 0.0001) 
and 150 ng dsRNA also reduced Bm-cpl-1 transcript by 83% (P < 0.0001) (Figure 8).  Bm-flp-14 
reference gene transcript was slightly reduced by both RNAi treatments but these reductions 
were not significant (siRNA, 9%, P = 0.38; dsRNA, 12%, P = 0.17).  These data support the gel-
based semi-quantitative RT-PCR experimental findings and demonstrate the efficacy of this 
novel method of RNAi delivery. 
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Figure 8. Quantitative PCR demonstrates significant reduction in Bm-cpl-
1 transcript levels as a result of siRNA and dsRNA RNAi trigger injection 
into B. malayi infected Aedes. aegypti. Both siRNA (A) and dsRNA (B) 
injection reduces Bm-cpl-1 transcript by 83% compared to controls (saline 
injected Ae. aegypti infected with B. malayi). Bm-cpl-1 and control gene, Bm-
flp-14, are normalized to a reference gene Bm-tph-1. qPCR was performed 48 
h post-injection of RNAi trigger at 10 d post-injection. Each bar represents 13 
mosquitoes from three biological replications.  
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C. Bm-cpl-1 Suppression Elicits Marked Motility and Developmental Phenotypes 
Previous studies have described aberrant filarial worm phenotypes associated with cathepsin 
L-like gene suppression in vitro including decreased microfilariae (mf) release from adult B. 
malayi [200] and an inhibition of the L3 to L4 molt in Onchocerca volvulus [2]. Based on these 
data, we predicted that Bm-cpl-1 suppression would produce a phenotype in vivo in the mosquito 
host.  Mosquitoes were injected with 150 ng Bm-cpl-1 dsRNA 10 d post-infection (dpi) then 
microdissected four d post-injection to harvest L3-stage parasites.  Worm motility was digitally 
recorded and scored according to a five-point schema of one (immobile), to five (all parts of the 
worm in constant motion).  100% of control worms from mosquitoes injected with Aedes 
physiologic saline were categorized as four or five on this scale.  Bm-cpl-1 suppression 
significantly inhibited this normal worm motility (P < 0.001), with only 67% of worms ranked as 
four or five on the scale (Figure 9).  To confirm that this effect was Bm-cpl-1 specific and not 
due to exogenous dsRNA impairing worm viability, this experiment was repeated with dsRNA 
for enhanced GFP (eGFP) as a random exogenous RNA.  These worms were phenotypically 
identical to saline-injected controls (100% category four or five), confirming the specificity of 
the aberrant phenotype in Bm-cpl-1 suppressed worms. 
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The effect of changing the timing of Bm-cpl-1 suppression on worm motility was also 
examined.  Bm-cpl-1 transcript levels are elevated in L3 stage parasites, such that this gene 
has a purported role in the L3 to L4 molt [2].  The temporal expression of Bm-cpl-1 was 
reported to be up-regulated during the L2 to L3 transition, at six to seven dpi [229].  Based 
on the timing of Brugia development in Ae. aegypti [62], infected mosquitoes were injected 
with Bm-cpl-1 dsRNA at 10 dpi in order to target L3-stage worms (described above) and at 
seven dpi to target the L2 to L3 transition.  Parasites exposed to Bm-cpl-1 dsRNA at seven 
dpi showed significantly inhibited motility compared to saline controls (P < 0.001) with only 
31% of worms displaying normal motility.  The difference between parasites exposed to 
dsRNA at seven and 10 dpi was significant (P < 0.001), and may reflect an important 
biological role for Bm-cpl-1 during the transition from L2 to L3 stages.  More explicitly, 
earlier exposure to the RNAi trigger could impose more significant detrimental impact on the 
parasite by disrupting the L2 to L3 molt, or it may simply be a consequence of the longer 
period of time from gene suppression to phenotype assay, allowing Bm-CPL-1 rundown and 
maturation of the phenotype. 
In addition to depressed activity, other morphological and motility phenotypes were 
apparent in Bm-cpl-1 suppressed worms.  A highly active, convoluted body form 
characterizes motility of healthy B. malayi L3s, both the heads and tails of the parasites in 
particular are conspicuously tortuous – curvature we described as ‘knotted’.  Control worms 
from saline-injected mosquitoes frequently (86% of worms) displayed knotting at both ends.  
Suppression of Bm-cpl-1 10 dpi significantly inhibited this motility, because only 14% of 
worms presented with both ends knotted (P < 0.001) (Figure 10).  This phenotype was 
enhanced by an early suppression of Bm-cpl-1 at seven dpi such that no Bm-cpl-1 suppressed 
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parasites exhibited this knotting morphology.  The difference between L2 and L3 Bm-cpl-1 
suppression was significant (P = 0.005).  Worms exposed to the exogenous eGFP dsRNA 
control confirmed that this phenotype was gene-specific because parasite motility was not 
significantly different from saline controls (85% knotted at both ends, P = 0.2).  Another 
aberrant motility observed was the presence of a perturbed section of body wall slightly 
caudal to the midpoint of the worm.  This abnormal kinked morphology was absent from 
control worms (4% of worms from saline-injected and 0% from eGFP-injected mosquitoes 
displayed this morphology), but evident with significantly greater frequency in 10 dpi Bm-
cpl-1 suppressed worms (47%, P < 0.001) (Figure 11).  This kink rate increased with Bm-cpl-
1 suppression at seven dpi (63%), but compared to 10 dpi this was not significant (P = 0.08).  
Finally, partial paralysis of Bm-cpl-1 suppressed worms was evident, presenting as 
immobility in the caudal third of the worm.  This paralysis was observed in 61% of 10 dpi 
Bm-cpl-1 suppressed worms, and 83% of seven dpi suppressed worms (this increase was 
significant, P = 0.005) but was generally absent from control worms (5% of worms from 
saline-injected mosquitoes and 3% of worms from eGFP-injected mosquitoes) (Figure 11). 
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To examine the consequence of this aberrant motility on B. malayi development, mosquitoes 
were injected with 150 ng Bm-cpl-1 dsRNA 10 dpi then microdissected four d post-injection, 
partitioning the mosquitoes into head, thorax and abdomen preparations.  Control worms from 
mosquitoes injected with either saline or eGFP dsRNA were found exclusively (100%) in head 
preparations as expected.  Bm-cpl-1 suppressed worms were most frequently observed escaping 
from the thorax and abdomen (Figure 12).  Parasites in Bm-cpl-1 dsRNA-injected mosquitoes, 
however, did not leave the thorax (94% of worms were found here) or abdomen (6%).  Bm-cpl-1 
suppression, therefore, prevents worm migration to the head of the mosquito, effectively 
preventing normal progression of the parasite life cycle and thus abolishing the potential for 
parasite transmission. 
A significant negative effect also was seen on growth and development of parasites subjected 
to Bm-cpl-1 suppression.  Parasitized mosquitoes were injected with 150 ng Bm-cpl-1 dsRNA 
seven dpi then microdissected 14 dpi and the length, width and appearance of the worms 
recorded.  Mosquitoes were injected seven dpi because the previous motility experiments 
dictated that this experimental timing generated the most pronounced motility phenotypes.  Bm-
cpl-1 suppression significantly reduced the length of L3 worms by 48% (P < 0.0001) (Figure 13).  
The mean length of control L3, removed from mosquitoes seven d after saline injection and 14 
dpi, was 1347 ± 18 µm.  This was reduced to 700 ± 49 µm after RNAi treatment.  Unlike parasite 
length, width was not significantly affected by Bm-cpl-1 suppression, although a slight decrease 
of 5% was observed (P = 0.39) from 31 ± 1 µm in control worms to 30 ± 2 µm in RNAi worms.  
In addition to worm length, the majority of Bm-cpl-1 dsRNA parasites also presented with 
additional aberrant developmental phenotypes.  Most evident was a disruption of the cuticle 
(Figure 13B), which extended significantly beyond the body of the worm.  Some degree of this 
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cuticular sloughing was noticed in most worms but the severity of this phenotype was variable.  
Finally, the integrity of the gut appeared compromised in Bm-cpl-1 worms.  In such instances, 
the gastrointestinal tract of the parasites appeared incomplete and porous when examined at the 
light microscope level. 
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Figure 13. Bm-cpl-1 suppressed B. malayi are significantly shorter than 
control worms. Parasites were dissected from Ae. aegypti mosquitoes 14 days 
post-infection and 4 d post-infection of saline (control, A) or 150 ng Bm-cpl-1 
dsRNA (B). Scale bar 250 µm. (C) RNAi exposed parasites are significantly 
shorter in length, but not width, than control worms. Numbers of parasites from 
three biological replicates: n=19 (control) and n=13 (dsBm-cpl-1) (P<0.001).  
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D. Bm-cpl-1 Suppression Enhances Mosquito Survival and Decreases Parasite Prevalence 
Phenotype data resoundingly demonstrate that Bm-cpl-1 suppression decreases B. malayi 
viability.  It is logical to predict that this decreased viability would also have an impact on 
mosquito survival and prevalence of parasite infection.  To examine this, mosquitoes were 
injected with 150 ng Bm-cpl-1 dsRNA 10 dpi and the number of mosquitoes that survived 
through the development of parasites to the infectious stage, 14 dpi, was counted.  Surviving 
mosquitoes then were microdissected to determine the proportion that harbored parasite 
infections.  Bm-cpl-1 suppression increases host mosquito survival.  The survival rate of control 
mosquitoes injected with saline or eGFP dsRNA was 62% and 65% respectively (P = 0.6) as 
compared to 80% in Bm-cpl-1 RNAi-exposed mosquitoes (P < 0.001) (Figure 14A).  Early 
suppression of Bm-cpl-1 at seven dpi enhanced the phenotype even more significantly such that 
93% of mosquitoes were alive at the termination of the experiment (P = 0.007).  This increased 
mosquito survival rate after Bm-cpl-1 suppression may be as a result of the parasite’s 
compromised ability to feed on, and migrate through, the host or may result from a more 
successful or effective host response against parasites with decreased viability.  This hypothesis 
is supported by our observation that Bm-cpl-1 suppression also decreased prevalence of infection 
– fewer surviving mosquitoes harbored parasites after Bm-cpl-1 RNAi (Figure 14B).  Every 
surviving mosquito injected with saline or eGFP was found to contain parasites 14 dpi, but 14 
dpi Bm-cpl-1 suppressed parasites (exposed to dsRNA at 10 dpi) were found in just 76% of 
mosquitoes, a significant reduction in prevalence (P < 0.001).  Prevalence was further reduced to 
62% in parasites exposed to Bm-cpl-1 dsRNA at seven dpi, a statistically significant decrease 
compared to worms exposed to the dsRNA trigger at 10 dpi (P = 0.03). 
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Figure 14. Ae. aegypti survival significantly increases as infection prevalence 
decreases in Bm-cpl-1 dsRNA exposed mosquitoes. The effects on survival (A) 
and infection prevalence (B) are most profound in parasites exposed to Bm-cpl-1 
dsRNA at the L2/L3 transition (7 d post-infection, dpi). Parasites were exposed to 
saline (control), 150 ng eGFP dsRNA or 150 ng Bm-cpl-1 dsRNA at 7 or 10 dpi, 
then were dissected from Ae. aegypti mosquitoes at 14 dpi.  
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V. DISCUSSION 
Here we report the development of a novel in vivo approach to RNAi in the filarial nematode 
Brugia malayi, and describe its application first to suppress the expression of Bm-cpl-1, a B. 
malayi gene encoding a cathepsin L-like cysteine protease, then to validate this gene as a 
potentially potent anthelmintic drug target.  To the best of our knowledge, this is the first 
description of in vivo RNAi in parasitic nematodes and represents an advance in the study of 
filarial nematode biology that may aid in the development of drugs to combat parasitic nematode 
infection.  The rationale for developing an in vivo RNAi protocol stems from the hypothesis that 
RNAi is ineffective in animal parasitic nematodes because the supply of an RNAi trigger to the 
worms is inappropriate [224].  Our overarching hypothesis was that RNAi would work 
effectively and robustly if a trigger is supplied to healthy, viable worms in a host environment.  
Supporting this hypothesis, we were able to specifically reduce target gene transcript abundance 
in B. malayi larvae by 83% by supplying an RNAi trigger to parasites developing within the 
mosquito host.  This level of transcript knockdown has not previously been reported using 
current in vitro RNAi soaking methods.  The ‘in squito’ approach to RNAi we describe is 
effective for the specific suppression of cathepsin genes in Brugia larval stages as they develop 
within their cognate mosquito host; it is therefore possible that this in vivo approach may 
represent a more effective means of eliciting gene suppression in filarial nematodes. 
The mechanism by which the RNAi trigger is delivered to the parasites ‘in squito’ is unclear, 
but could be a result of bathing the parasite in the trigger within a cell, or as a result of uptake by 
tissue ingestion.  In support of the former, Cy3-labeled siRNA injected into the haemocoel 
rapidly disseminates throughout the mosquito supporting a hypothesis that the developing 
parasites are effectively incubating in a host milieu containing an RNAi trigger, essentially a 
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scenario analogous to in vitro RNAi by soaking.  If this is the case, the ‘in squito’ approach 
represents an efficient way to generate gene suppression by soaking.  Most successful animal 
parasitic nematode in vitro soaking protocols use large amounts of ds- or siRNA with 
concentrations of 1 mg/ml typical, meaning anywhere between 25 µg and 2 mg of RNAi trigger 
are required per suppression experiment [2, 112, 198, 200, 210-215], with the exception of one 
report showing that lower trigger concentrations could still be effective at producing gene 
suppression by soaking [216].  Here we showed that gene suppression can be achieved using just 
150 ng of ds- or siRNA per RNAi event, and indeed, a reduction in transcript abundance was 
observed after injecting as little as 15 ng dsRNA.  In addition to the obvious cost saving 
advantages to performing RNAi experiments in this manner, such low RNA concentrations may 
also improve the specificity of gene suppression.  Soaking plant parasitic nematodes in serial 
dilutions of ds- and siRNAs has been shown to reduce off-target effects in RNAi experiments 
[223, 230].  A second delivery hypothesis is that the developing parasites are ingesting the RNAi 
trigger.  Microfilariae taken in during the blood meal rapidly penetrate the mosquito midgut 
[231], and migrate to the thoracic musculature where they grow and develop to the L3 stage [232, 
233], a process completed in under two weeks [62].  From the L2 stage, the developing larvae 
are active feeders and consume host tissue [62, 234, 235], a behavior that would lead to the 
ingestion of an injected RNAi trigger in our experimental model.  RNAi by feeding is a well-
established method in free-living nematodes [217, 218, 236, 237]; by feeding these worms 
bacteria expressing dsRNA, systemic gene suppression can be effected in a relatively simple and 
efficient manner.  This approach has not been successful with parasitic nematodes, however, as 
most parasitic species are not bacteriotrophic, and even for those species with bacteriotrophic life 
stages, this method is unreliable [225].  Resolution of the RNAi trigger delivery mechanism 
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afforded by our in vivo protocol may come through targeting B. malayi L1 worms in the 
mosquito.  If target gene expression can be reduced in this non-feeding stage, this would support 
soaking as the prime mechanism. 
The in squito suppression of Bm-cpl-1 reveals new phenotypes associated with molting, 
growth and development, and motility that shed light on the important biological functions of 
this gene family in larval stages of B. malayi.  Nematode molting is a three-stage process 
characterized by a shedding or separation of the old cuticle from the epidermis (apolysis), 
generation of a new cuticle, then the shedding of the old cuticle (ecdysis).  The use of specific 
cysteine protease inhibitors markedly inhibits the L3 to L4 molt in filarial worms implicating 
cysteine proteases in general in this process [229, 238, 239].  More explicitly, both apolysis and 
ecdysis are disrupted giving rise to L4 parasites constrained within an L3 cuticle, termed an 
‘accordion’ phenotype [229].  Multiple members of the cathepsin L-like family appear to be 
involved in molting as the specific suppression of cpl-1 alone in Onchocerca vovlvulus reduced 
but did not abrogate the L3 to L4 molt [2].  We show that Bm-cpl-1 is also involved in similar 
processes in B. malayi as its suppression manifested an aberrant cuticular phenotype in L3 
worms.  Examination of worms suppressed at seven dpi revealed an apparent sloughing of the 
cuticle without the accordion phenotype.  As the L3 to L4 molt occurs in the vertebrate host this 
phenotype is not a disruption of the L3 to L4 molt, but rather a dysfunction in L3 cuticle 
formation, maintenance or development.  Alternatively, we could be observing a disruption of 
the L2 to L3 molt.  Bm-cpl-1 expression is up-regulated in the L3 stage but the exact timing of 
this up-regulation as it relates to the transition from L2 to L3 stages is unclear.  Guiliano et al.. 
[229] report Bm-cpl-1 up-regulation at six dpi, a window consistent with the L2 to L3 transition.  
If Bm-cpl-1 performs the same function for the L2 to L3 molt as for the L3 to L4 molt, then the 
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sloughed cuticle we observe upon dsRNA injection at seven dpi could be that of the L2, with 
Bm-cpl-1 suppression preventing ecdysis.  Further examination of cuticle ultrastructure in these 
suppressed worms at the electron microscope level could provide evidence to this effect. 
We observed a stunting of Bm-cpl-1 suppressed L3 growth compared to control worms, a 
phenotype previously unreported either after chemical inhibition of cysteine proteases or gene 
suppression in other parasite stages.  Normally at the end of the L2 stage parasites are 750 – 795 
µm long and increase in length to approximately 1350 µm at the L3 stage within four d [232].  
Our control L3, taken from mosquitoes injected with saline, had a mean length of 1347 µm 
corresponding closely with the published data.  The mean length of Bm-cpl-1 suppressed L3, 
however, was significantly shorter (700 µm).  Suppression of this gene at the L2/L3 interface 
(seven dpi) arrests parasite growth and the L3 worms remain L2-sized within the mosquito.  One 
explanation for this observation is that Bm-cpl-1 suppression at the L2/L3 interface is inhibiting 
the L2 to L3 molt, L2 cuticle ecdysis is not successful and therefore the worms are constrained 
within it, unable to increase their length.  Alternatively, the stunting may not be due to aberrant 
molting but rather an inhibition of normal CPL-regulated development or cellular remodeling 
post-molt as is seen in other nematodes [240].  RNAi suppression of cpl-1 in C. elegans L3 by 
soaking produced significantly shorter and thinner adults [240] and the localization of cpl-1 to 
the hypodermis in C. elegans, O. volvulus and B. malayi is consistent with a developmental role 
in nematodes [2, 229, 240].  Further, germline suppression of cpl-1 in C. elegans by dsRNA 
injection generated an embryonic lethal phenotype but some embryos did progress to the L1 
stage and those had incomplete gut development [240].  A repeatedly observed phenotype in our 
Bm-cpl-1 suppressed L3 was a compromised gut that appeared fenestrated and poorly developed. 
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Finally, Bm-cpl-1 suppression reduced normal L3 motility by up to 69%, increased atypical 
postural phenotypes including caudal paralysis, kinked appearance and reduced normal 
convolution at the head and tail of B. malayi L3 as compared to control worms.  These behaviors 
made it impossible for the treated L3 to progress through to the culmination of development in 
the mosquito host, i.e., transfer to the definitive host.  The dystaxic behaviors produced by the 
suppression of Bm-cpl-1 suggest this gene has some role, directly or indirectly, in the 
neuromuscular activity of B. malayi L3 in the mosquito.  It is certainly true that cathepsins are 
required for normal neuromuscular behavior in other helminths; suppression of a cathepsin L-
like gene in the flatworm Fasciola hepatica generated several aberrant motile phenotypes 
including paralysis [241]. 
This study is the first to use the host as a delivery mechanism for animal parasitic nematode 
RNAi.  The model of using the host as a delivery mechanism for RNAi has been established but 
has been restricted to plant pathology where the concept has an applied use with transgenic 
plants helping to control nematode infestation by RNAi mechanisms in planta [242-244].  An 
alluring corollary is that by generating transgenic mosquitoes capable of suppressing key 
nematode genes in vivo we may be able to abolish parasite transmission.  We have already 
demonstrated here that Bm-cpl-1 suppression in vivo prevents parasites migrating to the mosquito 
head and proboscis thus eliminating transmission potential.  Transformation of a mosquito with 
an inverted-repeat (IR) transgene derived from Bm-cpl-1 may result in endogenous transcription 
of a hairpin dsRNA, a trigger that conceptually would induce RNAi in vivo as described here and 
produce a mosquito incapable of transmitting lymphatic filariasis-causing worms.  Methods to 
introduce transgenes into mosquito germlines are well established [245- 249] and proof of this 
principle has already been demonstrated for a mosquito-borne virus; transgenic lines of Dengue 
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virus-resistant mosquitoes were generated using a Dengue virus IR transgene driven by the 
carboxypeptidase A promoter, reducing virus transmission by an RNAi mechanism [250].  The 
viability of this approach is enhanced not only by the ability to transform important vector 
species but also by the identification of tissue-specific promoters to drive transgene expression in 
favorable tissues, for example, act88F [251] is a fly-specific promoter that drives gene 
expression in the flight musculature – the precise site of parasite development.  Another positive 
impact this protocol may have on lymphatic filariasis control is as a means of better 
understanding the biology of current putative drug targets and generating new data that may 
validate proposed novel drug targets.  This protocol introduces the ability to investigate 
mosquito-borne parasite life stages, allowing the critical examination of gene function in worms 
growing and developing in an optimum environment.  This makes it possible to assay genes that 
encode known or proposed drug targets in a parasite within its native intermediate host, 
contextualizing the null phenotypes in vivo and accurately determining the consequences of 
target gene suppression producing a more valuable target validation.  As an illustration, 
nematode cathepsins have been proposed as attractive novel drug targets [252] and we have 
further validated these drug targets in vivo, revealing new phenotypes, defining new biological 
roles and showing that B. malayi sans Bm-cpl-1 are incapable of completing their life cycle.  
These data enhance the appeal of cathepsins as novel anthelmintic drug targets.  Beyond 
cathepsins, this technique will have most utility in the investigation of known and potential 
antifilarial drug target genes expressed in both the mosquito-borne life stages and those life 
stages that are vulnerable to chemotherapeutic intervention. 
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CHAPTER 3.  Confirming Robustness of the In Vivo RNAi Protocol Through Investigating 
Gene Function of Known and Potential Drug Targets in the Filarial Nematode, Brugia 
malayi 
 
A paper to be submitted  
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I. ABSTRACT 
Lymphatic filariasis is a global public health concern, with over 120 million people infected 
in 81 endemic countries. Current efforts to control the spread of lymphatic filariasis are 
constrained by a limited portfolio of effective anti-filarial drugs and a paucity of tools to 
investigate parasitic nematode biology. The two currently available anti-filarial drugs, ivermectin 
and diethylcarbamazine citrate (DEC), are both inefficient at curing LF-causing worms like 
Brugia malayi from the host and function only to interrupt transmission through poorly 
understood microfilaricidal effects. As such, a deeper understanding of existing and new drug 
targets needs to be gained for the development of more efficient anti-filarial drugs. RNA 
interference (RNAi) is a reverse-genetics tool with great potential to identify novel drug targets 
and interrogate parasite gene function but RNAi on various parasitic nematodes has proven 
inconsistent and unreliable. Many current RNAi protocols are carried out in vitro, necessitating  
removal of the parasite from host prior to executing RNAi in an artificial environment. We have 
developed an alternative in vivo RNAi protocol (we term “in squito” RNAi) targeting the filarial 
nematode B. malayi as it develops in an intermediate host, the mosquito Aedes aegypti. To verify 
the consistency and potential of our previously developed in squito RNAi protocol to interrogate 
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potential novel drug targets, we suppressed the expression of two known and three putative 
anthelmintic drug targets in  larval-stage B. malayi. The drug targets were genes encoding β-
tubulin (Bm-tub-1), glutamate-gated chloride channel alpha subunit (Bm-GluCl-α3A), G-protein 
coupled acetylcholine receptor 2 (Bm-gar-2), FMRFamide-like peptide 21 (Bm-flp-21), and 
prohormone convertase 2 (Bm-pc-2). Three repeated double-stranded RNA (dsRNA) injections 
of dsBm-GluCl-α3A, dsBm-tub-1, dsBm-gar-2, or dsBm-flp-21 resulted in phenotypic 
abnormalities including aberrant worm motility, survival and migration within the mosquito host. 
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II. INTRODUCTION 
The filarial worm parasites, Wuchereria bancrofti (90% of cases) and Brugia malayi (10% of 
cases) [23] are the etiological agents of lymphatic filariasis (LF). The transmission of filarial 
worms is facilitated by mosquitoes that transmit infectious L3 stage filarial worms during blood 
feeding. LF causes damage to the infected individual’s lymph system [29-35] that can lead to 
crippling morbidity and social stigmatization. The World Health Organization estimates that over 
120 million or approximately 2% of the global population are infected and 1.2 billion in 81 
endemic countries are considered at risk [24, 26]. Of the 120 million infected individuals, 
approximately 12.5% exhibit clinical symptoms associated with lymphedema such as 
elephantiasis, resulting in over 5 million Disability Adjusted Life Years (DALYs – healthy life 
years lost) annually [53]. 
Following the identification of LF as one of six potentially eradicable diseases by the World 
Health Assembly’s International Task Force for Disease Eradication in 1997 [25], the Global 
Program for the Elimination of Lymphatic Filariasis (GPELF) has implemented a systemic mass 
drug administration (MDA) of diethylcarbamazine citrate (DEC) and albendazole, or ivermectin 
and albendazole in regions co-endemic with other filarial nematodes such as Onchocerca 
volvulus, in an effort to alleviate morbidity and eliminate the transmission of this disease. 
Despite reduced prevalence in many areas, LF remains a significant global health concern [45, 
85] due, in part, to key weaknesses in MDA chemotherapy. Current control efforts can only 
interrupt disease transmission because DEC and ivermectin are only effective as microfilaricidal 
agents so do not function in a macrofilaricidal, curative manner [45, 86, 87]. Although drug 
resistance in lymphatic filarial nematodes has not been reported so far, a report in 2004 of 
onchocerciasis patients failing to respond to ivermectin treatments in Ghana raises concern about 
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possible development of drug resistance strains among Onchocerca volvulus [288, 289]. As such 
there is an urgent need for more effective anti-filarial agents. Unfortunately our current limited 
understanding of filarial worm biology and the mode of action of existing drugs hinders our 
ability both to rationally develop more effective anti-filarial drugs, and to make better use of 
existing compounds. 
Since the 1998 characterization of RNA interference (RNAi) in the free-living nematode 
Caenorhabditis elegans by Fire et al., RNAi has evolved into a powerful novel reverse genetic 
tool that enables researchers to rapidly and specifically “turn off” genes of interest. Since its 
characterization in C. elegans, RNAi have rapidly become a standard tool in the identification 
and validation of potential new drug targets for rational drug discovery [207, 208]. The ability 
for RNAi to suppression specific genes enables researchers to examine the resulting phenotypes 
to delineate specific gene functions and evaluate the encoded protein’s value as potential drug 
target. We have previously established a novel in vivo RNAi protocol to suppress gene 
expression in Brugia malayi where the intermediate host, the mosquito Aedes aegypti, is used as 
a culture and RNAi delivery mechanism [257]. Using this protocol, we demonstrated the 
important role of Bm-cpl-1, a gene encoding a cathepsin L-like cysteine protease, in the biology 
of larval stage B. malayi. Suppression of the gene produced potent behavioral and developmental 
worm phenotypes, supporting the contention that this protein has potential as a novel anti-filarial 
drug target. 
Here we attempt to utilize our previously developed in squito RNAi protocol on two known 
drug targets, a glutamate-gated chloride channel alpha subunit (ivermectin) and β-tubulin 
(benzimidazole anthelmintics) as well as three putative drug targets, a G protein-coupled 
acetylcholine receptor (GAR), a prohormone convertase (PC), and a FMRFamide-like peptide 
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(FLP) to shed light on the biology of these genes by examining loss of function phenotypes. We 
used both semi-quantitative and quantitative RT-PCR to confirm and quantify suppression. To 
examine individual target gene functions, gene-suppressed L3 worms were compared 
phenotypically to normal control L3 worms. Phenotypic differences such as reduced worm 
motility, knotting behavior, frequency distribution, and mean intensity were observed between 
normal and dsRNA exposed worms.  
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III. MATERIAL AND METHODS 
A. Mosquito Maintenance and Injection Protocol 
The mosquito, Aedes aegypti (Liverpool strain), was selected based on its susceptibility to 
filarial worm infection [253]. Ae. aegypti were maintained in a contained environment under a 
constant temperature of 25°C, 80% relative humidity and a 14 h light to 10 h dark photoperiod.  
The mosquitoes were fed a diet of 0.3 M sucrose.  Mosquitoes to be injected were anesthetized 
on ice and immobilized on a vacuum saddle before being microinjected intrathoracically. 
Intrathoracic microinjection took place at the base of the mosquito head via pulled borosilicate 
glass pipette attached to a manual syringe for injection by volume displacement.  A maximum 
volume of 0.5 µl could be injected per injection using this approach. 
B. Establishing Brugia Infection 
Infected cat blood containing B. malayi microfilariae (mf) was obtained from the University 
of Georgia NIH/NIAID Filariasis Research Reagent Resource Center.  As with our previous 
experiment [257], a filtration protocol [254] was used to isolate and purify the mf from the cat 
blood in order to establish a consistent and repeatable inoculum. B. malayi infected cat blood 
was first diluted with phosphate buffered saline (1:5 ratio, blood: phosphate-buffered saline 
(PBS)) before being syringe filtered through a 0.45µm filter to isolate microfilariae (mf). Filter-
captured mf were subsequently washed three to five times with PBS followed by a further three 
to five times with Aedes physiologic saline [255]. Following wash, the mf containing supernatant 
was centrifuged at 6,800g for five min. Supernatant was removed and the pelleted mf was 
subsequently resuspended in fresh Aedes saline to a concentration of 40 worms per µl. To infect 
mosquitoes, 20 mf were microinjected as described.  
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C. Gene Selection & dsRNA Generation 
The five target genes were: Bm-tub-1 (XM001896580 [112]) for β-tubulin, Bm-GluCl-α3A 
(XM001891558) for glutamate-gated chloride channel, Bm-gar-2 (XP001893809) for a G 
protein-coupled acetylcholine receptor, Bm-flp-21 (AA991111 [283]) for a FMRFamide-like 
peptide precursor, and Bm-pc-2 (XM001901916) for a prohormone convertase (Table 3). Gene 
sequence for each of the five drug targets under investigation was obtained using the Basic Local 
Alignment Search Tool (BLAST) homology searches of the B. malayi expressed sequence tag 
(EST) dataset. Double stranded RNA (dsRNA) duplexes for each target gene were generated in-
house using a T7 transcription-based approach as prior [257].  
 
 
KNOWN DRUG TARGETS 
 
 
 Beta-tubulin Bm-tub-1 (XM001896580) 
Glutamate-gated Cl- Channel Bm-GluCl-α3A (XM001891558) 
 
 
PUTATIVE DRUG TARGETS  
 
 G protein-coupled Acetylcholine Receptor Bm-gar-2 (XP001893809) 
FMRFamide-like Peptide Bm-flp-21 (AA991111) 
Prohormone Convertase-2 Bm-pc-2 (XM001901916) 
    
  Table 3. Targets for in squito suppression 
 
 
For each suppression target, a transcription template was PCR amplified from a B. malayi L3 
stage cDNA library (kindly provided by Dr. S. Williams, Smith College, MA) using gene 
specific oligonucleotides designed to incorporate a T7 promoter sequence 
(TAATACGACTCACTATAGGGTACT) at both the 5’ and 3’ ends of the amplicon.  These 
primer sequences can be found in Table 4.  
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The location of this transcription template was carefully chosen so as to exclude any region 
of high sequence homology within the Ae. aegypti genome to avoid off-target transcriptional 
suppression effects on the host.  Transcription templates were gel purified and dsRNA duplexes 
synthesized using the MEGAscript RNAi Kit (Ambion, TX) according to the manufacturer’s 
protocols.  DsRNA species were quantified with a NanoVue spectrophotometer (GE Healthcare, 
NJ) prior to use.   
For this experiment, we noticed that the progeny from newly infected B. malayi worms were 
exhibed higher survival rate in the mosquitoes with an increase in the number of worms that 
successfully develop to the L3 life stage as compared to parasites used in prior experiments that 
have expired due to natural aging. Using the new mf we found that our previously protocol was 
less effective in eliciting consistent suppression. Reoptimization of the protocol produced 
effective target suppression following an initial injection of target dsRNA at 6 day post-infection 
(dpi), at a time just prior to the molt from second larval stage (L2) parasites developing into the 
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third larval stage (L3) parasite [62], followed by two subsequent injections at 9 and 12 dpi.  The 
mosquitoes were processed to confirm suppression of the target gene, as described below, 48 h 
post final injection of dsRNA. 
D. Relative Quantitative RT-PCR 
B. malayi infected mosquitoes injected with either saline (control) or dsRNA were cold 
anesthetized on ice. Total RNA from individual mosquitoes was extracted using the RNAqueous 
Kit (Ambion, TX) followed by DNase treatment using the TURBO DNA-free Kit (Ambion, TX) 
in thin-walled PCR tubes.  The RNA was stabilized with RNase Out Inhibitor (Invitrogen, CA) 
and stored at 4°C in RNase-free microcentrifuge tubes.  Relative semi-quantitative RT-PCR was 
performed using this RNA as template. Relative semi-quantitative RT-PCR was performed using 
the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase (Invitrogen, 
CA).  The B. malayi cathepsin L-like gene, Bm-cpl-1 (Accession number AF331035 [229]), 
served as the internal standard on which the intensity of the target gene amplified from the same 
RNA sample is compared to.  This gene was chosen as we had previously determined its stable 
transcript production during the B. malayi L3 stage by PCR  [257].   
The oligonucleotide primers used to amplify targets were designed to flank the gene regions 
covered by the dsRNA. These primer sequences can be found in Table 5. The profile for Bm-cpl-
1, Bm-gar-2, Bm-pc-2, Bm-flp-21, and Bm-tub-1 PCR were: cDNA synthesis at 50°C for 30 
minutes; an initial denaturation phase of 94°C for 2 min; 42 cycles of 94°C for 30 s, 60°C for 30 
s, 68°C for 1 min and a final extension phase of 68°C for 5 min. The profile for Bm-GluCl-α3A 
PCR was: cDNA synthesis at 50°C for 30 minutes; an initial denaturation phase of 94°C for 2 
min; 32 cycles of 94°C for 30 s, 60°C for 30 s, 68°C for 1 min and a final extension phase of 
68°C for 5 min. Reactions were visualized on a 1.2% agarose gel containing ethidium bromide. 
94 
 
 
 
  
95 
 
 
 
 
E. Quantitative RT-qPCR 
Total RNA from each individual B. malayi infected mosquito injected with saline (control) or 
dsRNA was extracted and DNase-treated as described above for three replicated RNAi 
experiments. Following DNase treatment, RNase Out Inhibitor was added to each sample. Each 
RNA sample was quantified spectrophometrically. This RNA served as a template in our RT-
qPCR assays using the qScript One-Step Fast RT-PCR Kit with ROX (Quanta BioSciences, MD). 
Establishing PREXCEL-Q Parameters 
To establish our RT-qPCR parameters and determine the valid working ranges for all of our 
samples (target and reference genes), PREXCEL-Q, a qPCR assay development and project 
management software, was employed. To determine the optimum template concentration to use 
while avoiding RT-qPCR inhibition for each of the seven targets, a mixture of the RNA samples 
at concentration range between 0.02 to 0.14 ng/µl was used. For subsequent quantitative 
assessment of transcript abundance, each RNA sample was diluted to 0.11 ng/µl with 6 µl of 
sample used per 25 µl reaction. 
Primers and Probes 
The target sequences under evaluation in the RT-qPCR study were the B. malayi β-tubulin 1,  
glutamate-gated chloride channel alpha-3A subunit, G-protein coupled acetylcholine receptor-2, 
FMRFamide-like peptide-21, and prohormone convertase-2 transcript previously described.  
Two reference genes were used, a cathepsin L-like gene Bm-cpl-1 also previously described, and 
Bm-tph-1 (Accession number U80971), a tumor protein homolog-encoding gene that is a proven 
reference gene for qPCR of Brugia development in mosquitoes [228].  To facilitate the use of 
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shorter gene specific primer-probe sets for this study, TaqMan minor groove binding (MGB) 
probes were used.  All primers and probes were designed using Primer Express v. 2.0 software 
(Applied Biosystems, CA) and synthesized by Applied Biosystems.  The primer and probe 
sequences used are shown in Table 6. 
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Gene Primer sequence (5' - 3') 
Amplicon 
size (bp) 
  
Bm-tub-1 
Forward GAACGCCGATCTCCGTAAAC 
62 Reverse AGAAATGCAACCGTGGAAATG 
Probe 6FAM-TGCCGTCAATATGG-MGBNFQ 
  
Bm-GluCl-α3A 
Forward GGATGCTGTACCTGCTCGTGTA 
71 Reverse ATACCTGATGCTTGTGTAGTCATTGTT 
Probe 
6FAM-CATTAGGTGTAACAACATTG-
MGBNFQ 
  
Bm-gar-2 
Forward CCGCCTCGGATTGAGGTTA 
62 Reverse CGTACTTCCTCCGATGTTACCAA 
Probe 6FAM-CGAGGAACCAAAGCA-MGBNFQ 
  
Bm-flp-21 
Forward CAGTGCTACAAACTGCTAAGGATGA 
71 Reverse TGCTGCTGGAATAGCGTGAT 
Probe 
6FAM-TGATAGTACTCAGTATTCTAC-
MGBNFQ 
  
Bm-pc-2 
Forward CCCTCGACCGGAAATCTTGT 
61 Reverse CTGTCGGAGTTCCCAAGCA 
Probe 
6FAM-CTGGAATTGATTACTGATGC-
MGBNFQ 
  
Bm-cpl-1 
Forward GGTTACGGAACGCATCGAA 
62 Reverse TGGGTTCCCCAGCTATTTTTAA 
Probe 
6FAM-TCACGGTGATTACTGGAT-
MGBNFQ 
  
Bm-tph-1 
Forward TTGCAACGATATGTTGATCTTCAA 
62 Reverse ACGAGTCCGACGCAAGCT 
Probe 6FAM-ATGCATTCACAGATGAC-MGBNFQ 
  
Table 6. Primer and TaqMan probe sequences for RT-qPCR experiment. 
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TaqMan RT-qPCR 
For each RNA sample, 25 µl volume reactions were prepared in duplicate and 20 µl of this 
reaction mixture was applied per well on a 96-well plate (using white-well reaction plates, 
Eppendorf, NY).  Individual components of each RT-qPCR reaction were as follows: 6 µl 
prediluted RNA (as determined by PREXCEL-Q), 6.25 µl 4X One-step Fast Master Mix with 
ROX, 1.25 µl qScript One-Step Fast RT, 775 nM each primer, 150 nM probe, nuclease-free 
water to 25 µl.  Cycling conditions included an initial cDNA synthesis step of 50°C for 5 min 
followed by an RT denaturation/Taq activation phase of 95°C for 30 s then 45 cycles of 95°C for 
3 s and 58°C for 30 s.  Four point standard curves were created for each target (within the ng/µl 
ranges already specified above) by diluting the RNA sample mixture in each case according to 
precise, PREXCEL-Q-determined parameters (eight-fold dilution from highest to lowest 
concentration).  Nuclease-free water was substituted for RNA in No-template control reactions. 
Thermocycling was performed on an ABI GeneAmp 5700 SDS (Applied Biosystems).  
Quantification cycle (Cq) values were obtained at an appropriate threshold per each target (~0.1 
DRn in all cases), and data were processed using custom Excel files by the efficiency-corrected 
(E∆∆Cq) relative quantification method [227]. 
F. Phenotype Analysis 
After confirmation of target gene suppression, multiple assays were performed to describe 
worm phenotypes.  Each phenotypic assay was performed 14 dpi. Infected mosquitoes were 
inoculated with target specific dsRNA at 6, 9, and 12 dpi. Mosquitoes were cold-anesthetized on 
ice before the wings and legs were removed and discarded.  The head, thorax and abdomen were 
partitioned and further dissected to release the parasites.  The following characteristics of 
dissected parasites were observed:  (1) Parasite location:  In order to be successfully transmitted, 
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these parasites have to actively migrate to the head of the mosquito and vigorously writhe free of 
the proboscis.  Parasite migration through the mosquito was recorded and measured according to 
escape point from the mosquito body (abdomen, thorax or head).  (2) Worm motility: A scoring 
schema ranging from one (immotile) to five (constantly, highly motile) was used to quantify 
parasite movement in a blind fashion by an independent evaluator.  (3) Kinked morphology: 
The number of parasites with a perturbed section of body wall slightly caudal to the midpoint of 
the worm was noted.  (3) Parasite survival / viability:  The number of parasites that survived to 
the infectious stage was recorded so that infection prevalence and mean intensity could be 
calculated.  (4) Mosquito survival / viability: The number of mosquitoes that survived through 
the development of parasites to the infectious stage was recorded because B. malayi inflict 
significant pathology and decrease mosquito survival. 
G. Statistical Analysis 
To analyze the effect of RNAi on gene expression in the RT-qPCR experiments and parasite 
size, t-tests were used. To analyze the effect of RNAi on worm motility based on our one 
through five blind-scoring schema and worm viability based on the number of parasites 
harvested from each infected mosquito, ANOVA was employed. To analyze the effect of RNAi 
on all other worm and mosquito behaviors assayed, chi square tests were used.  For all tests, P 
values ≤ 0.05 were considered statistically significant. 
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IV. RESULTS 
A. Target Genes were Expressed During Mosquito Borne Life Cycle Stages 
The target genes were checked for expression during the intermediate host life cycle using 
Brugia malayi microfilaria, L2 and L3 cDNA libraries (kindly provided by Dr. S. Williams, 
Smith College, MA) as PCR templates. Bm-tub-1 was expressed at all three life stages (Figure 
15A) but Bm-GluCl-α3A was expressed only at the L3 life stage (Figure 15B).  Similarly, Bm-
gar-2 was strongly expressed at the L3 larvae life stage with faint expression at the mf life stage 
and no expression at the L2 life stage (Figure 15C).  Bm-flp-21 was found to be expressed at all 
three stages (Figure 15D) and Bm-pc-2 was expressed weakly at the mf life stage and strongly at 
the L3 life stage with no expression at the L2 life stage (Figure 15E). The expression of all gene 
targets during the mosquito-borne life stages provides a basis to evaluate their potential and 
effectiveness as drug targets using our mosquito-based in squito RNAi protocol. 
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Figure 15. Target genes are expressed during mosquito life cycle stages. (A) 
Bm-tub-1 was expressed at all three life stages (microfilaria (mf), L2 and L3 
stages). (B) Bm-GluCl-α3A was expressed only at the L3 stage. (C) Similarly, 
Bm-gar-2was expressed strongly at the L3 larvae life stage with faint expression 
at the mf life stage and no expression at the L2 stage. (D) Bm-flp-21 was 
expressed at all three life stages. (E) Bm-pc-2 was expressed weakly at the mf life 
stage and strongly at the L3 stage with no expression at the L2 stage.  
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B. In squito Suppression of Target Genes was Potent and Specific 
Infected mosquitoes were separated into six different groups: control, Bm-tub-1, Bm-GluCl-
α3A, Bm-gar-2, Bm-flp-21, and Bm-pc-2. Each group was injected with 150 ng of the appropriate 
dsRNA at 6, 9, and 12 dpi except for the control group, which was injected with an equal volume 
of Aedes physiological saline. Gene suppression was assayed 48 h post last dsRNA injection 
using a semi quantitative RT-PCR in which the intensity of the target gene amplification in the 
linear phase of the reaction was compared to an internal B. malayi reference gene (Bm-cpl-1) that 
is expressed stably. Suppression was consistent for four of the five target genes; Bm-pc-2 could 
not be consistently suppressed but rather was potently up-regulated (Figure 16). 
Real time quantitative PCR (RT-qPCR) was used to quantify the level of Bm-tub-1,Bm-
GluCl-α3A,Bm-gar-2, and Bm-flp-21suppression relative to two reference genes (Bm-cpl-1 and 
Bm-tph-1) using the E∆∆Cq relative quantification method [227]. PREXCEL-Q software was used 
to optimize the performance of the RT-qPCR assay; and important data pertinent to PCR 
efficiency, linear dynamic range and normalization of the assay are documented in Table 7. Bm-
tph-1 showed stable Cq values across the experiment and therefore was the most appropriate 
reference gene for these studies, as shown previously [228]. Bm-pc-2 mRNA abundance after 
RNAi was quantified relative to Bm-cpl-1 only, as Bm-tph-1 transcript level was reduced by 38.2% 
(P<0.0001) after dsBm-pc-2 treatment. The suppression of Bm-tub-1, Bm-GluCl-α3A, Bm-gar-2, 
and Bm-flp-21 was potent and specific. Thrice RNAi reduced Bm-tub-1 transcript by 37% 
compared to saline injected controls (P<0.0001) (Figure 17A), thrice Bm-GluCl-α3A by 28% 
(P<0.001) (Figure 17A), thrice Bm-gar-2 by 53% (P<0.0001) (Figure 17A) and thrice Bm-flp-21 
by 45% (P<0.0001) (Figure 17A). Thrice injection of 150 ng Bm-pc-2 dsRNA surprisingly 
increased Bm-pc-2 transcript by 341% compared to saline injected controls (P<0.0001) (Figure 
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17B). Bm-cpl-1 reference gene transcript was slightly reduced by Bm-tub-1, Bm-GluCl-α3A, Bm-
gar-2, and Bm-flp-21 RNAi treatments but these reductions were not significant (Bm-gar-2 
dsRNA, 10.0%, P=0.06; Bm-GluCl-α3A, 9.4%, P=0.071; Bm-tub-1, 13.4%, P=0.47; Bm-flp-21, 
12.1%, P=0.55). These data support the gel based semi-quantitative RT-PCR experimental 
findings and provided evidence that Bm-pc-2 dsRNA exposure resulted in an up-regulation of 
Bm-pc-2.  
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Figure 16. Target genes are suppressed using in squito RNAi protocol. 
Micrograph shows gel electrophoresis of relative RT-PCR analysis of individual, 
B. malayi-infected mosquitoes 48 h post-injection of RNAi trigger. (A) 
amplification product of the reference gene Bm-cpl-1 and all six target genes: Bm-
flp-21, Bm-gar-2, Bm-pc-2, Bm-tub-1, and Bm-GluCl-α3A of control B. malayi-
infected mosquito injected with saline (B) Amplified product for the target gene, 
Bm-tub-1, is shown right of the reference gene Bm-cpl-1 (C) Amplified product 
for the target gene, Bm-GluCl-α3A, is shown left of the reference gene Bm-cpl-1 
(D) Amplified product for the target gene, Bm-gar-2, is shown right of the 
reference gene Bm-cpl-1 (E) Amplified product for the target gene, Bm-flp-21, is 
shown left of the reference gene Bm-cpl-1 (F) Amplified product for the target 
gene, Bm-pc-2, is shown right of the reference gene Bm-cpl-1.  
  
107 
 
 
 
  
108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
 
 
 
 
 
Figure 17. Quantitative RT-PCR demonstrates significant reduction in 
transcript abundance of Bm-tub-1, Bm-GluCl-α3A, Bm-gar-2, and Bm-flp-21 
and a dramatic up-regulation of Bm-pc-2 following dsRNA. (A) Injection with 
Bm-tub-1 dsRNA decreased Bm-tub-1 transcript by 37% compared to control. 
Injection with Bm-GluCl-α3A dsRNA reduced Bm-GluCl-α3A transcript by 33% 
compared to control. Injection with Bm-gar-2 dsRNA reduced Bm-gar-2 
transcript by 55% compared to control. Injection with Bm-flp-21 dsRNA 
decreased Bm-flp-21 transcript by 45% compared to control. Bm-GluCl-α3A, Bm-
tub-1, Bm-gar-2, and Bm-flp-21 are normalized to two reference genes Bm-tph-1 
and Bm-cpl-1. (B) Injection with Bm-pc-2 dsRNA increased Bm-pc-2 transcript 
by 341% compared to control. Bm-pc-2 is normalized to Bm-cpl-1 reference gene 
since Bm-pc-2 dsRNA injection resulted in a significant Bm-tph-1 reduction of 38% 
(P<0.001). Quantitative RT-PCR was performed 48 h post last injection of RNAi 
trigger at 14 dpi. Each bar represents 10 mosquitoes from three biological 
experimental replicates.  
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C. Brugia Gene Suppression Result in Aberrant Motility 
Mosquitoes were injected with 150 ng of target dsRNA or saline (control) at 6, 9, and 12 dpi 
then microdissected at 14 dpi to harvest L3-stage parasites. Worm motility was digitally recorded 
and scored according to a five-point schema of one (immobile) to five (all parts of the worm in 
constant motion). Bm-tub-1 suppression decreased worm motility by 11.0% compared to control 
(P<0.001). Similarly, Bm-GluCl-α3A, Bm-gar-2, and Bm-pc-2 suppressions also elicited 9.5% 
(P<0.001), 6.7% (P=0.001), and 5.5% (P=0.017) reduction in worm motility. With Bm-flp-21 
suppression, an increased motility of 1.8% was observed, but this increase was not statistically 
significant (P=0.420) (Figure 18). 
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Figure 18. Bm-tub-1, Bm-GluCl-α3A, Bm-gar-2, and Bm-pc-2 dsRNA 
exposure elicited reduced motility. Frequency distribution for motility of L3 
stage B. malayi recovered from Ae. Aegypti. Bm-tub-1, Bm-GluClα3A, Bm-gar-2, 
and Bm-pc-2 dsRNA exposure resulted in 11.0%, 9.5%, 6.7%, and 5.5% motility 
reduction compared to control. Bm-flp-21 suppression did not alter worm motility. 
Parasitized mosquitoes were injected with saline (control) or 150 ng B. malayi 
target dsRNA at 6, 9, and 12 dpi, then microdissected to obtain parasites at 14 dpi. 
Parasite motility was scored on a 1-5 scale, with 1 = immobile and 5 = highly 
mobile. Control n=88, dsBm-tub-1 n=57(P < 0.001), dsBm-GluCl-α3A n=75 
(P<0.001), dsBm-gar-2 n=106 (P=0.001), dsBm-flp-21 n = 65 (P=0.420), and 
dsBm-pc-2 n=56 (P=0.017) 
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D. Effect of dsRNA Exposure on Normal Knotting Behavior of L3 B. malayi 
Healthy B. malayi L3 are characterized by a highly, continuously active and convoluted body 
form with either one, or both ends of the parasite being noticeably tortuous; we describe this 
curvature phenotype as “knotted’. Using the control and RNAi suppressed worms extracted for 
motility evaluation we took note of whether the worm exhibited zero, one, or both ends knotted. 
Control worms exhibited 1% zero ends knotting, 51% one end knotted, and 48% both ends 
knotted. Compared to controls, gene suppression elicited a marked decrease in knotting behavior. 
Bm-tub-1 suppression elicited an 8-fold increase in zero ends knotted and a 30% decrease in both 
ends knotted (P<0.001). Bm-GluCl-α3A suppression resulted in a 19-fold increase in zero end 
knotting frequency and decreased both ends knotted frequency by 58% (P<0.001). The incidence 
of zero ends knotted was increased 12-fold following Bm-gar-2 suppression. One and both end 
knotting among Bm-gar-2 suppressed worms also decreased by 13% and 13% (P<0.001). Bm-
flp-21 suppression resulted in a 26 fold increase in incidence of zero ends knotted and a decrease 
in one and both ends knotted frequency of 16% and 45% (P<0.001). Bm-pc-2 dsRNA exposure 
produced a 4-fold increase in zero end knotting frequency and a 9% reduction in one end 
knotting frequency (P=0.011) (Figure 19). 
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Figure 19. Suppression of target Brugia malayi genes altered normal 
knotting behavior. Frequency of control worms exhibited zero, one, and both 
end knotting are 1%, 515, and 48%. Bm-tub-1 suppression resulted in zero, one, 
and both end knotting frequency of 11%, 56%, and 33%. Bm-GluCl-α3A 
suppression resulted in zero, one, and both end knotting frequency of 23%, 57%, 
and 20%. Bm-gar-2 suppression resulted in zero, one, and both end knotting 
frequency of 14%, 44%, and 42%. Bm-flp-21 suppression resulted in zero, one, 
and both end knotting frequency of 31%, 43%, and 26%. Bm-pc-2 dsRNA 
exposure resulted in zero, one, and both end knotting frequency of 5%, 46%, and 
48%. Infected mosquitoes were injected with Aedes physiological saline (control) 
or 150 ng B. malayi target dsRNA at 6, 9, and 12 dpi, then microdissected to 
obtain parasites at 14 dpi. Control n = 88, dsBm-tub-1 n=57 (P<0.001), dsBm-
GluCl-α3A n=75 (P<0.001), dsBm-gar-2 n=106 (P<0.001), dsBm-flp-21 n=65 
(P<0.001), and dsBm-pc-2 n=56 (P=0.011). 
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E. Worm Distribution is Significantly Altered with RNAi Suppression.  
To further examine the effect of B. malayi gene suppression, worm distribution was 
examined. Two days after RNAi treatment, each mosquito was partitioned into head, thorax, and 
abdomen and the number of worms harvested from each segment was counted. Since no control 
or RNAi suppressed worms were found in the abdomen, the dissected mosquitoes were further 
divided into five categories based on where the worms were harvested: all worms found in the 
head, majority of worms found in the head, half of the worms found in head and half in thorax, 
majority of worms found in the thorax, and all worms found in the thorax. Worms in control 
mosquitoes were predominantly found in the head with 90% of the mosquitoes having either all 
or the majority of worms extracted from the head region. Bm-tub-1, Bm-GluCl-α3A, and Bm-gar-
2 suppression significantly disrupted worm migration with only 22% (Bm-tub-1 P<0.001), 13% 
(Bm-GluCl-α3A P<0.001), and 39% (Bm-gar-2 P<0.001) of mosquitoes having all or the 
majority of worms present in the head region. No statistically significant change in worm 
migration was noted with Bm-flp-21 and Bm-pc-2 dsRNA exposure (Figure 20). 
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Figure 20. Frequency distribution of worms extracted from control and 
dsRNA injected mosquitoes. Control mosquitoes: 72% with all worms present in 
head region, 18% with majority of worms present in head region, 5% with half of 
worms present in head region and half of worms present in thorax region, 2% 
with majority of worms present in thorax, and 3% with all worms present in the 
thorax. Bm-tub-1 dsRNA injected mosquitoes: 10% with all worms present in 
head region, 12% with majority of worms present in head region, 12% with half 
of worms present in head region and half of worms present in thorax region, 35% 
with majority of worms present in thorax, and 31% with all worms present in the 
thorax. Bm-GluCl-α3A dsRNA injected mosquitoes: 5% with all worms present in 
head region, 8% with majority of worms present in head region, 7% with half of 
worms present in head region and half of worms present in thorax region, 17% 
with majority of worms present in thorax, and 63% with all worms present in the 
thorax. Bm-gar-2 dsRNA injected mosquitoes: 11% with all worms present in 
head region, 28% with majority of worms present in head region, 25% with half 
of worms present in head region and half of worms present in thorax region, 23% 
with majority of worms present in thorax, and 13% with all worms present in the 
thorax. Bm-flp-21 dsRNA injected mosquitoes: 78% with all worms present in 
head region, 20% with majority of worms present in head region, and 2% with 
majority of worms present in thorax. Bm-pc-2 dsRNA injected mosquitoes: 72% 
with all worms present in head region, 12% with majority of worms present in 
head region, 9% with half of worms present in head region and half of worms 
present in thorax region, 2% with majority of worms present in thorax, and 5% 
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with all worms present in the thorax. Infected mosquitoes were injected with 
saline (control) or 150 ng B. malayi target dsRNA at 6, 9, and 12 dpi, then 
microdissected to obtain parasites at 14 dpi. Based on where the majority or all of 
the worms are harvested, mosquitoes were each sub-divided into five categories: 
all worms found in the head, majority of worms found in the head, half of the 
worms found in head / thorax, majority of worms found in the thorax, and all 
worms found in the thorax.  Control n = 88, dsBm-tub-1 n=58 (P<0.001), dsBm-
GluCl-α3A n=77 (P<0.001), dsBm-gar-2 n=107 (P<0.001), dsBm-flp-21 n=65 
(P=0.064), and dsBm-pc-2 n=58 (P=0.335). 
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F. Effect of B. malayi Target Gene Suppression on Worm Survival 
Parasitized mosquitoes were injected with saline (control) or 150 ng B. malayi target dsRNA 
at 6, 9, and 12 dpi, and then microdissected at 14 dpi. The number of extracted worms per 
mosquito was counted. The mean intensity of worms found among n=88 control mosquitoes was 
3.44 worms per mosquito. Bm-tub-1, Bm-GluCl-α3A, and Bm-pc-2 dsRNA exposure 
significantly reduced the average number of worms found per mosquito by 19% (Bm-tub-1, 
P<0.001), 17% (Bm-GluCl-α3A, P<0.001), and 13% (Bm-pc-2, P=0.004). Bm-gar-2 suppression 
had no effect on worm survival, but Bm-flp-21 suppression increased worm survival by 30% 
(P<0.001) (Figure 21). 
 
G. Effect of B. malayi Target Gene Suppression on Mosquito Survival  
To examine mosquito survival, the number of mosquitoes that survived to 14 dpi for each of 
the dsRNA and saline injected groups was counted.  Mosquito survival rate was determined 
based on the ratio of surviving mosquitoes to total infected mosquitoes per dsRNA or saline 
injection group. We found that Bm-tub-1, Bm-GluCl-α3A, Bm-gar-2, and Bm-pc-2 dsRNA 
injection did not significantly alter mosquito survival rate, but Bm-flp-21 suppression resulted in 
a 22% reduction in mosquito survival rate (P=0.004).  
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Figure 21: Parasite mean intensity of control and dsRNA injected Aedes 
aegypti. Average number of worms extracted from control group mosquitoes was 
3.44. Average number of worms extracted from Bm-tub-1, Bm-GluCl-α3A, Bm-
gar-2, Bm-flp-21, and Bm-pc-2 dsRNA injected mosquitoes were 2.79, 2.87, 3.69, 
4.48, and 3.00. Infected mosquitoes were injected with saline (control) or 150 ng 
B. malayi target gene dsRNA at 6, 9, and 12 dpi, and then microdissected to 
obtain an infection count. Control n = 88, dsBm-tub-1 n=58 (P<0.001), dsBm-
GluCl-α3A n=77 (P<0.001), dsBm-gar-2 n=107 (P=0.055), dsBm-flp-21 n= 65 
(P<0.001), and dsBm-pc-2 n=58 (P=0.004).  
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V. DISCUSSION 
A. The Robustness of the in squito RNAi Protocol 
In this study we examined five B. malayi genes encoding known and putative drug targets 
using in squito RNAi. Of the five target genes, consistent RNAi mediated suppression was 
achieved with Bm-tub-1 (37%), Bm-GluCl-α3A (28%), Bm-gar-2 (53%), and Bm-flp-21 (45%) 
and up-regulation of 341% was observed with Bm-pc-2 dsRNA RNAi trigger exposure. The 
relatively reliable knock down of target gene expression compares favorably with other RNAi 
methodologies applied to a broad cross section of parasitic nematodes that have met with limited 
success. The consistency of our RNAi protocol may be a result of in vivo RNAi suppression 
within the host because all previous RNAi protocols introduce RNAi triggers within artificial in 
vitro RNAi environments. 
B. Bm-tub-1 
Benzimidazole-type anthelmintics, such as albendazole, exert their effect by binding to β-
tubulin and inhibiting microtubule formation. Microtubules have a wide variety of functions such 
as intracellular transport, nutrient (glucose) uptake, cell shape, and synaptic formation among 
others [266, 270-273]. Thus the disruption of microtubule formation interrupts parasite survival 
in a multitude of ways including preventing the uptake of glucose, inhibiting egg production and 
impairing muscle movement leading to nematode death [266, 270-273]. While albendazole alone 
has no anti-filarial effect, when giving in conjunction with either ivermectin or DEC it has 
proven to enhance both anti-filarial drugs’ potency [80]. Based on this proven activity, B. malayi 
β-tubulin (Bm-tub-1) was selected as a gene target for our evaluation. In our in squito RNAi 
suppression of Bm-tub-1, we observed a reduction in worm motility. In addition, the parasite 
mean intensity for Bm-tub-1 suppressed mosquitoes was significantly reduced compared to 
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control. Worms from Bm-tub-1 infected mosquitoes were more predominantly found in the 
thorax. The decrease in worm motility and survival as well as disruption to worm migration 
indicates that Bm-tub-1plays an important role in normal worm survival and transmission. It 
should be noted that suppression of Bm-tub-1 in the mosquito stages of the parasite lifecycle did 
not result in a lethal phenotype as observed by Blaxter and Aboobaker using in vitro RNAi 
method on adult female B. malayi [9].  
C. Bm-GluCl-α3A 
At present, of the two anti-filarial drugs available, only ivermectin’s potential site of action is 
known. Based on studies using various non-filarial nematodes, ivermectin has been found to 
selectively bind to the glutamate-gated chloride channel alpha subunit exerting complementary, 
and potentially additive, effects with glutamate on the glutamate-gated chloride channel resulting 
in confirmation changes and the observed slow and irreversible channel opening [93, 97, 99, 101, 
111, 258]. This irreversible activation of glutamate-gated chloride channel leads to the two 
observed effects of ivermectin on non-filarial nematodes: paralysis of body wall muscle [294] 
and pharyngeal musculature [259. 260, 262]. As such gastrointestinal nematodes experience 
compromised motility and feeding, and are subsequently expelled from the host body [263]. The 
mode of action for ivermectin is  less certain for filarial nematodes where it is only effective as a 
microfilaricide [264, 265]. Thus, at present, little is know about anti-filarial drug actions. 
The exposure of dsBm-GluCl-α3A resulted in a 28% reduction in Bm-GluCl-α3A transcript 
level. The mean Cq value for Bm-GluCl-α3A in our quantitative RT-qPCR experiments was 
37.04 ± 1.65,  a Cq value typically associated with approximately one copy of the target 
transcript, given such low initial transcript abundance, quantification by RT-qPCR is likely to be 
less reliable than for the other targets and given that the reaction efficiency for this gene was low 
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(30%) it is reasonable to expect this 28% reduction is an underestimate of the actually knock 
down achieved, which may actually be closer to 50-60%. 
Bm-GluCl-α3A suppression significantly reduced the worm survival within infected mosquito. 
Bm-GluCl-α3A suppression also compromised the L3 worms’ capability to navigate within the 
mosquito host body toward the head region. Studies using the filarial worm B. pahangi 
demonstrated that ivermectin effectively blocked amphid response to chemical stimuli [267, 268]. 
Amphids are the sensory organs within the nematode head that contains sensory neurons. 
Additionally in H. contortus, the ivermectin resistant strains were found to have defective 
amphids [269]. The phenotypes observed in Bm-GluCl-α3A suppression are as expected of 
worms with sensory disruption thus hinting at a potential role for ivermectin in disrupting the 
worms’ sensory system. 
It would be expected that compromised navigation would result in worms migrating to the 
abdomen as well, but this is not the case. Lack of migration to the abdomen could be attributed to 
suppression of Bm-GLuCl-α3A merely diminishing the worm’s capability in distinguishing 
sensory stimuli directly related to migration out of the head. 
Moreno et al. reported that ivermectin acts to prevent B. malayi microfilarial excretory-
secretory capability of microfilaria [282]. In B. malayi, the glutamate-gated chloride channel, 
which is the target site for ivermectin, was found to be expressed only in the muscle structure 
surrounding and controlling the microfilarial excretory-secretory vesicles [282]. Moreno et al. 
postulated that the suppression of glutamate-gated chloride channel, which regulates the release 
of excretory-secretory vesicle contents, prevents the release / secretion of proteins that facilitate 
in parasite host immune evasion [282]. The reduction in the number of parasites found within 
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Bm-GluCl-α3A dsRNA injected mosquito may be a result of Bm-GluCl-α3A suppressed worms’ 
diminished capability to release host immune evasion proteins. 
In non-filarial nematodes, the paralysis of body wall muscle is due to ivermectin’s action on 
inhibitory motor neurons. The irreversible opening of glutamate-gated chloride channel result in 
the irreversible hyperpolarization of inhibitory motor neurons. This hyperpolarization renders the 
inhibitory motor neuron incapable of producing the inhibitory action potentials that is necessary 
for muscle relaxation [263]. This capacity for muscle relaxation is required for normal worm 
movement [263]. Here we observed that Bm-GluCl-α3A suppression resulted in reduced worm 
motility which is consistent with a reduced capacity to regulate inhibitory neuromuscular 
signaling. The lack of worm paralysis with Bm-GluCl-α3A suppression could be due to the 
presence of multiple glutamate-gated chloride channel subtypes and that suppression of Bm-
GluCl-α3A renders only those channel subtypes consisting of the Bm-GluCl-α3A subunit 
defective. The defective channel subtypes could be compensated for to a certain extent by 
replacement with other channel subtypes, thus Bm-GluCl-α3A suppression would not completely 
abolish inhibitory motor neuron regulation.  
D. Bm-gar-2 
Neurotransmitter gated G protein-coupled receptors such as GARs regulate cellular activities 
via cytoplasmic second messengers. Because of the fast action of direct ligand gated channels, 
the slower indirect GPCRs like GARs have been largely ignored in the past. Recent studies on 
GARs demonstrate their importance in regulating neuromuscular movement in organisms such 
as C. elegans have spurred interest in GARs as potential anthelmintic drug targets [280]. Dittman 
and Kaplan (2008) demonstrated that Ce-gar-2 plays a role in inhibiting cholinergic motor 
neurons in C. elegans and the loss of Ce-gar-2 function result in a decrease of both reversal and 
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large-angle (omega) turning behavior [280]. Stegger and Avery (2004) found evidence 
suggesting that Ce-gar-3 may play a role in regulating C. elegans pharyngeal pumping [281]. 
The removal of Ce-gar-3 resulted in an increased pharyngeal pump rate [281]. Conversely, over 
activation of Ce-gar-3 resulted in the pharyngeal muscle unable to relax to the closed position 
thus inhibiting the effective transport of bacteria into the worm intestine [281]. As such, 
interruption in the regulatory component of the parasitic nematodes may impair its survival 
capability. Thus a putative B. malayi GAR (Bm-gar-2) was selected to evaluate whether GARs in 
B. malayi are sites for potential anti-filarial drug development.  
In our study, suppression of Bm-gar-2 elicited reduced motility and disrupted worm 
migration. These observed phenotypes correlate with the neuronal regulatory function of GARs 
and gar-2’s role in inhibiting cholinergic motor neurons as demonstrated in C. elegans [280]. A 
reduced ability to inhibit cholinergic motor neurons would disrupt normal smooth body motion 
in line with the observed reduction in worm motility accompanying Bm-gar-2 suppression. It is 
also observed that Bm-gar-2 suppression diminished worm migratory capability. Unlike Bm-
GluCl-α3A,and Bm-tub-1 suppression, Bm-gar-2 suppression did not result in a predominance of 
incidence where all or majority of worms found in thorax, but instead, Bm-gar-2 suppressed 
worms had relatively equal occurance of majority or all of the harvested worms found in the 
head as occurance of majority or all of the harvested worms found in the thorax. Why this is 
remains a puzzle and is something that warrants further investigation. At present it can only be 
speculated that the suppression of Bm-gar-2 possibly disrupted the worm’s migratory and 
navigation capability. While much more needs to be investigated about the role GARs play in 
filarial nematodes, the information gleaned from our Bm-gar-2 suppression study shines light on 
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Bm-gar-2 as a potential drug target that merits further consideration for GARs as potential new 
anthelmintic drug targets.  
E. Bm-flp-21 
FMRFamide-like peptides (FLPs) are the largest and most diverse family of neuropeptides 
within invertebrates [221, 274, 284, 285]. FLPs are highly conserved between parasitic 
nematodes [283] and have a broad role within its nervous system [283] and are associated with 
parasite motor and sensory functions [274]. Studies on FLPs using various nematode systems 
including such as A. suum and C. elegans have demonstrated that they play a role in both 
inhibitory and excitatory modulation of motor neuron activities [286, 290, 291]. In A. suum, the 
FLP gene af1 was found to function in abolishing spontaneous motor neuron activities [292-294]. 
Similarly, the peptide encoded by A. suum FLP gene af8, predicted from the C. elegansflp-6 gene, 
was found to elicit ventral somatic muscle contraction and dorsal somatic muscle relaxation 
[295]. The C. elegans flp-13 peptide has been shown to elicit both ventral and dorsal somatic 
muscle relaxation in A. suum [296]. As such, based on the findings from previous studies, we 
postulate that FLPs may prove to be an important gene for proper filarial worm function and a 
potentially overlooked anti-filarial drug target. Of the B. malayi FLP genes considered, Bm-flp-
21 is the only one whereby dsRNA at sufficient concentration can be consistently produced. As 
such for this study we chose to investigate the importance of Bm-flp-21 in juvenile B. malayi and 
evaluate its potential as anti-filarial drug target.  
In C. elegans, the peptides encoded by the flp-18 and flp-21 genes were also found to 
activate both neuropeptide receptor (NPR)-1 215F and NPR-1 215V receptors [278, 279]. 
Moffett et al. found that peptides encoded in C. elegans Ce-flp-21 gene elicited excitatory effect 
on ovijector of A. suum causing tissue lengthening and the termination of muscle activity leading 
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to flaccid paralysis [297]. In this study, Bm-flp-21 suppressed worms were observed to exhibit an 
increase in worm survival. As expected with the increase in worm survival, mosquito survival 
diminished. The exact reason for the increase in worm survival needs to be further investigated.  
F. Bm-pc-2 
Many biologically important proteins are synthesized as larger inactive polypeptides that 
require prohormone convertase to activate them through proteolytic cleavage at the carboxyl side 
of the mono-, di- or oligomeric basic amino acid sites [287] thus making prohormone convertase 
a potential drug target of interest. Thus for this study we targeted the B. malayi PC2 (Bm-pc-2). 
Suppression of prohormone convertase 2 (PC2) in C. elegans through RNAi elicited aberrant 
phenotypes such as deficient egg laying and uncoordinated movement [287]. The in squitoBm-
pc-2 suppressions were observed to elicit up-regulation of target gene transcription. Quantitative 
RT-qPCR demonstrated significant up-regulation (341%) of Bm-pc-2 with dsBm-pc-2 exposure. 
Why Bm-pc-2 dsRNA exposure resulted in a three to four fold transcription increase is puzzling. 
Geldhof et al. in 2005 reported that attempt to RNAi suppress the Haemonchus contortus 
vacuolar ATPase Hc-vha-10 using electroporation and soaking resulted in the up-regulation of 
Hc-vha-10 expression [213]. Despite the 3.4 fold up-regulation, Bm-pc-2 dsRNA exposure did 
result in a reduction in worm survival. In addition dsBm-pc-2 exposure also elicited a 38% 
reduction in Bm-tph-1 expression not seen with other gene targets investigated in this study. 
Thus it is very possible that the difference in worm survival and motility may be a result of the 
Bm-tph-1 suppression. 
In summary, in this study we examined five existing and putative drug targets Bm-tub-1, Bm-
GluCl-α3A, Bm-gar-2, Bm-flp-21 and Bm-pc-2 using our in squito RNAi protocol. Of the five 
drug targets, consistent RNAi mediated suppression was achieved with Bm-tub-1, Bm-GluCl-
129 
 
 
 
α3A, Bm-gar-2, and Bm-flp-21 RNAi and up-regulation was observed with Bm-pc-2 dsRNA 
exposure. Various phenotypes have been observed with each of the target gene dsRNA exposure 
allowing us to glean a deeper understanding of these gene targets. In the case of Bm-tub-1, Bm-
GluCl-α3A, and Bm-gar-2, RNAi mediated suppression disrupted normal worm motility and 
migration thus severely compromised parasite transmission potential. The significant (30%) 
increase of worm survival rate associated with Bm-flp-21 suppression and the up-regulation of 
Bm-pc-2 both warrants further investigation. Of puzzling interest is the fact that up-regulation of 
Bm-pc-2 resulting from Bm-pc-2 dsRNA exposure resulted in a decrease in worm motility. Why 
this is needs further investigation.  
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CHAPTER 4. GENERAL CONCLUSIONS 
The development of an in vivo RNAi method to study and better understand the biology of 
filarial worm Brugia malayi was achieved and verified. In vivo RNAi was achieved using the 
mosquito host as a culture and delivery system. RNAi trigger was introduced into the infected 
mosquito host via intrathoracic injection and subsequently the developing B. malayi larva is 
exposed to the RNAi trigger.  Suppression was potent and specific for five target genes that 
represent either known or putative drug targets: B. malayi cathepsin L-like cysteine protease 
(Bm-cpl-1), B. malayi β-Tubulin (Bm-tub-1), B. malayi glutamate-gated chloride channel alpha-
3A subunit (Bm-GluCl-α3A), B. malayi G-protein coupled acetylcholine receptor-2 (Bm-Gar2) 
and B. malayi FMRFamide-like peptide-21 (Bm-flp-21). Up-regulation of transcript was 
observed with in vivo dsRNA exposure for B. malayi prohormone convertase-2 (Bm-PC2). The 
consistency and reliability of the in vivo RNAi protocol may be due to exposing the filarial worm 
within its host environment unlike previous in vitro RNAi protocols which requires the worm to 
be extracted from its host prior to carrying out RNAi.  
Bm-cpl-1 suppression revealed new phenotypes associated with molting, growth and 
development, and motility that shed light on the important biological functions of this gene 
family in larval stages of B. malayi. Bm-cpl-1 suppression significantly inhibited worm motility 
and inhibited normal worm terminal curvatures with a significant reduction of exhibited rigorous 
knotting behavior. In addition, Bm-cpl-1 suppression compromised normal worm migration 
within the mosquito intermediate host. With Bm-cpl-1 suppression, mosquito host survival was 
significantly increased as parasite prevalence decreased. Bm-cpl-1 suppression also resulted in a 
significantly shorter worm length. Thus cathepsin L-like cysteine proteases may have potential 
as targets for the development of more efficient anthelmintic drugs.  
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Bm-tub-1and Bm-GluCl-α3A suppression showed we could reduce the expression of B. 
malayi genes that encode proven drug targets and also showed we could reveal phenotypes 
associated with drug target knock down through the use of an array of simple assays. Bm-tub-1 
suppression revealed the importance of β-tubulin for normal parasite motility, survival & 
development, and migration in vivo. Bm-tub-1 suppressed worms exhibited increased kinked 
posture. Furthermore, Bm-tub-1 suppression was found to compromise normal worm motility, 
migration and survival. Bm-GluCl-α3A suppression revealed effects on normal parasite motility, 
survival and development. Bm-GluCl-α3A suppressed worms were found to compromise normal 
worm motility, migration and survival.  
Bm-gar-2 suppression confirmed the importance of G-protein coupled acetylcholine receptor 
as potential site for novel anthelmintic drug development. Bm-gar-2 suppressed worms exhibited 
compromised normal worm motility and migration.  
Bm-flp-21 suppression confirmed the importance of FMRFamide-like peptide for normal 
parasite movement, survival & development, and migration implicating it as peptides of interest 
for further investigation and consideration as basis for anthelmintic drug development. Bm-flp-21 
suppressed worms were found to enhance worm survival and detrimentally impact host 
survivability.  
Bm-pc-2 dsRNA exposure did not result in suppression but instead incidences of what would 
appear to be up-regulation was observed using relative quantitative RT-PCR. Quantitative RT-
qPCR confirmed dsBm-pc-2 exposure resulted in up-regulation of Bm-pc-2 expression level by 3 
to 4 fold. This up-regulation is not unprecedented as Geldhelf et al. in 2005 also noticed similar 
phenomenon with H. contortus vacuolar ATPase gene He-vha-10 [213]. Although motility, 
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worm behavior and development were not altered with Bm-pc-2 dsRNA exposure, worm 
survival was reduced by 13%.  
In conclusion, previous RNAi protocols for parasitic nematodes were unreliable and 
inconsistent. We have developed a new in squito RNAi protocol whereby instead of removing 
parasite form its host to perform in vitro RNAi as previous protocols we here target the filarial 
nematode B. malayi as it develops within the intermediate host, the mosquito Aedes aegypti. The 
consistency and reliability of our in squito RNAi protocol was verified on five target genes of 
interest and its validity as a reverse-genetic tool for identifying novel drug targets and elucidating 
parasite gene functions was also confirmed. In addition in squito RNAi allowed us to gain further 
insight into the biology of targeted genes in larval B. malayi.  
 
  
133 
 
 
 
REFERENCES 
1. Hotez, P.J., Brindley, P.J., Bethony, J.M, King, C.H., Pearce, E.J., and Jacobson, J. (2008) Helminth 
infections: the great neglected tropical diseases. J. Clin. Invest. 118: 1311-1321. 
 
2. Lustigman, S., Zhang, J., Liu, J., Oksov, Y., and Hashmi, S. (2004) RNA interference targeting cathepsin L 
and Z-like cysteine proteases of Onchocerca volvulus confirmed their essential function during L3 molting. 
Mol. Biochem. Parasitol. 138: 165-170. 
 
3. Bethony, J., Brooker, S., Albonico, M., Geiger, S.M., Loukas, A., Diemert, D., and Hotez, P.J. (2006) Soil-
transmitted helminth infections: ascaiasis, trichuriasis, and hookworm. Lancet. 367: 1521-1532. 
 
4. Crompton, D. W. and Nesheim, M.C. (2002) Nutritional impact of intestinal helminthiasis during the human 
life cycle. Ann. Rev. Nutr. 22: 35-59. 
 
5. Miguel, E.A. and Kremer, M. (2003) Worms: identifying impacts on education and health in the presence of 
treatment externalities. Econometrica. 72: 159-217. 
 
6. Bleakley, H. (2007) Disease and development: evidence from hookworm eradication in the American South. 
Q. J. Econ. 122: 73-112. 
 
7. Martin, R.J., Clark, C.L., Trailovic, S.M., and Robertson, A.P. (2004) Oxantel is an N-type (methyridine and 
nicotine) agonist not an L-type (Levamisole and pyrantel) agonist: classification of cholinergic anthelmintics 
in Ascaris. Int. J. Parasitol. 34: 1083-1090. 
 
8. Stewart, T.B. and Hale, O.M. (1988) Losses to internal parasites in swine production. J. Anim. Sci. 66: 1548-
1554. 
 
9. Lu, J., Todd, T., Lee, J., and Trick, H. (2011) Biotechnological application of functional genomics towards 
plant-parasitic nematode control. Plant Biotechnol. J. Epub: j.1467-7652.211.00601.x 
 
10. James, C.E., Hudson, A.L., and Davey, M.W. (2009) Drug resistance mechanisms in helminthes: is it survival 
of the fittest? Trends Parasitol. 25: 328-335. 
 
11. Doenhoff, M.J., Cioli, D., and Utzinger, J. (2008) Praziquantel: mechanisms of action, resistance and new 
derivatives for schistosomiasis. Curr. Opin. Infect. Dis. 21: 659-667. 
 
12. Chirac, P. and Torreele, E. (2006) Global framework on essential health R&D. Lancet. 367: 1560-1561. 
 
13. Hotez, P.J. (2008) Forgotten people and forgotten diseases, the neglected tropical diseases and the impact on 
global health and development. ASM Press. Washington D.C., USA 215 pp. 
 
14. Ottesen, E.A., Hooper, P.J., Bradley, M., and Biswas, G. (2008) The global programme to eliminate 
lymphatic filariasis: health impact after 8 years. PLoS Negl. Trop. Dis. 2: e317. 
 
15. Bennett, J.L., Williams, J.F., and Dave, V. (1988) Pharmacology of ivermectin. Parasitol. Today 4: 226-228. 
 
16. Noroes, J., Dreyer, G., Santos, A., Mendes, V.G., Medeiros, Z., and Addiss, D. (1997) Assessment of the 
efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo. Trans. R. Soc. Trop. Med. Hyg. 91: 78-
81. 
 
17. Pax, R.A., Williams, J.F., and Guderian, R.H. (1988) In vitro motility of isolated adults and segments of 
Onchocerca volvulus, Brugia pahangi and Acanthocheilonema viteae. Trop. Med. Parasitol. 39: 450-455. 
 
18. Sangster, N. C. and Gill, J. (1999) Pharmacology of anthelmintic resistance. Parasitol. Today 15: 141-146. 
134 
 
 
 
 
19. Geary, T.G., Woo, K., McCarthy, J.S., Mackenzie, C.D., Horton, J., Prichard, R.K., de Silva, N.R., Olliaro, 
P.L., and Lazdins-Helds, J.K. (2010) Unresolved issues in anthelmintic pharmacology for helminthiasis of 
humans. Int. J. Parasitol. 40: 1-13. 
 
20. Martin, R.J., Robertson, A.P., and Bjorn, H. (1997) Target sites of anthelmintics. Parasitology. 114: S111-
S124. 
 
21. Bennett, J.L. Williams, J.F., and Dave, V. (1993) Pharmacology of ivermectin. Parasitol. Today. 4: 226-228. 
 
22. McGary, J.F., Plant, L.D., and Taylor, M.J. (2005) Diethylcarbamazine activity against Brugia malayi 
microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. Filaria J. 4: 4. 
 
23. Ottesen, E. (1992) Infection and disease in lymphatic filariasis: an immunologic perspective. Parasitology 
104: S71-S79. 
 
24. World Health Organization (2009) Global programme to eliminate lymphatic filariasis. Weekly 
Epidemiological Record 42: 437-444. 
 
25. Molyneux, D.H., Neira, M., Liese, B., and Heymann, D. (2000) Lymphatic filariasis: setting the scene for 
elimination. Trans. R. Soc. Trop. Med. Hyg. 94: 589-591. 
 
26. de Almeida, A.B. and Freedman, D.O. (1999) Epidemiology and immunopathology of brancroftian filariasis. 
Microbes Infect. 1: 1015-1022. 
 
27. Routh, H. and Bhowmik, K. (1993) History of elephantiasis. Int. J. Dermatol. 32: 913-916. 
 
28. Brattig, N.W., Bazzocchi, C., Kirschning, C.J., Reiling, N., Buttner, D.W., Ceciliani, F., Geisinger, F., 
Hochrein, H., Ernst, M., Wagner, H., Bandi, C., and Hoerauf, A. (2004) The major surface protein of 
Wolbachia endosymbionts in filarial nematodes elicits immune responses through TLR2 and TLR4. J. 
Immunol. 173: 437-445. 
 
29. Dreyer, G., Noroes, J., Addiss, D., Santos, A., Medeiros, Z., and Fiueredo-Silva, J. (1999) Bancroftian 
filariasis in a paediatric population: an ultrasonographic study. Trans. R. Soc. Trop. Med. Hyg. 93: 633-636. 
 
30. Freedman, D.O. (1998) Immune dynamics in the pathogenesis of human lymphatic filariasis. Parasitol. 
Today 14: 229-234. 
 
31. Freedman, D.O., Horn, T.D., Maia e Silva, C.M., Braga, C., and Maciel, A. (1995) Predominant CD8+ 
infiltrate in limb biopsies of individuals with filarial lymphedema and elephantiasis. Am. J. Trop. Med. Hyg. 
53: 633-638. 
 
32. Hise, A.G., Daehnel, K., Gillette-Ferguson, I., Cho, E., McGarry, H.F., Taylor, M.J., Golenbock, D.T., 
Fitzgerald, K.A., Kazura, J.W., and Pearlman, E. (2007) Innate immune responses to endosymbiotic 
Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and 
Mal, but not TLR4, TRIF, or TRAM. J. Immunol. 178: 1068-1076. 
 
33. Mand, S., Marfo-Debrekyei, Y., Dittrich, M., Fischer, K., Adjei, O., and Hoeauf, A., (2003) Animated 
documentation of the filarial dance sign (FDS) in bancoftian filariasis. Filaria J. 3: 3. 
 
34. Olszewski, W.L., Jamal, S., Manokaran, G., Pani, S., Kumaraswami, V., Kubicka, U., Lukomska, B., 
Dworczynski, A., Swoboda, E., and Meisel-Mikolajczyk, F. (1997) Bacteriologic studies of skin, tissue fluid, 
lymph, and lymph nodes in patients with filarial lymphedema. Am. J. Trop. Med. Hyg. 57: 7-15. 
 
35. Tesh, R. and Guzman, H. (1990) Mortality and infertility in adult mosquitoes after the ingestion of blood 
containing ivermectin. Am. J. Trop. Med. Hyg. 43: 229-233. 
135 
 
 
 
 
36. Amaral, F., Dreyer, G., Figueredo-Silva, J., Noroes, J., Cavalcanti, A., Samico, S.C., Santos, A., and 
Coutinho, A. (1994) Live adult worms detected by ultrasonograph in human bancroftian filariasis. Am. J. 
Trop. Med. Hyg. 50: 753-757. 
 
37. Freedman, D.O., de Almeido Filho, P.J., Besh, S., Maia e Silva, M.C., Braga, C., and Maciel, A. (1994) 
Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis. 
J. Infect. Dis. 170: 927-933. 
 
38. Debrah, A.Y., Mand, S., Specht, S. Marfo-Debrekyei, Y., Batsa, L., Pfarr, K., Larbi, J., Lawson, B., Taylor, 
M., Adjei, O., and Hoerauf, A. (2006) Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves 
pathology in lymphatic filariasis. PLoS Pathog. 2: e92. 
 
39. Dissanayake, S., Watawana, L., and Piessens, W. (1995) Lymphatic pathology in Wuchereria bancrofti 
micofilaraemic infections. Trans. R. Soc. Trop. Med. Hyg. 89: 517-521. 
 
40. Freedman, D., de Almeida Filo, M., Besh, S., de Silva, M., Braga, C., and Maciel, A. (1994) 
Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis. 
J. Infect. Dis. 170: 927-933. 
 
41. Freedman, D., de Almeida Filo, M., Besh, S., de Silva, M., Braga, C., Maciel, A., and Furtado, A. (1995) 
Abnormal lymphatic function in presymptomatic bancroftian filariasis. J. Infect. Dis. 171: 997-1001. 
 
42. Ottesen, E. (1994) The human filariasis: new understandings, new therapeutic strategies. Curr. Opin. Infect. 
Dis. 7: 550-558. 
 
43. Maizels, R.M., Sartono, E., Kurniawan, A., Partono, F., Selkirk, M.E., and Yazdanbakhsh, M. (1995) T-cell 
activation and the balance of antibody isotypes in human lymphatic filariasis. Parasitol. Today. 11: 50-56. 
 
44. Wijesinghe, R.S., Wickremasinghe, A.R., Ekanayake, S., and Perera, M.S. (2008) Treatment-seeking 
behavior and treatment practices of lymphatic filariasis patients with lymphoedema in the Colombo district, 
Sri Lanka. Asia Pac. J. Public Health 20: 129-138. 
 
45. Kazura, J.W. (2002) Lymphatic filarial infections: an introduction to the filariae. In: Black, S.J. and Seed, J.R., 
editors. World Class Parasites: Volume 5 The Filaria. Massachusettes, Kluwer Academic Publishers p. 1-8. 
 
46. WHO (1997) Lymphatic Filariasis: Reasons for Hope, WHO, Geneva. 
 
47. WHO (1997) Lympahtic Filariasis Elimination. Report of a Meeting of the Principals for the Further 
Enhancement of Public/Private Partnership. WHO, Geneva. 
 
48. Nores, J., Addis, D., Santos, A., Medeiros, ZA., Coutinho, A., and Dreyer, G. (1996) Ultrasonographic 
evidence of abnormal lymphatic vessels in young men with adult Wuchereria bancrofti infection in the 
scrotal area. J. Urol. 156: 409-412. 
 
49. Noroes, J., Addiss, D., Amaral, F., Coutinho, A., Medeiros, Z., and Dreyer, G. (1996) Occurrence of living 
adult Wuchereia bancrofti in the scrotal area of men with mcirofilaremia. Trans. R. Soc. Trop. Med. Hyg. 90: 
55-56. 
 
50. Noroes, J., Addiss, D., Cedenho, A., Figueredo-Silva, J., Lima, G., and Dreyer, G. (2003) Filarial hydrocoele: 
risk associated with intrascrotal nodules caused by death of adult Wuchereria bancrofti. Trans. R. Soc. Trop. 
Med. Hyg. 97: 561-566. 
 
51. Noroes, J., Dreyer, G., Santos, A., Mendes, V.G., Medeiros, Z., and Addiss, D. (1997) Assessment of the 
efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo. Trans. R. Soc. Trop. Med. Hyg. 91: 78-
81. 
136 
 
 
 
 
52. Case, T., Leis, B., Witte, M., Way, D., Bernas, M., Borgs, P., Crandall, C., Crandall, R., Nagle, R., Jamal, S. 
et al. (1991) Vascular abnormalities in experimental and human lymphatic filariasis. Lymphology 24: 174-183. 
 
53. WHO (2002) Lymphatic Filariasis, WHO, Geneva. 
 
54. Samarasinghe, B., Knox, D.P., and Britton, C. (2011) Factors affecting susceptibility to RNA interference in 
Haemonchus contortus and in vivo silencing of an H11 aminopeptidase gene. Int. J. Parasitol. 41: 51-59. 
 
55. Dreyer, G., Santos, A., Noroes, J., and Addiss D. (1996) Amicrofilaraemic carriers of adult Wuchereria 
bancrofti. Trans. R. Soc. Trop. Med. Hyg. 90: 288-289. 
 
56. Bartholomay, L.C. and Christensen, B.M. (2002) Vector-Parasite Interactions in Mosquito-Borne Filariasis. 
In: Black, S.J. and Seed, J.R., editors. World Class Parasites: Volume 5 The Filaria. Massachusettes, Kluwer 
Academic Publishers p. 9-20. 
 
57. Hunter, S.J., Thompson, F.J., Tetley, L., and Devaney, E. (2001) Temperature is a cue for gene expression in 
the post-infective L3 of the parasitic nematode Brugia pahangi. Mol. Biochem. Parasitol. 112: 1-9. 
 
58. Thompson, F.J., Cockroft, A.C., Wheatley, L., Britton, C., and Devancy, E. (2001) Heat shock and 
developmental expression of hsp83 in the filarial nematode Brugia pahangi. Eur. J. Biochem. 268: 5808-5815. 
 
59. Devaney, E. and Lewis, E. (1993) Temperature-induced refractoriness of Aedes aegypti mosquitoes to 
infection with the filaria Brugia pahangi. Med. Vet. Entomol. 7: 297-298. 
 
60. Fang, J. and McCutchan, T.F. (2002) Thermoregulation in a parasite's life cycle. Nature 418: 742. 
 
61. Beckett, E.B. (1971) Histological changes in mosquito flight muscle fibers associated with parasitization by 
filarial larvae. Parasitology 63: 365-372. 
 
62. Erickson, S.M., Xi, Z., Mayhew, G.F., Ramirez, J.L., Aliota, M.T., Christensen, B.M., and Dimopoulos, G. 
(2009) Mosquito infection responses to developing filarial worms. PLoS Negl. Trop. Dis. 3: e529. 
 
63. Devaney, E. and Osborne, J. (2000) The third-stage larva (L3) of Brugia: its role in immune modulation and 
protective immunity. Microbes Infect. 2: 1363-1371. 
 
64. Rama, K., Ramaiah, K.D., Guyatt, H., and Evans, D. (1996) Impact of lymphatic filariasis on the productivity 
of male weavers in a south Indian village. Trans. R. Soc. Trop. Med. Hyg. 90: 669-670. 
 
65. Taylor, M.J., Cross, H.F., and Bilo, K. (2000) Inflammatory Responses induced by the filarial nematode 
Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria. J. 
Exp. Med. 191: 1429-1436. 
 
66. Chenthamarakshan, V., Reddy, M., and Harinath, B. (1995) Immuno-prophylactic potential of a 120 kDA 
Brugia malayi adult antigen fraction, Bma-2, in lymphatic filariasis. Parasite Immunol. 17: 277-285. 
 
67. Dissanayake, S., Perler, F., Xu, M., Southworth, M., Yee, C., Wang, S., Dreyer, G., Watawana, L., 
Kurniawan, A., Furhrman, J., and Piessens, W. (1995) Differential recognition of microfilarial chitinase, a 
transmission-blocking vaccine candidate antigen by sera from patients with Brugian and Bancoftian filariasis. 
Am. J. Trop. Med. Hyg. 53: 289-294. 
 
68. Grieve, R., Wisnewski, N., Frank, G., and Tripp, C. (1995) Vaccine research and development of the 
prevention of filarial nematode infections. Pharm. Biotechnol. 6: 737-768. 
 
69. McCarthy, J. and Nutman, T. (1996) Perspective prospects for development of vaccines against human 
helminth infection. J. Infect. Dis. 174: 1384-1390. 
137 
 
 
 
 
70. WHO. (2004) Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 
countries of the Global Programme to Eliminate Lymphatic Filariasis. Weekly Epidemiol. Rec. 79: 358-365. 
 
71. Selkirk, M., Maizels, R., and Yazdanbakhsh, M. (1992) Immunity and the prospects for vaccination against 
filariasis. Immunobiology 184: 262-281. 
 
72. Melrose, W.D. (2002) Lymphatic filariasis: new insights into an old disease. Int. J. Parasitol. 32: 947-960. 
 
73. Hawking, F. and Marques R.J. (1967) Control of bancroftian filariasis by cooking salt medicated with 
diethilcarbamazine. Bull. World Health Organization 37: 405-414. 
 
74. Gelband, H. (1994) Diethylcarbamazine salt in the control of lymphatic filariasis. Am. J. Trop. Med. Hyg. 50: 
655-662. 
 
75. Satti, M.Z., VandeWaa, E.A., Bennett, J.L., Williams, J.F., Conder, G.A., and McCall, J.W. (1988) 
Comparative effects of anthelmintics on motility in vitro of Onchocerca gutterosa, Brugia pahangi and 
Acanthocheilonema viteae. Trop. Med. Parasitol. 39: 480-483. 
 
76. Centers for Disease Control and Prevention (2011). Lymphatic Filariasis. Retrieved June, 28, 2011, from 
http://www.cdc.gov/parasites/lymphaticfilariasis/ treatment.html 
 
77. Mackenzie, C., Geary, T., Prichard, R., and Boussinesq, M. (2007) Where next with Loa loa encephalopathy? 
Data are badly needed. Trends Parasitol. 23: 237-238. 
 
78. Mackenzie, C.D., Geary, T., and Gerlach, J.A. (2003) Possible pathogenic pathways in the adverse clinical 
events seen following ivermectin administration to onchocerciasis patients. Filaria J. 2(suppl): S5. 
 
79. WHO (2007) Global programme to eliminate lymphatic filariasis. Weekly Epidemiol. Rec. 82: 361-380. 
 
80. Addiss, D., Beach, M., Streit, T., Lutwick, S., LeConte, F., Lafontant, J., Hightower, A., and Lammie, P. 
(1997) Randomized placebo-controlled comparison of ivermectin and albendazole alone and in combination 
for Wuchereria bancrofti micofilaraemia in Haitian children. Lancet 350: 480-484. 
 
81. Hooper, P.J., Bradley, M.H., Biswas, G., and Ottesen, E.A. (2009) The Global Programme to Eliminate 
Lymphatic Filariasis: health impact during its first 8 years (2000-2007). Ann. Trop. Med. Parasitol. 103: S17-
S21. 
 
82. Bockarie, M., Hii, J., Alexander, N., Bockarie, F., Dagoro, J., Kazura, J., and Alpers, M. (1999) Mass 
treatment with ivermectin for filariasis control in Papua New Guinea: impact on mosquito survival. Med. Vet. 
Entomol. 13: 120-123. 
 
83. Nasr, N., Bodghdadi, A., Allam, K., El-Adawi, A., and Soliman, M. (1996) Effect of ivermectin on survival 
and fecundity of Culex pipiens the vector of Wuchereria bancrofti. J. Egypt Soc. Parasitol. 26: 161-168. 
 
84. Tijsterman, M., Okihara, K.L., Thijssen, K., and Plasterk, R.H. (2002) PPW-1, a PAZ/PIWI protein required 
for efficient germline RNAi, is defective in a natural isolate of C. elegans. Curr. Biol. 12: 1535-1540. 
 
85. Xu, M.J., Chen, N., Song, H.Q., Liu, R.Q., Huang, C.Q., Yuan, Z.G., and Zhu, Q. (2010) RNAi-mediated 
silencing of a novel Ascaris suum gene expression in infective larvae. Parasitol. Res. 107: 1499-1503. 
 
86. Dreyer, G., Addiss, D., Santos, A., Figueredo-Silva, J., and Noroes, J. (1998) Direct assessment in vivo of the 
efficacy of combined single-dose ivermectin and diethylcarbamazine against adult Wuchereria bancrofti. 
Trans. Roy. Soc. Trop. Med. Hyg. 92: 219-22. 
 
138 
 
 
 
87. Freedman, D.O., Plier, D.A., de Almeida, A.B., de Oliveira, A.L., Miranda, J., and  Braga, C. (2001) effect of 
aggressive prolonged diethylcarbamazine therapy on circulating antigen levels in bancroftian filariasis. Trop. 
Med. Int. Health 6: 37-41. 
 
88. Pax, R.A., Williams, J.F., and Guderian, R.H. (1988) In vitro motility of isolated adults and segments of 
Onchocerca volvulus, Brugia pahangi and Acanthocheilonema viteae. Trop. Med. Parasitol. 39: 450-455. 
 
89. Schuurkamp, G., Matango, M., Kereu, R., and Napil, J. (1987) Malaria, splenomegaly and filariasis in the Ok 
Tedi area of the Star mountains Papua New Guinea: three years after residual DDT spray. Papua New Guinea 
Med. J. 30: 39-44. 
 
90. Caffrey, C.R., Rohwer, A., Oellien, F., Marhöfer, R.J., Braschi, S., Oliveira, G., McKerrow, J.H., and Selzer, 
P.M. (2009) A comparative chemogenomics strategy to predict potential drug targets in the metazoan 
pathogen, Schistosoma mansoni. PLoS One 4: e4413 
 
91. Krasky, A., Rohwer, A., Schroeder, J., and Selzer, P.M. (2007) A combined bioinformatics and 
chemoinformatics approach for the development of new antiparasitic drugs. Genomics 89: 36-43. 
 
92. Kumar, S., Chaudhary, K., Foster, J.M., Novelli, J.F., Zhang, Y., Wang, S., Spiro, D., Ghedin, E., and Carlow, 
C.K. (2007) Mining predicted essential genes of Brugia malayi for nematode drug targets. PLoS One 2: 
e1189. 
 
93. Hejmadi, M.V., Jagannathan, S., Delany, N.S., Coles, G.C., and Wolstenholme, A.J. (2000) L-glutamate 
binding sites of parasitic nematodes: an association with ivermectin resistance? Parasitology 120: 535-545. 
 
94. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998) Potent and specific 
genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669): 806-811. 
 
95. Elbashir, S.M., Lendeckel, W., and Tuschl, T. (2001) RNA interference is mediated by 21- and 22- nucleotide 
RNAs. Genes Dev. 15: 188-200. 
 
96. Nykänen, A., Haley, B., and Zamore, P.D. (2001) ATP requirements and small interfering RNA structure in 
the RNA interference pathway. Cell 107: 309-321. 
 
97. Cully, D.F., Vassilatis, D.K., Liu, K.K., Paress, P., van Derploeg, L.H.T., Schaeffer, J.M., and Arena, J.P. 
(1994) Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. 
Nature 371: 707-711. 
 
98. Winston, W.M., Sutherlin, M., Wright, A.J., Feinberg, E.H., and Hunter, C.P. (2007) Caenorhabditis elegans 
SID-2 is required for environmental RNA interference. PNAS 104: 10565-10570. 
 
99. Vassilatis, D.K., Arena, J.P., Plasterk, R.H.A., Wilkinson, H., Schaeffer, J.M., Cully, D.F., and van der Ploeg, 
L.H.T. (1997) Genetic and biochemical evidence for a novel avermectin sensitive chloride channel in C. 
elegans: isolation and characterization. J. Biol. Chem. 272: 33167-33174. 
 
100. Jose, A.M. and Hunter, C. P. (2007) Transport of sequence-specific RNA interference information between 
cells. Annu. Rev. Genet. 41: 305-330. 
 
101. Horoszok, L., Raymond, V., Sattelle, D.B., and Wolstenholme, A.J. (2001) GLC-3: a novel fipronil and 
BIDN-sensitive, but picrotoxinin-insensitive, L-glutamate-gated chloride channel subunit from 
Caenorhabditis elegans. British J. Pharmacol. 132: 1247-1254. 
 
102. Winston, W., Sutherlin, M., Wright, A., Feinberg, E., and Hunter, C. (2007) Caenorhabditis elegans SID-2 is 
required for environmental RNA interference. PNAS 104: 10565-10570. 
 
139 
 
 
 
103. Timmons, L., Tabara, H., Mello, C.C., and Fire, A.Z. (2003) Inducible systemic RNA silencing in 
Caenorhabditis elegans. Mol. Biol. Cell 14: 2972-2983. 
 
104. Tijstermann, M., May, R.C., Simmer, F., Okihara, K.L., and Plasterk, R.H. (2004) Genes required for 
systemic RNA interference in Caenorhabditis elegans. Curr. Biol. 14: 111-116. 
 
105. Jose, A.M., Smith, J.J., and Hunter, C.P. (2009) Export of RNA silencing from C. elegans tissues does not 
require the RNA channel SID-1. PNAS 106: 2283-2288. 
 
106. Legendre-Guillemin, V., Wasiak, S., Hussain, N.K., Angers, A., and McPherson, P.S. (2004) ENTH/ANTH 
proteins and clathrin-mediated membrane budding. J. Cell Sci. 117: 9-18. 
 
107. Saleh, M.C., van Rij, R.P., Hekele, A., Gillis, A., Foley, E., O'Farrell, P.H., and Andino, R. (2006) The 
endocytic pathway mediates cell entry of dsRNA to induce RNAi silencing. Nature Cell Biol. 8: 793-802. 
 
108. Winston, W.M., Molodowitch, C., and Hunter, C.P. (2002) Systemic RNAi in C. elegans requires the 
putative transmembrane protein SID-1. Science 295: 2456-2459. 
 
109. Feinberg, E.H. and Hunter, C.P. (2003) Transport of dsRNA into cells by the transmembrane protein SID-1. 
Science 301: 1545-1547. 
 
110. Tavernarakis, N., Wang, S.L., Dorovkov, M., Ryazanov, A., and Driscoll, M. (2000) Heritable and inducible 
genetic interference by double-stranded RNA encoded by transgenes. Nat. Gene. 24: 180-183. 
 
111. Forrester, S.G., Prichard, R.K., Dent, J.A., and Beech, R.N. (2003) Haemonchus contortus: HcGluCla 
expressed in Xenopus oocytes forms a glutamate-gated ion channel that is activated by ibotenate and the 
antiparasitic drug ivermectin. Mol. Biochem. Parasitol. 129: 115-121. 
 
112. Aboobaker, A.A. and Blaxter, M.L. (2003) Use of RNA interference to investigate gene function in the 
human filarial nematode parasite Brugia malayi. Mol. Biochem. Parasitol. 129: 41-51. 
 
113. Filipowicz, W. (2005) RNAi: the nuts and bolts of the RISC machine. Cell 122: 17-20. 
 
114. Pak, J. and Fire, A. (2007) Distinct populations of primary and secondary effectors during RNAi in C. 
elegans. Science 315: 241-244. 
 
115. Ruby, J.G., Jan, C., Playe, C., Axtell, M.J., Lee, W., Nusbaum, C., Ge, H., and Bartel, D.P. (2006) Large-
scale sequencing reveals 21U-RNAs and additional microRNAs and endogenous siRNAs in C. elegans. Cell 
127: 1193-1207. 
 
116. Zhang, H., Kolb, F. A., Jaskiewicz, L., Westhof, E. and Filipowicz, W. (2004) Single processing center 
models for human Dicer and bacterial RNase III. Cell 118: 57-68. 
 
117. Bernstein, E., Daudy, A.A., Hammond, S.M., and Hannon, G.J. (2001) Role for a bidentate ribonuclease in 
the initiation step of RNA interference. Nature 409:  363-366. 
 
118. Meister, G. and Tuschl, T. (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343-
349. 
 
119. Parker, G.S., Eckert, D.M., and Bass, B.L. (2006) RDE-4 preferentially binds long dsRNA and its 
dimerization is necessary for cleavage of dsRNA to siRNA. RNA 12: 807-818. 
 
120. Parrish, S. and Fire, A. (2001) Distinct roles for RDE-1 and RDE-4 during RNA interference in 
Caenorhabditis elegans. RNA 7: 1397-1402. 
 
140 
 
 
 
121. Wu, H. Henras, A., Chanfreau, G., and Feigon, J. (2004) Structural bases for recognition of the AGNN 
tetraloop RNA fold by the double-stranded RNA-binding domain of Rnt1p Rnase III. PNAS 101: 8307-8312. 
 
122. Ryter J.M. and Schultz, S.C. (1998) Molecular basis of double-stranded RNA-protein interactions: structure 
of a dsRNA-binding domain complexed with dsRNA. EMBO J. 17: 7505-7513. 
 
123. Gan, J. Tropea, J.E., Austin, B.P., Court D.L., Waugh, D.S., and Ji, X. (2006) Structural insight into the 
mechanism of double-stranded RNA processing by ribonuclease III. Cell 124: 355-366. 
 
124. Tian, B., Bevilacqua, P.C., Diegelman-Parente, A., and Mathews M.B. (2004) The double stranded-RNA-
binding motif: interference and much more. Nat. Rev. Mol. Cell Biol. 5: 1013-1023. 
 
125. Yan, K.S., Yan, S., Farooq, A., Han, A., Zeng, L., and Zhou, M.M. (2003) Structure and conserved RNA 
binding of the PAZ domain. Nature 426: 468-474. 
 
126. MacRae, I.J., Zhou, K., Li, F., Repic, A., Brooks, A.N., Cande, W.Z., Adams, P.D., and Doudna, J.A. (2006) 
Structural basis for double-stranded RNA processing by Dicer. Science 311: 195-198. 
 
127. Jinek, M. and Doudna, J.A. (2009) A three-dimensional view of the molecular machinery of RNA 
interference. Nature 457: 405-412. 
 
128. Zhang, H., Kolb, F. A., Brondani, V., Billy, E., and Filipowicz, W. (2002) Human Dicer preferentially 
cleaves dsRNAs at their termini without a requirement for ATP. EMBO J. 21: 5875-5885. 
 
129. Nowotny, M. and Yang, W. (2009) Structural and functional modules in RNA interference. Curr. Opin. 
Struct. Biol. 19: 286-293. 
 
130. Ma, E., Macrae, I.J., Kirsch, J.F., and Doudna, J.A. (2008) Autoinhibition of human Dicer by its internal 
helicase domain. J. Mol. Biol. 380: 237-243. 
 
131. Sijen, T., Fleenor, J., Simmer, F., Thijssen, K.L., Parrish, S., Timmons, L., Plasterk, R.H., and Fire, A. (2001) 
On the role of RNA amplification in dsRNA-triggered gene silencing. Cell 107: 465-476. 
 
132. Smardon, A., Spoerke, J.M., Stacey, S.C., Klein, M.E., Machin, N., and Maine, E.M. (2000) EGO-1 is related 
to RNA-directed RNA polymerase and functions in germ-line development and RNA interference in C. 
elegans. Curr. Biol. 10: 169-178. 
 
133. Sijen, T., Steiner, F. A., Thijssen, K. L. and Plasterk, R. H. (2007) Secondary siRNAs result from unprimed 
RNA synthesis and form a distinct class. Science 315: 244-247. 
 
134. Parrish, S., Fleenor, J., Xu, S., Mello, C., and Fire, A. (2000) Functional anatomy of a dsRNA trigger: 
differential requirement of the two trigger strands in RNA interference. Mol. Cell 6: 1077-1087. 
 
135. Dalmay, T., Hamilton, A., Rudd, S., Angell, S., and Baulcombe, D.C. (2000) An RNA-dependent RNA 
polymerase gene in Arabidopsis is required for posttranscriptional gene silencing mediated by a transgene but 
not by a virus. Cell 101: 543-553. 
 
136. Mourrain, P., Béclin, C., Elmayan, T., Feuerbach, F., Godon, C., Morel, J.B., Jouette, D., Lacombe, A.M., 
Nikic, S., Picault, N., Rémoué, K., Sanial, M., Vo, T.A., and Vaucheet, H. (2000) Arabidopsis SGS2 and 
SGS3 genes are required for  post transcriptional gene silencing and natural virus resistance. Cell 101: 533-
542. 
 
137. Alder, M.N., Dames, S., Gaudet, J., and Mango, S.E. (2003) Gene silencing in Caenorhabditis elegans by 
transitive RNA interference. RNA 9: 25-32. 
 
141 
 
 
 
138. Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P.D. (2003) Asymmetry in the 
assembly of the RNAi enzyme complex. Cell 115: 199-208. 
 
139. Khvorova, A., Reynolds, A. and Jayasena, S. D. (2003) Functional siRNAs and miRNAs exhibits strand bias. 
Cell 115: 209-216. 
 
140. Steiner, F.A., Okihara, K.L., Hoogstrate, S.W., Sijen, T., and Ketting, R. (2009) RDE-1 slicer activity is 
required only for passenger-strand cleavage during RNAi in Caenorhabditis elegans. Nat. Struct. Mol. Bio. 
16: 207-211. 
 
141. Hutvagner, G. and Simard, M. J. (2008) Argonaute proteins: key players in RNA silencing. Nature Rev. Mol. 
Cell Biol. 9:22-32. 
 
142. Faehnle, C. R. and Joshua-Tor, L. (2007) Argonautes confront new small RNAs. Curr. Opin. Chem. Biol. 11: 
569-577. 
 
143. Wang, Y., Sheng, G., Juranek, S., Tuschl, T. and Patel, D. J. (2008) Structure of the guide-strand-containing 
argonaute silencing complex. Nature 456: 209-213. 
 
144. Okamura, K., Ischizuka, A., Siomi, H., and Siomi, M.C. (2004) Distinct roles for Argonaute proteins in small 
RNA- directed RNA cleavage pathways. Genes Dev. 18: 1655-1666. 
 
145. Lingel, A., Simon, B., Izaurralde, E., and Sattler, M. (2003) Structure and nucleic-acid binding of the 
Drosophila Argonaute 2 PAZ domain. Nature 426: 465-469. 
 
146. Lingel, A., Simon, B., Izaurralde, E., and Sattler, M. (2004) Nucleic acid 3'-end recognition by the 
Argonaute2 PAZ domain. Nat. Struct. Mol. Biol. 11: 576-577. 
 
147. Ma, J.B., Ye, K., and Patel, D.J. (2004) Structural basis for overhang-specific small interfering RNA 
recognition by the PAZ domain. Nature 429: 318-322. 
 
148. Song, J.J., Liu, J., Tolia, N.H., Schneiderman, J., Smith, S.K., Martienssen, R.A., Hannon, G.J., and Joshua-
Tor, L. (2003) The crystal structure of the Argonaute2 PAZ domain reveals an RNA-binding motif in RNAi 
effecter complexes. Nat. Struct. Biol. 10: 1026-1032. 
 
149. Ma, J.B., Yuan, Y.R., Meister, G., Pei, Y., Tuschl, T., and Patel, D.J. (2005) Structural basis for 5'-end-
specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature 434: 666-670. 
 
150. Parker, J.S., Roe, S.M., and Barford, D. (2005) Structural insights into mRNA recognition from a PIWI 
domain-siRNA guide complex. Nature 434: 663-666. 
 
151. Rashid, U.J., Paterok, D., Koglin, A., Gohike, H., Piehler, J., and Chen, J.C. (2007) Structure of Aquifex 
aeolicus argonaute highlights conformational flexibility of the PAZ domain as a potential regulator of RNA-
induced silencing complex function. J. Biol. Chem. 282: 13824-13832. 
 
152. Rivas, F.V., Tolia, N.H., Song, J.J., Aragon, J.P., Liu, J., Hannon, G.J., and Joshua-Tor, L. (2005) Purified 
Argonaute2 and a siRNA form recombinant human RISC. Nat. Struct. Mol. Biol. 12: 340-349. 
 
153. Song, J.J., Smith, S.K., Hannon, G.J., and Joshua-Tor, L. (2004) Crystal structure of Argonaute and its 
implications for RISC slicer activity. Science 305: 1434-1437. 
 
154. Yuan, Y. R., Pei, Y., Ma, J. B., Kuryavyi, V., Zhadina, M., Meister, G., Chen, H. Y., Dauter, Z., Tuschl, T., 
and Patel, D. J. (2005) Crystal structure of A. aeolicus argonaute, a site-specific DNA-guided 
endoribonuclease, provides insights into RISC-mediated mRNA cleavage. Mol. Cell 19: 405-419. 
 
142 
 
 
 
155. Parker, J.S., Roe, S.M., and Barford, D. (2004) Crystal structure of a PIWI protein suggests mechanisms for 
siRNA recognition and slicer activity. EMBO J. 23: 4727-4737. 
 
156. Nowotny, M., Gaidamakov, S.A., Crouch, R.J., and Yang, W. (2005) Crystal structures of RNase H bound to 
an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121: 1005-1016. 
 
157. Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W., and Tuschl, T. (2001) Functional anatomy of 
siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20: 6877-6888. 
 
158. Kawamata, T. and Tomari, Y. (2010) Making RISC. Trends Biochem. Sci. 35: 368-376. 
 
159. Siomi, H. and Siomi M. C. (2009) On the road to reading the RNA-interference code. Nature 457: 396-404. 
 
160. Tomari, Y., Du, T., Haley, B., Schwarz, D.S., Bennett, R., Cook, H.A., Koppetsch, B.S., Theurkauf, W.E., 
and Zamore P.D. (2004) RISC assembly defects in the Drosophila RNAi mutant armitage. Cell 116: 831-841. 
 
161. Pham, J.W., Pellino, J.L., Lee, Y.S., Carthew, R.W., and Sontheimer E.J. (2004) A Dicer-2-dependent 80s 
complex cleaves targeted mRNAs during RNAi in Drosophila. Cell, 117: 83-94. 
 
162. Pham, J.W. and Sontheimer, E.J. (2005) Molecular requirements for RNA-induced silencing complex 
assembly in the Drosophila RNA interference pathway. J. Biol. Chem. 280: 39278-39283. 
 
163. Matranga, C., Tomari, Y., Shin, C., Bartel, D. P. and Zaamore, P. D. (2005) Passenger-strand cleavage 
facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123: 607-620. 
 
164. Rand, T. A., Petersen, S., Du, F. and Wang, X. (2005) Argonaute2 cleaves the anti-guide strand of siRNA 
during RISC activation. Cell 123: 621-629. 
 
165. Miyoshi, K., Tsukumo, H., Nagami, T., Siomi, H. and Siomi, M C. (2005) Slicer function of Drosophila 
Argonautes and its involvement in RISC formation. Genes Dev. 19: 2837-2848. 
 
166. Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P.and Burge, C. B. (2003) Prediction of 
mammalian microRNA targets. Cell 115: 787-798. 
 
167. Lewis, B. P, Burge, C. B., and Bartel, D. P. (2005) Conserved seed pairing, often flanked by adenosines, 
indicates that thousands of human genes are microRNA targets. Cell 120(1): 15-20. 
 
168. Ameres, S. L., Martinez, J., and Schroeder, R. (2007) Molecular basis for target RNA recognition and 
cleavage by human RISC. Cell 130: 101-112. 
 
169. Haley, B. and Zamore, P. D. (2004) Kinetic analysis of the RNAi enzyme complex. Nat. Struct. Mol. Biol. 11: 
599-606. 
 
170. Aoki, K., Moriguchi, H., Yoshioka, T., Okawa, K., and Tabara, H. (2007) In vitro analyses of the production 
and activity of secondary small interfering RNAs in C. elegans. EMBO J. 26: 5007-5019. 
 
171. Vagin, V.V., Sigova, A., Li, C., Seitz, H., Gvozdev, V., and Zamore, P.D. (2006) A distinct small RNA 
pathway silences selfish genetic elements in the germline. Science 313: 320-324. 
 
172. Yigit, E. et al. (2006) Analysis of the C. elegans Argonaute family reveals that distinct Argonautes act 
sequentially during RNAi. Cell 127: 747-757. 
 
173. Preall, J.B., He., Z., Gorra, J.M., and Sontheimer, E.J. (2006) Short interfering RNA strand selection is 
independent of dsRNA processing polarity during RNAi in Drosophila. Curr. Biol. 16: 530-535. 
 
143 
 
 
 
174. Liu, J., Carmell, M. A., Rivas, F. V., Marsden C. G., Thomson, J. M., Song, J.J., Hammond, S.M., Joshua-
Tor, L., and Hannon, G. J. (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437-
1441. 
 
175. Yoda, M., Kawamata, T., Paroo, Z., Ye, X., Iwasaki S., Liu, Q., and Tomari, Y. (2010) ATP-dependent 
human ISC assembly pathways. Nat. Struct. Mol. Biol. 17: 17-23. 
 
176. Liu, Q., Rand, T.A., Kalidas, S., Du, F., Kim, H. E., Smith, D. P., and Wang, X. (2003) R2D2, a bridge 
between the initiation and effecter steps of the Drosophila RNAi pathway. Science 301: 1921-1925. 
 
177. Lee, Y.S., Nakahara, K., Pham, J.W., Kim, K., He, Z., Sontheime, E.J., and Carthew R.W. (2004) Distinct 
roles of Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 117: 69-81. 
 
178. Tomari, Y., Du, T., and Zamore P.D. (2007) Sorting of Drosophila small silencing RNAs. Cell 130: 299-308. 
 
179. Steiner, F.A., Hoogstrate, S.W., Okihara, K.L., Thijssen, K.L., Ketting, R.F., Plasterk, R.H., and Sijen, T. 
(2007) Structural features of small RNA precursors determine Agonaute loading in Caenorhabditis elegans. 
Nat. Struct. Mol. Biol. 14: 927-933. 
 
180. Tomari, Y., Matranga, C., Haley, B., Martinez, N. and Zamore, P. D. (2004) A protein sensor for siRNA 
asymmetry. Science 306: 1377-1380. 
 
181. Kennedy, S., Wang, D., and Ruvkun, G. (2004) A conserved siRNA-degrading RNase negatively regulates 
RNA interference in C. elegans. Nature 427: 645-649. 
 
182. Scadden, A.D. and Smith, C.W. (2001) RNAi is antagonized by A → I hyper-editing. EMBO Rep. 2: 1107-
1111. 
 
183. Scadden, A.D. and Smith, C.W. (2001) Specific cleavage of hyperedited dsRNAs. EMBO J. 20: 4243-4252. 
 
184. Ngo, H., Tschudi, C., Gull, K., and Ullu, E. (1998) Double-stranded RNA induces mRNA degradation in 
Trypanosoma brucei. PNAS 95: 14687-14692. 
 
185. Webber, R. (1991) Can anopheline-transmitted filariasis be eradicated? J. Trop. Med. Hyg. 94: 241-244. 
 
186. Oelgeschlager, M., Larrain, J., Geissert, D., and DeRobetis, E.M. (2000) The evolutionarily conserved BMP-
binding protein Twisted gastrulation promotes BMP signaling. Nature London 405: 757-763. 
 
187. Elbashir, S.M., Martinez, J., Patkaniowsk, A., Lendeckel, W., and Tuschl, T. (2001) Functional anatomy of 
siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20: 6877-6888. 
 
188. Kennerdell, J.R. and Carthew, R.W. (1998) Use of dsRNA-mediated genetic interference to demonstrate that 
frizzled and frizzled 2 act in the wingless pathway. Cell 95: 1017-1026. 
 
189. Hannon, G.J. (2002) RNA interference. Nature 418: 244-251. 
 
190. Ullu, E., Tshudi, C., and Chakraborty, T. (2004) RNA interference in protozoan parasites. Cell Microbiol. 6: 
509-519. 
 
191. Hussein, A.S., Kichenin, K., and Selkirk, M.E. (2002) Suppression of secreted acetylcholinesterase 
expression in Nippostrongylus brasiliensis by RNA interference. Mol. Biochem. Parasitol.122: 91-94. 
 
192. Islam, M.K., Miyoshi, T., Yamada, M., and Tsuji, N. (2005) Pyrophosphatase of the Roundworm Ascaris 
suum plays an Essential Role in the Worm's Molting and Development. Infect. Immun. 73: 1995-2004. 
 
144 
 
 
 
193. Ford, L., Guiliano, D.B., Oksov, Y., Debnath, A.K., Liu, J., and Williams, S.A. (2005) Characterization of a 
novel filarial serine protease inhibitor, Ov-SPI-1, from Onchocerca volvulus, with potential multifunctional 
roles during development of the parasite. J. Biol. Chem. 280: 40845-40856. 
 
194. Issa, Z., Grant, W.N., Stasiuk, S., and Shoemaker, C.B. (2005) Development of methods for RNA 
interference in the sheep gastrointestinal parasite, Trichostrongylus colubriformis. Int. J. Parasitol.. 35: 935-
940. 
 
195. Kotze, A. and Bagnall, N. (2006) RNA interference in Haemonchus contortus: suppression of beta-tubulin 
gene expression in L3, L4 and adult worms in vitro. Mol. Biochem. Parasitol. 145: 101-110. 
 
196. Geldhof, P., Murray, L., Couthier, A., Gilleard, J.S., McLauchlan, G., Knox, D.P., and Britton, C. (2006) 
Testing the efficacy of RNA interference in Haemonchus contortus. Int. J. Parasitol.. 36: 801-810. 
 
197. Pfarr, K., Heider, U, and Hoerauf, A. (2006) RNAi mediated silencing of actin expression in adult 
Litomosoides sigmodontis is specific, persistent and results in a phenotype. Int. J. Parasitol. 36: 661-669. 
 
198. Visser, A., Geldhof, P., de Maere, V., Knox, D.P., Vercruysse, J. et al. (2006) Efficacy and specificity of 
RNA interference in larval life-stages of Ostertagia ostertagi. Parasitology 133: 777-783. 
 
199. Lendner, M., Doligalska, M., Lucius, R., and Hartmann, S. (2008) Attempts to establish RNA interference in 
the parasitic nematode Heligmosomoides polygyrus. Mol. Biochem. Parasitol 161: 21-31. 
 
200. Ford, L., Zhang, J., Liu, J., Hashmi, S., Fuhrman, J.A. et al. (2009) Functional analysis of the cathepsin-like 
cysteine protease genes in adult Brugia malayi using RNA interference. PLoS Negl. Trop. Dis. 3: e377. 
 
201. Philip, M., Davis, T., Storey, N., and Callow, C. (1988) Immunity in filariasis: perspectives for vaccine 
development. Annu. Rev. Microbiol. 42: 685-716. 
 
202. Chen, N., Xu, M.J., Nisbet, A.J., Huang, C.Q., Lin, R.Q., Yuan, Z.G., Song, H.Q., and Zhu, X.Q. (2011) 
Ascaris suum: RNAi mediated silencing of enolase gene expression in infective larvae.  Exp. Parasitol. 127: 
142-146. 
 
203. Santiago-Stevenson, D., Oliver-Gonzalez, J., and Hewitt, R. (1947) Treatment of Filariasis bancrofti with 1-
diethylcarbamyl-4-methylpiperazine hydrochloride (Hetrazan). J. Am. Med. Assoc. 135: 708-712. 
 
204. Tabara, H., Yigit, E., Siomi, H., and Mello, C.C. (2002) The dsRNA binding protein RDE-4 interacts with 
RDE-1, DCR-1, and a DExH-box helicase to direct RNAi in C. elegans. Cell 109: 861-871. 
 
205. MacRae, I.J., Zhou, K. and Doudna, J. A. (2007) Structural determinants of RNA recognition and cleavage by 
Dicer. Nature Struct. Mol. Biol. 14: 934-940. 
 
206. Geary, T.G., Woo, K., McCarthy, J.S., Mackenzie, C.D., Horton, J., Prichard, R.K., de Silva, N.R., Olliaro, 
P.L., Lazdins-Helds, J.K., Engels, D.A., and Bundy, D.A. (2010) Unresolved issues in anthelmintic 
pharmacology for helminthiases of humans. Int. J. Parasitol. 40: 1-13. 
 
207. Bartz, S. and Jackson, A.L. (2005) How will RNAi facilitate drug development? Science 295: e39. 
 
208. Blake, R. (2007) Target validation in drug discovery. In: Taylor D, Haskins J, Guiliano K, editors. Methods in 
Molecular Biology: High Content Screening: Humana Press. pp. 367-377. 
 
209. Geldhof, P., Visser, A., Clark, D., Saunders, G., Britton, C., Gilleard, J., Berriman, M., and Knox, D. (2007) 
RNA interference in parasitic helminths: current situation, potential pitfalls and future prospects. Parasitology 
134: 609-619. 
 
145 
 
 
 
210. Hussein, A.S., Kichenin, K. and Selkirk, M.E. (2002) Suppression of secreted acetylcholinesterase expression 
in Nippostrongylus brasiliensis by RNA interference. Mol. Biochem. Parasitol 122: 91-94. 
 
211. Islam, M.K., Miyoshi, T., Yamada, M. and Tsuji, N. (2005) Pyrophosphatase of the roundworm Ascaris suum 
plays an essential role in the worm's molting and development. Infect. Immun. 73: 1995-2004. 
 
212. Issa, Z., Grant, W.N., Stasiuk, S. and Shoemaker, C.B. (2005) Development of methods for RNA interference 
in the sheep gastrointestinal parasite, Trichostrongylus colubriformis. Int. J. Parasitol. 35: 935-940. 
 
213. Geldhof, P., Murray, L., Couthier, A., Gilleard, J.S., McLauchlan, G., Knox, D.P., and Britton, C. (2006) 
Testing the efficacy of RNA interference in Haemonchus contortus. Int. J. Parasitol. 36: 801-810. 
 
214. Kotze, A.C. and Bagnall, N.H. (2006) RNA interference in Haemonchus contortus: suppression of beta-
tubulin gene expression in L3, L4 and adult worms in vitro. Mol. Biochem. Parasitol 145: 101-110. 
 
215. Ford, L., Guiliano, D.B., Oksov, Y., Debnath, A.K., Liu, J., Williams, S.A., Blaxter, M.L., and Lustigman, S. 
(2005) Characterization of a novel filarial serine protease inhibitor, Ov-SPI-1, from Onchocerca volvulus, 
with potential multifunctional roles during development of the parasite. J. Biol. Chem. 280: 40845-40856. 
 
216. Pfarr, K., Heider, U. and Hoerauf, A. (2006) RNAi mediated silencing of actin expression in adult 
Litomosoides sigmodontis is specific, persistent and results in a phenotype. Int. J. Parasitol. 36: 661-669. 
 
217. Fraser, A.G., Kamath, R.S., Zipperlen, P., Martinez-Campos, M., Sohrmann, M., and Ahringer, J. (2000) 
Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 408: 325-
330. 
 
218. Kamath, R.S., Martinez-Campos, M., Zipperlen, P., Fraser, A.G., and Ahringer, J. (2001) Effectiveness of 
specific RNA-mediated interference through ingested double-stranded RNA in Caenorhabditis elegans. 
Genome Biol. 2: RESEARCH0002. 
 
219. Urwin, P.E., Lilley, C.J., and Atkinson, H.J. (2002) Ingestion of double-stranded RNA by parasitic juvenile 
cyst nematodes leads to RNA interference. Mol. Plant. Microbe. Interact. 15: 747-752. 
 
220. Bakhetia, M., Charlton, W., Atkinson, H.J., and McPherson, M.J. (2005) RNA interference of dual oxidase in 
the plant nematode Meloidogyne incognita. Mol. Plant. Microbe. Interact. 18: 1099-1106. 
 
221. Kimber, M.J., McKinney, S., McMaster, S., Day, T.A., Fleming, C.C., and Maule, A.G. (2007) Flp gene 
disruption in a parasitic nematode reveals motor dysfunction and unusual neuronal sensitivity to RNA 
interference. Faseb. J. 21: 1233-1243. 
 
222. Shingles, J., Lilley, C.J., Atkinson, H.J., and Urwin, P.E. (2007) Meloidogyne incognita: molecular and 
biochemical characterization of a cathepsin L cysteine proteinase and the effect on parasitism following 
RNAi. Exp. Parasitol. 115: 114-120. 
 
223. Dalzell, J.J., McMaster, S., Fleming, C.C., and Maule, A.G. (2010) Short interfering RNA-mediated gene 
silencing in Globodera pallida and Meloidogyne incognita infective stage juveniles. Int. J. Parasitol. 40: 91-
100. 
 
224. Viney, M.E. and Thompson, F.J. (2008) Two hypotheses to explain why RNA interference does not work in 
animal parasitic nematodes. Int. J. Parasitol. 38: 43-47. 
 
225. Lendner, M., Doligalska, M., Lucius, R., and Hartmann, S. (2008) Attempts to establish RNA interference in 
the parasitic nematode Heligmosomoides polygyrus. Mol. Biochem. Parasitol. 161: 21-31. 
 
226. Boisson, B., CJaques, J., Choumet, V., Martin, E., Xu, J., Vernick, K., and Bourgouin, C. (2006) Gene 
silencing in mosquito salivary glands by RNAi. FEBS Letters 580: 1988-1992. 
146 
 
 
 
 
227. Pfaffl, M.W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic 
Acids Res. 29: e45. 
 
228. Laney, S.J., Buttaro, C.J., Visconti, S., Pilotte, N., Ramzy, R.M., Weil, G.J., and Williams, S.A. (2008) A 
reverse transcriptase-PCR assay for detecting filarial infective larvae in mosquitoes. PLoS Negl. Trop. Dis. 2: 
e251. 
 
229. Guiliano, D.B., Hong, X., McKerrow, J.H., Blaxter, M.L., Oksov, Y. et al. (2004) A gene family of cathepsin 
L-like proteases of filarial nematodes are associated with larval molting and cuticle and eggshell remodeling. 
Mol. Biochem. Parasitol. 136: 227-242. 
 
230. Dalzell, J.J., McMaster, S., Johnston, M.J., Kerr, R., Fleming, C.C. et al. (2009) Non-nematode-derived 
double-stranded RNAs induce profound phenotypic changes in Meloidogyne incognita and Globodera pallida 
infective juveniles. Int. J. Parasitol. 39: 1503-1516. 
 
231. Christensen, B.M. and Sutherland, D.R. (1984) Brugia pahangi: exsheathment and midgut penetration in 
Aedes aegypti. Trans. of Amer. Microscop. Society 103: 423-433. 
 
232. Murthy, P.K. and Sen, A.B. (1981) Sequential development changes in microfilariae of subperiodic Brugia 
malayi to infective larvae in susceptible strain of Aedes aegypti (Macdonald). J. Commun. Dis. 13: 102-109. 
 
233. Bartholomay, L.C. and Christensen, B.M. (2002) Vector-parasite interactions in mosquito-borne filariasis. In: 
Klei T, Rajan T, editors. The Filaria. 1 ed. Boston: Kluwer Academic Publishers. pp. 9-19. 
 
234. Beckett, E.B. and Boothroyd, B. (1970) Mode of nutrition of the larvae of the filarial nematode Brugia 
pahangi. Parasitology 60: 21-26. 
 
235. Aliota, M.T., Fuchs, J.F., Rocheleau, T.A., Clark, A.K., Hillyer, J.F. et al. (2010) Mosquito transcriptome 
profiles and filarial worm susceptibility in Armigeres subalbatus. PLoS Negl. Trop. Dis. 4: e666. 
 
236. Timmons, L., Court, D.L., and Fire, A. (2001) Ingestion of bacterially expressed dsRNAs can produce 
specific and potent genetic interference in Caenorhabditis elegans. Gene 263: 103-112. 
 
237. Shannon, A.J., Tyson, T., Dix, I., Boyd, J., and Burnell, A.M. (2008) Systemic RNAi mediated gene silencing 
in the anhydrobiotic nematode Panagrolaimus superbus. BMC Mol. Biol. 9: 58. 
 
238. Richer, J.K., Hunt, W.G., Sakanari, J.A., and Grieve, R.B. (1993) Dirofilaria immitis: effect of fluoromethyl 
ketone cysteine protease inhibitors on the third- to fourth-stage molt. Exp. Parasitol. 76: 221-231. 
 
239. Lustigman, S., McKerrow, J.H., Shah, K., Lui, J., Huima, T. et al. (1996) Cloning of a cysteine protease 
required for the molting of Onchocerca volvulus third stage larvae. J. Biol. Chem. 271: 30181-30189. 
 
240. Hashmi, S., Britton, C., Liu, J., Guiliano, D.B., Oksov, Y. et al. (2002) Cathepsin L is essential for 
embryogenesis and development of Caenorhabditis elegans. J. Biol. Chem. 277: 3477-3486. 
 
241. McGonigle, L., Mousley, A., Marks, N.J., Brennan, G.P., Dalton, J.P. et al. (2008) The silencing of cysteine 
proteases in Fasciola hepatica newly excysted juveniles using RNA interference reduces gut penetration. Int. 
J. Parasitol. 38: 149-155. 
 
242. Huang, G., Allen, R., Davis, E.L., Baum, T.J., and Hussey, R.S. (2006) Engineering broad root-knot 
resistance in transgenic plants by RNAi silencing of a conserved and essential root-knot nematode parasitism 
gene. PNAS 103: 14302-14306. 
 
147 
 
 
 
243. Steeves, R.M., Todd, T.C., Essig, J.S., and Trick, H.N. (2006) Transgenic soybeans expressing siRNAs 
specific to a major sperm protein gene suppress Heterodera glycines reproduction. Funct. Plant Biol. 33, 
991–999. 
 
244. Sindhu, A.S., Maier, T.R., Mitchum, M.G., Hussey, R.S., Davis, E.L. et al. (2009) Effective and specific in 
planta RNAi in cyst nematodes: expression interference of four parasitism genes reduces parasitic success. J. 
Exp. Bot. 60: 315-324. 
 
245. Coates, C.J., Jasinskiene, N., Miyashiro, L., and James, A.A. (1998) Mariner transposition and transformation 
of the yellow fever mosquito, Aedes aegypti. PNAS 95: 3748-3751. 
 
246. Jasinskiene, N., Coates, C.J., Benedict, M.Q., Cornel, A.J., Rafferty, C.S. et al. (1998) Stable transformation 
of the yellow fever mosquito, Aedes aegypti, with the Hermes element from the housefly. PNAS 95: 3743-
3747. 
 
247. Catteruccia, F., Nolan, T., Loukeris, T.G., Blass, C., Savakis, C., Kafatos F.C., and Crisanti, A. (2000) Stable 
germline transformation of the malaria mosquito Anopheles stephensi. Nature 405: 959-962. 
 
248. Kokoza, V., Ahmed, A., Cho, W.L., Jasinskiene, N., James, A.A. et al. (2000) Engineering blood meal-
activated systemic immunity in the yellow fever mosquito, Aedes aegypti. PNAS 97: 9144-9149. 
 
249. Moreira, L.A., Edwards, M.J., Adhami, F., Jasinskiene, N., James, A.A. et al. (2000) Robust gut-specific 
gene expression in transgenic Aedes aegypti mosquitoes. PNAS 97: 10895-10898. 
 
250. Franz, A.W., Sanchez-Vargas, I., Adelman, Z.N., Blair, C.D., Beaty, B.J. et al. (2006) Engineering RNA 
interference-based resistance to dengue virus type 2 in genetically modified Aedes aegypti. PNAS 103: 4198-
4203. 
 
251. Allen, M.L. and Christensen, B.M. (2004) Flight muscle-specific expression of act88F: GFP in transgenic 
Culex quinquefasciatus Say (Diptera: Culicidae). Parasitol. Int. 53: 307-314. 
 
252. McKerrow, J.H. (1999) Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: 
insights on safety, target validation, and mechanism of action. Int. J. Parasitol. 29: 833-837. 
 
253. MacDonald, W.W. (1962) The selection of a strain of Aedes aegypti susceptible to infection with semi-
periodic Brugia malayi. Ann. Trop. Med. Parasit. 56: 368-372. 
 
254. Beerntsen, B.T., Bartholomay, L.C., and Lowery, R.J. (2007) Penetration of the mosquito midgut is not 
required for Brugia pahangi microfilariae to avoid the melanotic encapsulation response of Armigeres 
subalbatus. Vet. Parasitol. 144: 371-374. 
 
255. Hayes, R.O. (1953) Determination of a physiological saline solution for Aedes aegypti (L.). J. of Econ. 
Entomol. 46: 624-627. 
 
256. Gallup, J.M., Sow, F.B., Van Geelen, A., and Ackermann, M.R. (2009) SPUD qPCR assay confirms 
PREXCEL-Q software’s ability to avoid qPCR inhibition. Curr. Issues Mol. Biol. 12: 129-134. 
 
257. Song, C., Gallup, J.M., Day, T.A., Bartholomay, L.C., and Kimber, M.J. (2010) Development of an in vivo 
RNAi protocol to investigate gene function in the filarial nematode, Brugia malayi. PLoS Path 6: e1001239 
 
258. Yates, D.M. and Wolstenholme, A.J. (2004) An ivermectin sensitive glutamate-gated chloride channel 
subunit from Dirofilaria immitis. Int. J. Parasitol. 34: 1065-1071. 
 
259. Martin, R.J. (1996) An electrophysiological preparation of Ascaris suum pharyngeal muscle reveals a 
glutamate-gated chloride channel sensitive to the avermectin analogue, milbemycin D. Parasitology 112: 
247-252. 
148 
 
 
 
 
260. Adelsberg, H., Scheur, T., and Dudel, J. (1997) A patch clamp study of a glutamate chloride channel on 
pharyngeal muscle of the nematode Ascaris suum. Neuroscience Letters 230: 183-186. 
 
261. Saleh, M.C., Tassetto, M. van Rij, R.P., Goic, B., Gausson, V. Berry, B. Jacquier, C., Antoniewski, C., and 
Andino, R. (2009) Antiviral immunity in Drosophila requires systemic RNA interference spread. Nature 458: 
346-350. 
 
262. Pemberton, D.J., Franks, C.J., Walker, R.J., and Holden-dye, L. (2001) Characterization of glutamate-gated 
chloride channels in the pharynx of wild-type and mutant Caenorhabditis elegans delineates the role of the 
subunit GluCl-alpha 2 in the function of the native receptor. Molecular Pharmacology 59: 1037-1043. 
 
263. Wolstenholme, A.J. and Rogers (2005) Glutamate-gated chloride channels and the mode of action of the 
avermectin / milbemycin anthelmintics. Parasitology 131: S85-S95. 
 
264. Klager, S., Whitworth, J.A.G., Post, R.J., Chavasse, D.C., and Downham, M.D. (1993) How long do the 
effects of ivermectin on adult Onchocerca volvulus persist? Tropical Medicine and Parasitology 44: 305-310. 
 
265. Lok, J.B., Knight, D.H., Selavka, C.M., Eynard, J., Zhang, Y., and Bergman, R.N. (1995) Studies of 
reproductive competence in male Dirofilaria immitis treated with milbemycin oxime. Tropical Medicine and 
Parasitology 46: 235-240. 
 
266. Lacey, E. (1990) Mode of action of benzimidazoles, Parasitol. Today 6: 107-112. 
 
267. Perry, R.N. (2001) Analysis of the sensory responses of parasitic nematodes using electrophysiology. Int. J. 
Parasitol. 65: 55-63. 
 
268. Rolfe, R.N., Barrett, J., and Perry, R.N. (2001) Electrophysiological analysis of responses of adult female of 
Brugia pahangi to some chemicals. Parasitology 122: 347-357. 
 
269. Freeman, A.S., Nghiem, C., Li, J., Ashton, F.T., Guerrero, J., Shoop, W.L., and Schad, G.A. (2003) 
Amphidial structure of ivermectin-resistant and susceptible laboratory and field strains of Haemonchus 
contortus. Vet. Parasitol. 110: 217-226. 
 
270. McKellar, Q.A. and Scott, E.W. (1990) The benzimidazole anthelmintic agents-a review. J. Vet. Pharmacol. 
Ther. 13: 223-247. 
 
271. Lubega, G.W., Klein, R.D., Geary, T.G., and Prichard, R.K. (1994) Haemonchus contortus: the role of two 
beta-tubulin gene subfamilies in the resistance to benzimidazole anthelmintics. Biochem. Pharmacol. 47: 
1705-1715. 
 
272. Martin, R.J. (1997) Modes of action of anthelmintic drugs. Vet. J., 154: 11-34. 
 
273. Geary, T.G. and Kubiak, T.M. (2005) Neuropeptide G-protein-coupled receptors, their cognate ligands and 
behavior in Caenorhabditis elegans. Trends Pharmacol. Sci. 26: 56-58. 
 
274. Maule, A.G., Mousley, A., Marks, N.J., Day, T.A., Thompson, D.P., Geary, T.G., and Halton, D.W. (2002) 
Neuropeptide signaling systems - potential drug targets for parasite and pest control. Curr. Top. Med. Chem. 
2: 733-758. 
 
275. Mousley, A., Marks, N.J., and Maule, A.G. (2004) Neuropeptide signaling: a repository of targets for novel 
endectocides? Trends Parasitol. 20:  482-487. 
 
276. Canaff, L., Bennett, H.P., and Hendy, G.N. (1999) Peptide hormone precursor processing: getting sorted? 
Mol. Cell Endocrinol. 156: 1-6. 
 
149 
 
 
 
277. Li, C. and Kim, K. (2009) Neuropeptides. WormBook 1.142.1 
 
278. Rogers, C., Reale, V., Kim, K., Chatwin, H., Li, C., Evans, P., and de Bono, M. (2003) Inhibition of 
Caenorhabditis elegans social feeding by FMRFamide-related peptide activation of NPR-1. Nature Neurosci. 
6: 1178-1185. 
 
279. Kubiak, T.M., Larsen, M.J., Nulf, S.C., Zantello, M.R., Burton, K.J., Bowman, J.W., Modric, T., and Lowery, 
D.E. (2003) Differential activation of "social"  and "solitary" variants of the Caenorhabditis elegans G 
protein-coupled receptor NPR-1 by its cognate ligand AF9. J. Biol. Chem. 278: 33724-33729.   
 
280. Dittman, J.S. and Kaplan, J.M. (2008) Behavioral impact of neurotransmitter-activated GPCRs: Muscarinic 
and GABAB receptors regulate C. elegans locomotion. J. Neurosci. 28: 7104-7112. 
 
281. Steger, K.A. and Avery, L. (2004) The GAR-3 muscarinic receptor cooperates with calcium signals to 
regulate muscle contraction in the Caenorhabditis eleganspharynx. Genetics 167: 633-643 
 
282. Moreno, Y., Nabhan, J.F., Solomon, J., Mackenzie, C.D., and Geary, T.G. (2010) Ivermectin disrupts the 
function ft he excretory secretory apparatus in microfilariae of Brugia malayi. PNAS 107: 20120-20125. 
 
283. McVeigh, P., Geary, T.G., Marks, N.J., and Maule, A.G. (2006) The FLP-side of nematodes. Trends 
Parasitol. 22: 385-396. 
 
284. Brownlee, D.J.A., Fairweather, I., Holden-Dye, L., and Walker, R.J. (1996) Nematode neuropeptides: 
Localization, isolation and functions. Parasitology Today. 12: 343-351. 
 
285. Maule, A.G., Geary, T.G., Bowman, J.W., Shaw, C., Falton, D.W., and Thompson, D.P. (1996) The 
Pharmacology of Nematode FMRFamide-related Peptides. Parasitology Today 12: 351-357. 
 
286. Davis, R.E. and Stretton, A.O.W. (2001) Structure-activity relationships of 18 endogenous neuropeptides on 
the motornervous system of the nematode Ascaris suum. Peptides 22: 7-23. 
 
287. Thacker, C. and Rose, A.M. (2000) A look a the Caenorhabditis elegans Kex2/Subtilisin-like proprotein 
convertase family. BioEssays 22: 545-553. 
 
288. Awadzi, K., Attah, S.K., Addy, E.T., Opoku, N.O., Quartey, B.T., Lazdins-Helds, J.K., Ahmed, K., Boatin, 
B.A., Boakye, D.A., and Edwards, G. (2004) Thirty-month follow-up of sub-optimal responders to multiple 
treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann. Trop. Med. Parasitol. 98: 
359-370. 
 
289. Awadzi, K., Boakye, D.A., Edwards, G., Opoku, N.O., Attah, S.K., Osei-Atweneboana, M.Y., Lazdins-Helds, 
J.K., Ardrey, A.E., Addy, E.T., Quartey, B.T., Ahmed, K., Boatin, B.A., and Soumbey-Alley, E.W. (2004) 
An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two 
onchocerciasis-endemic foci in Ghana. Ann. Trop. Med. Parasitol. 98: 231-249. 
 
290. Nelson, L.S. and Li, C. (1996) Flp-1 deletion mutants suggest FMRF-amide like peptides are involved in 
multiple sensory and motor functions in Caenorhabditis elegans. Soc. Neurosci. Abstr. 22: 333 
 
291. Brownlee, D.A., Holden-Dye, L., Fairweather, I., and Walker, R.J. (1995) The action of serotonin and the 
nematode neuropeptide KSAYMRFamide on the pharyngeal muscle of the parasitic nematode, Ascaris suum. 
Parasitology 111: 379-384. 
 
292. Cowden, C., Stretton, A.W., and Davis, R.E. (1989) AF1, a sequenced bioactive neuropeptide isolated from 
the nematode Ascaris suum. Neuron 2: 1465-1473. 
 
293. Cowden, C. and Stretton, A.W. (1993) AF2, an Ascaris neuropeptide - isolation, sequence, and bioactivity. 
Peptides. 14: 423-430. 
150 
 
 
 
 
294. Pang, F.Y., Mason, J., Holden-Dye, L., Franks, C.J., Williams R.G., and Walker, R.J. (1995) The effects of 
the nematode peptide, KHEYLRFamide (AF2), on the somatic musculature of the parasitic nematode Ascaris 
suum. Parasitology 110: 353-362. 
 
295. Maule, A.G., Shaw, C., Bowman, J.W., Halton, D.W., Thompson, D.P., Geary, T.G., and Thim, L. (1994) 
KSAYMRFamide - a novel FMRFamide-related heptapeptide from the free living nematode, Panagrellus 
redivivus, which is myoactive in the parasitic nematode, Ascaris suum. Biochem. Biophys. Res. Commun. 200:  
973-980. 
 
296. Marks, J.N., Maule, A.G., Geary, T.G., Thompson, D.P., Davis, J.P., Halton, D.W., Verhaert, P., and Shaw C. 
(1997) APEASPFIRFamide, a novel FMRFamide-related decapeptide from Caenorhabditis elegans: 
Structure and myoactivity. Biochem. Biophys. Res. Commun. 231: 591-595. 
 
297. Moffett, C.L., Beckett, A.M., Mousley, A., Geary, T.G., Marks, N.J., Halton, D.W., Thompson, D.P., and 
Maule, A.G. (2003) The ovijector of Ascaris suum: multiple response types revealed by Caenorhabditis 
elegans FMRFamide-related peptides. Int. J. Parasitol. 33: 859-876. 
 
298. Mertens, I., Clinckspoor, I., Janssen, T., Nachman, R., and Schoofs, L. (2006) FMRFamide-related peptide 
ligands activate the Caenorhabditis elegans orphan GPCR Y59H11Al.1. Peptides 27: 1291-1296. 
 
299. Wijesinghe, R.S., Wickremasingh, A.R, Ekanayake, S., and Perera, M.S.A. (2008) Treatment-seeking 
behavior and treatment practices of lymphatic filariasis patients with lymphoedema in the Colombo district, 
Sri Lanka. Asia Pac. J. Public Health. 20: 129-138.  
 
300. Bockarie, M.J., Taylor, M.J., and Gyapong, J.O. (2009) Current practices in the management of lymphatic 
filariasis. Expert Rev. Anti. Infect. Ther. 7: 595-605.  
 
301. Sangster, N.C., Whitlock, H.V., Russ, I.G., Gunawan, M., Griffin, D.L., and Kelly, J.D. (1979) 
Trichostrongylus colubriformis and Ostertagia circumcincta resistant to levamisole, morantel tartrate and 
thiabendazole: occurrence of field isolates. Res. Vet. Sci. 27: 106-110. 
302. Egerton, J.R., Suhayda, D., and Eary, C.H. (1988) Laboratory selection of Haemonchus contortus for 
resistance to ivermectin. J. Parasitol. 74: 614-617.  
 
 
  
151 
 
 
 
ACKNOWLEDGEMENTS 
I would like to express my sincerest appreciation to Dr. Michael J. Kimber (Dept. of 
Biomedical Science / Neuroscience Program) and Dr. Timothy A. Day (Dept. of Biomedical 
Science / Neuroscience Program), my major professors, for their guidance and constructive 
criticism throughout this research. Special thanks to Dr. Lyric Bartholomay (Dept. of 
Entomology) for providing me with some of the essential tools and materials necessary to carry 
out this research. In addition I would like to thank Dr. Kimber, Dr. Day, and Dr. Bartholomay for 
providing me with invaluable criticisms, suggestions and direction throughout the creation and 
maturation of this manuscript. I would also like to thanks Dr. Steve Carlson (Dept. of Biomedical 
Science) and Dr. Thomas J. Baum (Dept. of Plant Pathology) for kindly serving as committee 
members and consultants.  
 
 
